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I. Enantioselective Rhodium-Catalysed Addition of Allylboron Reagents 
to Cyclic Imines  
Rhodium-catalysed enantioselective allylation reaction of imines in the presence of 
chiral diene ligands has been investigated. Under the optimised conditions, cyclic imines 
provided homoallylic amines in high yield and excellent enantioselectivities. The 
reaction most likely proceeds via allylrhodium(I) intermediates, and represents the first 
rhodium-catalysed enantioselective nucleophilic allylation of π-electrophiles with 
allylboron compounds. Furthermore, the allylations display a strong preference for 
carbon–carbon bond formation at the more substituted terminus of the allyl fragment of 
the allyltrifluoroborate. To demonstrate the utility of the allylation products, 
representative manipulations were conducted. 
 
II. Enantioselective Nickel-Catalysed Michael Additions of 
2-Acetylazaarenes to Nitroalkenes 
An enantioselective Michael addition of acylazaarenes with α-substituted 
β-nitroacrylates in the presence of a chiral Ni(II)–bis(oxazoline) complexes has been 
developed. A range of azaaryl nucleophiles were shown to react with a variety of 
nitroalkenes to construct highly functionalised Michael addition products which contain 
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a stereogenic all-carbon quaternary stereocentre with moderate to high yields and 
enantioselectivities. A possible mechanism for this reaction has been proposed. 
R1
Ligand (5.5 mol %)
Ni(OAc)2·4H2O (5 mol %)









Ni(OAc)2·4H2O (5 mol %)




R1, R2, R3 = alkyl
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1. Enantioselective Rhodium-Catalysed 
Addition of Allylboron Reagents to Cyclic 
Imines 
1.1 The Importance of Chiral Amines in Organic Chemistry 
Chiral amines are widespread structural units in both natural and synthetic bioactive 
molecules, such as those shown in Figure 1.1.1,2 These unique biological activities have 
resulted in them gaining much attention within chemical industries where they are 
powerful pharmacophores for defining new pharmaceutical drugs. Nowadays, a number 
of drugs are amines or contain functional groups derived from amines, and an increasing 
number of these molecules feature a non-racemic stereocentre. The development of such 
enantioenriched biologically active molecules, whether from natural or synthetic 
sources, relies on the development of general and efficient synthetic methods to prepare 
chiral amines.  
 
Figure 1.1: Amine containing natural and synthetic chiral compounds. 
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As mentioned above, chiral amines are crucially important, therefore, the following 
section was to understand the general approaches to obtain enantioenriched amines. 
1.1.1 The Synthesis of Enantioenriched Amines 
Chiral amine synthesis is a huge area and there are numerous routes to prepare 
enantioenriched amines using both metal catalysts and organocatalysts as well as 
biocatalysts.1 These numerous methods are too vast to concisely summarise within this 
text, thus, only chiral amines prepared from imines, racemic amines, enamines, 
enamides, and N-based heteroarenes will be discussed. 
The transformation of imines into chiral amines has been thoroughly investigated. 
Amongst several reduction pathways, asymmetric hydrogenation and transfer 
hydrogenation are a favoured due to atom economy and a straightforward protocol for 
the preparation of chiral α-secondary amines.3 Another useful method involves the 
addition of nucleophiles to imines which generates both chiral α-secondary amines and 
chiral α-tertiary amines as desired products.4 This method is possibly considered to be 
the widest studied process because it covers various types of nucleophiles such as 
stabilised and unstabilised carbanion reagents. In terms of stabilised carbanion reagents, 
Aza-Morita-Baylis-Hillman reactions,5 Mannich reactions6 and related reactions are a 
very common example. On the contrary, alkylation,7 allylation,8 alkenylation, arylation9 
and alkynylation10 are well-known reactions using sp3, sp2 and sp unstabilised carbanion 
reagents. Although ionic reaction is a major approach of chiral amine syntheses radical 
reaction is also investigated currently which uses hydrazone prochiral starting 





























































Scheme 1.1: Chiral amine synthesis using imine substrates. 
In terms of other compounds aside from imines and racemic amines, asymmetric 
hydrogenation is a clean and convenient way to achieve chiral α-secondary amines. 
Many efficient metal catalysts and organocatalysts for this chemistry have been explored 
and developed by using simple starting materials such as enamines, enamides and 
N-based heterocyclic compounds.12,13 Another option, reductive amination, the 
conversion of a ketone to an amine, has been gaining more and more attention in recent 
years.14 However, this approach is still fairly undeveloped compared with the field of 
imine reduction. The addition of an amine N−H bond across an unsaturated C−C, called 
hydroamination, also gives chiral amines.15 Nevertheless, the majority of catalysts for 
this transformation are currently confined to a limited set of substrates, requiring 
activated multiple C−C bonds. The last major approach to achieve chiral amines is a 
C−H activation process.16 Even though a number of the intramolecular C−H amination 





Scheme 1.2: Chiral amine synthesis using carbonyl compounds, alkenes, enamines, 
enanmides and related substrates. 
The preparation of chiral amines from racemic amines has also been reported recently. 
There are a few general methods that have been developed in the field, namely, kinetic 
resolution (KR), dynamic kinetic resolution (DKR), deracemisation, and asymmetric 
synthesis using enzymes, respectively.17,18 Although some metal-catalysed reactions 
have been reported, most of them use enzymes or biocatalysts to convert racemic amines 
to chiral amines (Scheme 1.3).19 
 
Scheme 1.3: Chiral amine synthesis from racemic amine substrates. 
In summary, chiral amines can be synthesised from both racemic amines and prochiral 
compounds such as imines, enamines etc. The addition of nucleophiles to prochiral 
imines is regarded as one of the most important pathways to afford enantioenriched 
amines. In the Lam group we are interested in the allylation of imines using rhodium 
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catalysts. Thus, in the next section, the advantages and previously reported scopes of this 
transformation are discussed (Section 1.2). 
1.2 Introduction to the Allylation of Imines 
As a significant class of chiral amines, homoallylic amines are particularly important 
structures. They are useful building blocks for organic synthesis which allow further 
possible synthetic transformations due to the presence of a double bond, for examples; 
ozonolysis, epoxidation, dihydroxylation, hydroboration, hydrogenation, 
hydroformylation, cycloaddition and olefin metathesis respectively.20 Therefore, in the 
last two decades, there have been many reported publications focused on developing a 
methodology to construct these amines.8,21 Unsurprisingly, enantioselective nucleophilic 
allylation to prochiral imines is one of the most common approaches for forming this 
important class of compounds. A range of allylmetal nucleophiles can undergo 
nucleophilic addition to an activated imine in a stereoselective manner to prepare chiral 
homoallylic amines. Thanks to this easy way to access amines by deprotection of 
activating groups, together with the efficiency of this route, various complex molecules 
have been synthesised by utilising this methodology.8,22,23 
As shown in the following sections, there are several straightforward ways to receive a 
high yield of enantiomerically pure homoallylic amines. Whereas most of methods are 
activated by transition metal catalysts such as Cu, Zn, Pd, Ag and In etc. (Scheme 1.4) 
some of them are mediated by chiral promoters along with either allylsilanes, allylic 
alcohols, allylstannanes, allylhalides, or allylborons as the allylating agent. 
 
Scheme 1.4: Metal-catalysed enantioselective allylation of imines. 
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1.2.1 Allylation Using Allylsilanes 
Allylsilanes have been widely used in organic synthesis for a long time.24 As silicon is 
more electropositive than carbon, it exerts an electronic effect on both α- and β-carbons. 
In terms of activated α-carbon (or α-carbanion), silanes can stabilise this position by its 
partial positive charge, known as the α-effect. On the contrary, activated β-carbon (or 
β-carbocation) can be stabilised by hyperconjugation, called the β-effect, which involves 
the overlap between the empty p-orbital of the carbocation and the filled sigma 
molecular orbital of the C−Si bond. The weak polarisation of the C−Si bond together 
with the unique α- and β-effects allows an easier handling of these stable 
organometallic-type reagents, which, therefore becomes a useful source of functional 
group transformations. There are several reports that demonstrate that allylsilanes are a 
good allylating reagent in enantioselective allylation of imines. However, most of these 
reported reactions require a strong Lewis acid catalyst in order for the reaction to 
proceed efficiently and more detailed discussions on this topic will commence in the 
following sections. 
Lectka and co-workers developed a methodology for the synthesis of non-natural amino 
acids via the catalytic, asymmetric alkyl- and allylations of (R)-imino esters by enol 
silanes, ketene acetals, alkenes, and allylsilanes using chiral copper(I)-phosphine 
complexes (Scheme 1.5).25 It was found that, alkylation and allylation products were 
obtained with high yields (up to 97%), high enantioselectivities (up to 99% ee) and 
anti-diastereoselectivities (up to 25:1/anti:syn). Interestingly, according to the kinetic 
studies, the reaction was believed to proceed via a concerted, closed transition state and 





Scheme 1.5: Copper-catalysed enantioselective allylation of imino ester 7 with 
allylsilane 8. 
In 2003, the catalytic enantioselective allylation of acylhydrazono esters in aqueous 
media was reported by Kobayashi and co-workers (Scheme 1.6). By using ZnF2 
(20 mol%) and chiral diamine ligand 13 (10 mol%), the product 14 was obtained in good 
yield and enantioselectivity. The proposed mechanism suggests that zinc(II) 15a acts as 
a Lewis acid to activate the hydrazone electrophile and the fluoride anion acts as Lewis 
base to activate the silicon atom of allyltrimethoxysilane (12) (Scheme 1.7). In addition, 
the methoxy substituent in the ligand 13 was found to have an essential role in attaining 
high yields and enantioselectivities.26 
 




Scheme 1.7: Proposed mechanism for zinc-catalysed enantioselective allyllation of 
acylhydrazono ester 11. 
A year later, Fernandes and Yamamoto reported the allylation of aldimines with 
tetraallylsilane (19) catalysed by palladium complex 20 (Scheme 1.8).27 Interestingly, 
the mechanism proposed also involved the fluoride anion from TBAF facilitatating the 
C−Si bond cleavage to form an allylpalladium complex. Methanol then promotes the 
protonation of the palladium amide to provide the chiral amine. 
 
Scheme 1.8: Palladium-catalysed enantioselective allylation of aryl imine 18 in the 
presence of TBAF. 
The first example of catalytic enantioselective allylations of iminophosphonates with 
allylsilanes using a copper catalyst with a diamine ligand was reported in 2006 
(Scheme 1.9). Both yields and selectivities of the reaction were high, especially when 
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3 Å molecular sieves were employed to ensure anhydrous conditions as water was 
believed to partially hydrolyse the nucleophile. The slow addition of the substrate 
suppressed an uncatalysed background reaction allowing good results to be obtained.28 
 
Scheme 1.9: Copper-catalysed enantioselective allylation of iminophosphonate 22. 
Itoh and co-workers reported the total synthesis of an isoquinoline alkaloid, ()-emetine 
(29). In the formal synthesis, the key step was a copper-catalysed enantioselective 
allylation of an unactivated cyclic imine 26 with allyltrimethoxysilane (12) 
(Scheme 1.10). Various phosphine-based ligands were investigated and it was found that 
(R)-tol-binap 27 in THF at room temperature afforded the best result with high yield and 
moderate selectivity.29 
 
Scheme 1.10: Enantioselective allylation of dihydroisoquinoline 26. 
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An enantioselective synthesis of homoallylic amines, using allyltrimethoxysilane 12 and 
a AgI−monophosphine catalyst was studied by Yamamoto and co-workers 
(Scheme 1.11).30 Under mild conditions and low catalyst loadings, chiral amines were 
produced with high yields and modest to high ee values (up to 80%). Moreover, it was 
shown that the methodology could be efficiently expanded to include crotylsilane 
nucleophiles to afford α-branched products with highly diastereoselectivy and modest 
enantioselectivities. 
 
Scheme 1.11: Enantioselective allylation of imine 30. 
Expanding the scope of this reaction, Nakamura and co-workers31 investigated the first 
enantioselective allylation of ketimines derived from isatins using 
bis(imidazoline)−palladium pincer complex 34 as a catalyst. The results showed that 
homoallylic amines containing a tetrasubstituted stereocentre could be obtained in high 
yields and very high stereoselectivities (Scheme 1.12). 
 
Scheme 1.12: Enantioselective allylation of isatin-derived imine 33. 
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Aside from metal-catalysed allylation, organic compound promoted-allylation has also 
been widely studied. Many research groups have reported the asymmetric allylation of 
imines using chiral promoters. In 2003, the group of Kobayashi studied the allylation of 
hydrazones with allyltrichlorosilane using chiral sulfoxide 38 (Scheme 1.13). Both 
aromatic and aliphatic hydrazones gave moderate yields and good enantioselectivities, 
and E- and Z-crotyltrichlorosilanes were found to produce the syn- and anti-products 
respectively.32 
 
Scheme 1.13: Chiral sulfoxide-mediated enantioselective allylation of hydrazone 36. 
Inspired by their previous work32, Kobayashi and co-workers investigated the allylation 
of α-hydrazono esters where chiral binap dioxide 41 was used as the source of inducing 
chirality. It was noted the yields and selectivities of products relied upon the 
concentration of the chiral ligand 41. When lower quantities of ligands were used, lower 
yields were obtained (Scheme 1.14).33 
 




Jagtap and Tsogoeva reported the first stereoselective allylation of aldimines in the 
presence of N-formylproline promoters.34 It was shown that the amide 44 was the best 
activator in terms of both yields and selectivities (Scheme 1.15). Although in all cases 
the yields were high, the enantioselectivity of the products were moderate. Interestingly, 
the enantioselectivities and the rate of the reaction were improved by adding L-proline. 
Moreover, based on MS and 1H NMR results, a plausible transition-state model was 
proposed. It was postulated that the formation of two covalent bonds between the 
nucleophilic atoms (N and O) in L-proline and a silicon atom of allyltrichlorosilane 
(37a), provides a chiral allylating reagent. The second formamide moiety of chiral 
bis-formamide 44 enhances the nucleophilicity of allylic complex by coordinating to the 
silicon atom. 
 
Scheme 1.15: Chiral N-formylproline-mediated enantioselective allylation of imine 43. 
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Fernández and co-workers evaluated the allylation of hydrazones with screening both 
monosulfinamide and disulfinamide organic chiral promoters. The results indicated that 
the size of alkyl substituents on the promoters determined the enantioselective outcome, 
the bulkier the alkyl group the higher the enantioselectivity (Scheme 1.16).35 
 
Scheme 1.16: Chiral mono- and disulfinamide-mediated enantioselective allylation of 
hydrazone 47. 
 
Scheme 1.17: Chiral disulfonimide-based Lewis acid catalysed enantioselective 
allylation of aldehydes. 
Gandhi and List recently reported the first catalytic asymmetric three-component 
synthesis of chiral homoallylic amines starting directly from aldehyde 51, carbamate 52, 
and allyltrimethylsilane (53).36 After screening different chiral acid motifs for example 
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phosphoric acid, phosphoramides, sulfonic acid and disulfonamides it was found that 
chiral disulfonimide-based Lewis acid catalyst 54 gave the best result (Scheme 1.17). 
Concerning the mechanism of this reaction, two distinct pathways were envisioned 
(Figure 1.2). Accordingly, the disulfonimide promoter may act as a Brønsted acid which 
activates the in situ generated imine by protonation (a). Alternatively, the catalyst 
species in turn may activate the imine by silicon-based Lewis acid catalysis (b). 
However, the authors suggested that Lewis acid catalysis pathway tends to be the 
promising route according to the preliminary experiments utilising a preformed imine 
and the preformed silylated catalyst which gave nearly identical enantioselectivity as 
those obtained in the corresponding three-component reaction. 
 
Figure 1.2: Modes of activation of asymmetric three component allylation. 
1.2.2 Allylation Using Allylic Alcohols 
Allyl alcohols are widely used as a raw material or a precursor in various chemical 
industries.37 Furthermore, several research groups have recently developed the reaction 
using allylic alcohols as a source of inexpensive and stable starting materials in an 
asymmetric allyation process. In 2009 Micalizio reported a convergent coupling reaction 
between allylic alcohols and imines that delivered complex homoallylic amines without 




Scheme 1.18: Complex allylation without an allylic organometallic reagent. 
 
Scheme 1.19: Designed mechanism of the direct cross-coupling of imines with 
unactivated allylic alcohols. 
It was proposed that the reaction mechanism involved the treatment of imine 57a with a 
low-valent metal-reagent resulting in the formation of intermediate 
azametallocyclopropane 60a. The addition of allylic alkoxide 58a to complex 60a led to 
a rapid and reversible ligand exchange to deliver 60b. Formal metallo-[3,3]-
rearrangement 60c brought about the formation of the C−C bond of homoallylic 
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metalated amine 60d. Finally, simple hydrolysis provided the complex homoallylic 
amine 59a (Scheme 1.19).38  
In 2010, the group of Zhou published the enantioselective allylation of arylimines with 
allylic alcohols by activating the alcohol with palladium-chiral spiro ligand catalyst 63.39 
This work was successful with allyl alcohols and crotyl and cinnamyl alcohols to obtain 
homoallylic amines in reasonable yields and average enantioselectivities (Scheme 1.20). 
 
Scheme 1.20: Palladium-catalysed enantioselective allylation of imine 61. 
The mechanism was proposed as shown in Scheme 1.21 to rationalise the ‘Umpolung’ 
of the π-allylpalladium.40 The transfer of the electron-rich ethyl group from boron to 
η3-allylpalladium species 67b promotes the formation of η1-allylpalladium species 67c 
which was thought to change the electronic property of the palladium centre to become a 
stronger nucleophile. Then the reaction proceeds further in enantioselective fashion via 




Scheme 1.21: Proposed mechanism of palladium-catalysed enantioselective allylation of 
aryl N-tosylated imines. 
Although catalytic asymmetric allylation reactions have been widely studied, there are 
also reports of using a chiral auxiliary reagent to induce stereoselectivity. Recently, Yus 
reported the palladium-catalysed allylation of N-tert-butanesulfinyl imines with allylic 
alcohols in the presence of InI as a reducing reagent. The reaction took place with 
modest diastereoselectivity in reasonable yields for both β-substituted allylic alcohols 
and crotyl alcohol (Scheme 1.22).41 
 




From a mechanistic point of view (Scheme 1.23),41 first, π-allylpalladium complex 71 is 
formed, then, it undergoes reductive transmetalation with indium(I) salts to give 
allylindium(III) species 72. The allylation proceeds via a six-membered cyclic transition 
state 73a or 73b where the indium is coordinated to both the nitrogen and the oxygen 
atoms of the imine 68a, and then a Si-face attack takes place with the imine. Regarding 
the crotylation reactions, the E-crotylindium species reacts at the γ-position through a 
cyclic boat-like six-membered transition state 73a (preferred over the chair-like 
transition state 73b due to the steric repulsion between the methyl group of crotylindium 
and the substituent of the aldimine) to produce the anti-product 70c. 
 
Scheme 1.23: Proposed mechanism of the addition of allylic alcohol to chiral substrates 
via allylindium species. 
1.2.3 Allylation Using Allyl Stannanes  
Also, the additions of organotin compounds to electrophiles are a very useful 
methodology in organic synthesis. Although organotin reagents are highly toxic, they are 




The first enantioselective allylation of aryl imines with allylstananes using a palladium 
complex catalyst was reported by Yamamoto and co-workers in 1998.42 The result 
demonstrated that the chiral amine products were achieved in modest to high yields and 
enantioselectivities (Scheme 1.24).43 
 
Scheme 1.24: Palladium-catalysed enantioselective allylation of aryl imines. 
A plausible mechanism for allylation was proposed. The transmetalation between 20 and 
allyltributylstannane (75) produces the bis-π-allylpalladium complex 77a. The key step 
for chiral induction was believed to be the coordination of imine 74a to the intermediate 
77a to give 77b. The allylation proceeds through a six-membered chair-like transition 
state 77c to generate 77e. Subsequently, the transmetalation of 75 to palladium produces 
the stannyl homoallylamide 76b and regenerate bis-π-allylpalladium complex 77a. 
Hydrolysis of 76b then affords the chiral homoallylamine 76c. The authors also 
suggested that the role of water is to form the pentacoordinate allylstannate, in which 
water facilitates the C−Sn bond cleavage and enhances the transmetalation step in giving 




Scheme 1.25: Proposed mechanism. 
In 2001, the zirconium-catalysed allylation of arylimines with allylstannanes was 
reported by Kobayashi and co-workers.44 The authors suggested that a hydroxyl group 
substituted at the o-position of the arylimine 78 and an unprotected hydroxyl group on 
the stannane nucleophile 79 were required to coordinate to the zirconium catalyst, 
without this functionality, high enantioselectivities were not achieved. The mechanism 
was proposed involved the bonding of zirconium (Lewis acid) with the hydroxyl group 
of the imine results in the active catalyst, then the allylstannane attacks the imine in an 




Scheme 1.26: Zirconium-catalysed enantioselective allylation of arylimine 78. 
Szabó’s group studied the asymmetric allylation of sulfonimines using pincer complex 
catalysts (Scheme 1.27). It was believed that the reaction proceeded via transition state 
86 in which the nitrogen atom of the sulfonylimine cannot coordinate to the palladium. 
Therefore the stereoselectivity of the product is determined by steric interactions 




Scheme 1.27: Palladium-catalysed enantioselective allylation of aryl sulfonimines. 
Benaglia and co-workers studied the catalytic enantioselective addition of 
allyltributylstannane 75 to N-protected α-imino esters promoted by silver(I) 
trifluoromethanesulfonate in the presence of imine ligands.47 After testing several chiral 
ligands derived from 1,2-diaminocyclohexane and binaphthyl diamine, a very simple 
experimental procedure was developed that allowed them to obtain homoallylic amines 
in excellent yields and modest enantioselectivities (Scheme 1.28). 
 
Scheme 1.28: Silver-catalysed enantioselective allylation of aryl imino ester 87. 
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Recently, Abdi and co-workers investigated an enantioselective copper(II)-catalysed 
allylation of aryl and alkenyl-substituted N-sulfonylimines with allylstannane 75.48 With 
the use of a simple in situ generated copper(II)-amino alcohol based Schiff base 
complex, desired homoallyl amines were obtained up to 90% yield and 98% 
enantioselectivity. Moreover, to demonstrate the utility of this process, the 
transformation of homoallylic amine 65 to β-phenylalanine (91) was conducted 
(Scheme 1.29).  
 
Scheme 1.29: Copper(II)-Schiff base catalysed enantioselective allylation of imines 
toward the synthesis of β-phenylalanine (91). 
1.2.4 Allylation Using Allyl Halides 
Allyl halides have gained much attention from organic chemists for a long time because 
they are synthetically useful and relatively cheap reagents. There are numerous 
examples of allyl halides used as an allylating reagent in Barbier-type reaction in the 
presence of metals such as Mg, Al, Zn, In and Sn etc.8a,49,50  
Cook and co-workers investigated the indium-mediated allylation of hydrazones. By 
varying ligands it was found that (R)-binol 94a provided chiral product 95 in moderate 
yields and ee (Scheme 1.30).51 Moreover, further investigation by Cook, Lloyd-Jones 
and co-workers showed that (R)-binol ligand 94b could afford superior results. This new 
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reaction conditions provided good results when aliphatic imines were used as a starting 
material as well as aromatic imines.52 
 
Scheme 1.30: Indium-mediated enantioselective allylation of hydrazone 92. 
During the same period of time, Kim and co-workers attempted an allylation of 
aldimines with allyl bromide (97) in the presence of an  indium-(+)-cinchonine 
complex.53 Unfortunately, although the isolated yields were high, the enantioselectivities 
were very poor (Scheme 1.31). 
 
Scheme 1.31: Indium-mediated enantioselective allylation of aryl imine 95. 
In 2007, Tan and Jacobsen studied the allylation of arylhydrazones using indium and 
sulfinamide-urea catalysts.54 After screening various types of these catalysts it was 
shown that sulfinamide-urea 101 promoted the allylation of acylhydrazones with high 
levels of both yield and enantioselectivity. However, acylhydrazones derived from 
aliphatic aldehydes underwent allylation with low enantioselectivity (normally lower 
than 50% ee). Fortunately, when substrates bearing electron deficient (N-acyl groups) 
were used the enantioselectivities improved (Scheme 1.32). This work is considered to 
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be the first application of urea catalysis for highly enantioselective additions of 
organometallic reagents. 
 
Scheme 1.32: Indium-sulfinamide urea-catalysed asymmetric allylation of hydrazones. 
1.2.5 Allylation Using Allylborons 
Organoboron reagents have been widely used in various new methodologies for 
carbon−carbon bond formation in organic synthesis both in the laboratory scale and 
industrial scale.55,56 In comparison with other organometallic reagents such as 
organomagnesium, organolithium and organotin etc., organoboron reagents have been 
shown to be less toxic. These reagents have many other advantages;57 e.g. (1) readily 
available by hydroboration and transmetallation, (2) stability in water and related 
solvents, (3) remarkably stable towards sensitive functional groups and (4) generates 
low or non-toxic byproducts. There are many examples for the use of organoborons as 
an allylating reagent in the allylations of imines as shown below. 
The catalytic enantioselective allylation of ketimines was reported by Kanai and 
Shibasaki.58 By using allylboronate esters, the optimum ligand, (R,R)-cyclopentyl-
DuPhos 107, and CuF combined with LiOi-Pr or LaOi-Pr co-catalysts it was possible to 
synthesise homoallylic amines featuring a quaternary stereocentre. The yields and 
enantioselectivities for arylketone substrates were high but aliphatic ketimines afforded 
unsatisfactory enantioselectivity (Scheme 1.33). The reaction mechanism proposed 
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involved the addition of LiOi-Pr, which improves the reaction rate by increasing the 
concentration of the active allylcopper nucleophile 109a (Scheme 1.34). 
 
Scheme 1.33: Copper(I)-catalysed enantioselective allylation of benzyl ketoimines. 
 
Scheme 1.34: Proposed mechanism for copper (I)-catalysed enantioselective allylation 
of benzyl ketoimines. 
As mentioned in Section 1.2.1, the group of Kobayashi reported the catalytic 
asymmetric allylation of hydrazono esters with allyltrimethoxysilane (12).26 However, 
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the disadvantages of that reaction are the requirement to employ an excess (3 equiv) of 
12, a relatively low reactivity, and a narrow substrate scope. To address these issues, 
having allylboronates as allylating agents instead of 12 was investigated. Using a similar 
catalytic system and acetone/ water as solvent it was found that the amount of allylating 
agent could be reduced from 3 equiv to 1.2 equiv and these optimal conditions gave 
products in high yields and enantioselectivities. Furthermore, when substituted 
allylboron reagents were used, α-addition products were obtained exclusively with high 
yields and stereoselectivities (Scheme 1.35).59 
 
Scheme 1.35: Zinc-catalysed enantioselective allylation of acylhydrazono ester 111. 
A catalytic cycle of this reaction was proposed which explained the stereoselectivity of 
the obtained chiral amine adducts (Scheme 1.36). The mechanism begins with the 
formation of γ-substituted Z-allylzincate 116d, which then reacts stereoselectively with 





Scheme 1.36: Plausible mechanism of zinc-catalysed asymmetric allyllation of imine 
111a. 
Scheme 1.37: Indium-catalysed enantioselective allylation of N-benzoyl hydrazones 
with the presence of the semicorrin ligand 118. 
In 2010, Kobayashi and co-workers60 reported the indium-catalysed allylation of 
hydrazones with allylboronate esters, using the chiral semicorrin ligand 118 
(Scheme 1.37). Unfortunately, low yields and poor enantioselectivities were obtained 
with aliphatic hydrazone substrates. The postulated mechanism suggested that the Lewis 
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basic hydrazone activates the allylic boronate leading to transmetalation. The 
allylindium then adds to the imines to form the non-racemic products. 
The first highly enantioselective Hosomi−Sakurai reactions with Csp3 centres employing 
boronates instead of the classic silicon-based reagents were reported by Kobayashi and 
co-workers.61 Under the optimal conditions, substituted aromatic, heteroaromatic and 
aliphatic aminals were allylated smoothly to provide the desired products with high 
asymmetric induction (Scheme 1.38). This transformation is thought to proceed via a 
Csp2 centre by the elimination of methoxy group to generate a reactive imine. It is 
considered as the first main group metal-catalysed activation of allyl boronates for 
asymmetric C−C bond formation with Csp3 centre starting materials. 
  
Scheme 1.38: A catalytic asymmetric borono variant of Hosomi−Sakurai reactions with 
N,O-aminals. 
The enantioselective allylation of aldimines with (pinacolato)allylborons catalysed by 
NHC−Cu complexes was investigated by Hoveyda and co-workers.62 It was showed that 
aryl-, heteroaryl-, alkyl-, and alkenyl-substituted N-phosphinoylimines underwent 
allylations efficiently to afford homoallylic amines in high yields and high 
enantioselectivities (Scheme 1.39). Furthermore, a mechanistic model was proposed that 
showed a preference for the reaction via 129a versus the competing mode 129b, due to 
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Scheme 1.39: NHC-Copper complex-catalysed enantioselective allylations of aldimines. 
Regarding organocatalysis, in 2007 Schaus and co-workers63 developed a highly 
enantioselective allylation of acyl imines catalysed by chiral binol-derived catalyst 131. 
It was found that the reaction was highly selective for aryl as well as aliphatic acyl 
imines (Scheme 1.40). The reaction of crotyl boronate 130 afforded the corresponding 
anti-product in high diastereoselectivity. Mechanistic investigations strongly suggest 
that acyclic boronates are activated by chiral diols via exchange of one of the boronate 




Scheme 1.40: Asymmetric allylboration of acyl imines catalysed by chiral diol 131. 
In 2013, Hoveyda and co-workers 64 discovered a set of small organic molecules that can 
catalyse the addition of allylboron reagents to imines and carbonyls (Scheme 1.41). 
Distinguishingly, this catalyst class has a “key” proton embedded within their structure. 
With the optimal condition in hand, aryl-, alkenyl-, alkynyl- and alkylimines were 
converted to homoallylic amides with high efficiency and enantioselectivities. 
Moreover, when α-substituted allylborons were used, homoallylamides with an 
additional tertiary or quaternary carbon stereogenic centre were obtained with high 





Scheme 1.41: Simple organic molecules as catalysts for enantioselective synthesis of 
amines. 
Stereochemical models accounted for the observed enantioselectivity, which was 
proposed as shown in Scheme 1.42. It involves hydrogen-bonding interactions, which 
bring the catalyst’s amine and amide carbonyl and the phosphinoyl unit together. Thus 
the bond formation proceeds via the organised transition state 137d, which minimises 
steric repulsion between the allyl and the i-Pr groups of the catalyst caused by the 
converging heteroatoms. This hypothesis is supported by computational studies together 
with X-ray crystallography analysis, which indicates a proton-bridge connecting the 




Scheme 1.42: Proposed transition states of allylation of dpp-imines. 
1.2.6 Allylation Using Other Allylating Reagents 
Shibasaki and co-workers demonstrated a catalytic asymmetric addition of allylic 
cyanides to N-diphenylphosphinoyl ketimines using copper catalysis. Fortunately, the 
α,β-unsaturated products (with a stereogenic tetrasubstituted carbon), which formed 
from isomerisation of the obtained β,γ-unsaturated nitriles, were achieved in high yields 
and high enantioselectivities. The reaction mechanism proposed that the imine substrate 
is activated by coordination to soft Lewis acid (Cu) and then deprotonated by 
neighbouring aryloxide to generate a nitrile nucleophile. This active nucleophile 





Scheme 1.43: Copper-catalysed enantioselective allylation of diphenylphosphinoyl 
imine 141. 
In 2014, a diastereoselective allylation of chiral hydrazones was developed by Cook and 
co-workers utilising an indium mediator and a palladium catalyst (Scheme 1.44).66 This 
method used an allylindium reagent generated from allylic acetates through a reductive 
transmetalation process. The reaction was inhibited when the phosphine concentration 
was increased. From this result, the authors suggested that an intermediate 149c 
(involving a Pd-In bond) is important for generating the nucleophilic allylindium species 
149d (Scheme 1.45). 
 




Scheme 1.45: Proposed mechanism of palladium-catalysed allylation of chiral 
hydrazones. 
In conclusion, the enantioselective nucleophilic allylation to prochiral imines is widely 
studied. A range of transition metal catalysts was used to obtain chiral homoallylic 
amines. However, among the variety of allylating reagents utilised, organoboron 
reagents were less toxic and have many more advantages. Therefore, in the Lam group, 
we are keen to further investigate the rhodium-catalysed enantioselective allylation of 
allylboron reagents to imines. Not only is rhodium a new metal in this transformation 
but it also has many advantages as discussed in Section 1.3. 
1.3 Rhodium-Catalysed Enantioselective Addition of 
Organoboron Reagents to Imines 
Rhodium catalysis has been an important industrial catalyst for many years and has been 
utilised in many important reactions (Monsanto process, hydrogenation, 
hydroformylation etc.). Although this rare metal is extremely expensive, its catalytic 
properties are very unique and useful. According to the several literature reviews 
mentioned above, the allylation reactions catalysed by other cheaper elements such as 
Cu, Zn, Pd, Ag and In also produced chiral homoallylic amines successively; however, 
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the yields and enantioselectivities were not good in all cases. When stoichiometric 
promoters were used both yields and enantioselectivities of products were high. 
Unfortunately, however, there is still the problem of the quantity of chiral additive 
(normally, more than one equivalent of chiral promoter being required). Owing to some 
significant drawbacks of using other metals in asymmetric allylation of imines, 
extensively studied metals such as rhodium should be investigated in this reaction. Apart 
from the advantages of rhodium mentioned above, there are many studies which have 
demonstrated that rhodium complexes are very powerful catalysts in the asymmetric 
synthesis of chiral amines which will be detailed below. 
1.3.1 Rhodium-Catalysed Arylation 
Rhodium-catalysed arylation has been investigated widely for nearly two decades. 
Therefore in this report only examples utilising imines as the electrophilic substrate will 
be covered. In 2000, Hayashi and Ishigedani reported a new chiral catalyst system for 
the asymmetric addition of arylmetal reagents to imines.67 The result demonstrated that 
some rhodium complexes coordinated with chiral monodentate phosphine ligands 
(MOP’s) catalysed the addition of arylstannanes to N-alkylidenesulfonamides to give 
sulfonamide of diarylmethylamines with high enantioselectivities. Pleasingly, this 
present catalytic asymmetric arylation could also be applied to sulfonamide of an 
α,β-unsaturated aldehyde, giving 1,2-addition allylic amine adduct 153b (Scheme 1.46). 
 
Scheme 1.46: Rhodium-catalysed arylation of aldimines with arylstannanes. 
Tomioka and co-workers developed a catalytic asymmetric arylation of sterically tuned 
imines with arylboroxines (Scheme 1.47).68 Using a N-Boc-L-valine-connected 
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amidomonophosphine rhodium(I) catalyst, chiral biarylmethylamides were obtained in 
high yields and selectivities. Moreover, the TMS group used for the steric tuning of the 
imine was easily converted to other functionalities. 
 
Scheme 1.47: Rhodium-catalysed arylation of imine 153 with arylboroxine 154. 
Continuing on their previous work67, Hayashi and co-workers investigated the 
preparation of new chiral diene ligands and their application towards catalytic 
asymmetric reactions.69 The result showed that the new C2-symmetric 
bicyclo[2.2.2]octadienes (bod*) had a clear superiority over chiral phosphorus ligands in 
both catalytic activity and enantioselectivity in the rhodium-catalysed arylation of 
N-tosylarylimines (Scheme 1.48). This is the first example of a rhodium-catalysed 
arylation utilising a C2-symmetric diene ligand, Ph-bod* 159. 
 
Scheme 1.48: Rhodium-catalysed arylation of imine 157. 
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Later Hayashi and co-workers reported an additional scope of the rhodium-catalysed 
asymmetric arylation (Scheme 1.49).70 It was shown that the reaction of sulfonylimines 
with aryltitanium reagents proceeded with high enantioselectivity under mild conditions 
to give diarylmethyl amines with up to 96% ee. By introducing isopropyl groups onto 
the phenyl ring of the arene sulfonamide moiety much higher enantioselectivities were 
achieved (86-96% ee). 
[Rh(CH2CH2)Cl/161b]2 (1.5 mol%)
THF, 30 °C, 1 or 5 h then H2O
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Scheme 1.49: Rhodium-catalysed arylation of imines with aryltitanium reagent 164. 
Ellmann and co-workers reported the diastereoselective rhodium-catalysed addition of 
arylboronic acids to both aromatic and aliphatic N-tert-butanesulfinylimines using 
1,2-bis(diphenylphosphino)benzene ligand 169. Furthermore, with the use of 
(R,R)-deguPhos ligand 170, N-diphenylphosphinoyl benzaldimine 138 was arylated with 
high yield and enantioselectivity (Scheme 1.50).71 Importantly, the authors believed that 
both N-tert-butanesulfinyl group and the N-diphenylphosphinoyl group could be cleaved 




Scheme 1.50: Rhodium-catalysed arylation of N-tert-butanesulfinylimines and 
N-diphenylphosphinoyl imines. 
In 2005, Hayashi and co-workers reported the use of a new C2-symmetric chiral diene in 
the rhodium-catalysed asymmetric arylation of N-4-nitrobenzenesulfonylimines. 
(Scheme 1.51).72 With the use of 2,6-diphenylbicyclo-[3.3.1]nona-2,6-diene 173, chiral 
biarylmethylamines were obtained in excellent yields and selectivities. 
 
Scheme 1.51: Rhodium-catalysed arylation of imine 171 using C2-symmetric chiral 
diene 173. 
Four years later, the same research group investigated the rhodium-catalysed asymmetric 
arylation of imines using electronically and sterically-modified chiral diene ligands. 73 
Fortunately, the corresponding diarylmethylamines were synthesised in high yield and 
high enantioselectivity using only 0.3 mol% of rhodium catalyst (Scheme 1.52). The 
results clearly demonstrated that arylation of imines can be successful employing a very 
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Scheme 1.53: Rhodium(I)-catalysed alkenylation and arylation of N-tert-butanesulfinyl 
aromatic and aliphatic imines. 
Brak and Ellmann studied the rhodium(I)-catalysed addition of alkenyl and aryl 
boronates to chiral N-tert-butanesulfinyl aromatic and aliphatic imines (Scheme 1.53). 
The reaction proceeded with high yields and very high diastereoselectivity. In 
comparison with using trifluoroborate reagents, MIDA boronates (slow release boronic 
acids) gave higher yields and selectivities in the addition to aromatic imines. This new 
method represents a versatility of the rhodium(I)-catalysed nucleophilic addition of 
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boron reagents to electrophiles which could be used for the synthesis of chiral 
α-branched amines.74 
In 2011, the rhodium-catalysed asymmetric addition of potassium organotrifluoroborates 
to both N-tosyl and N-nosyl ketimines was further developed by Hayashi and 
co-workers.75 To solve the problem of the requirement of tetraarylborates to effectively 
promote the reaction in previous works,68,69,72,73 the readily available potassium 
organotrifluoroborates were employed as the nucleophile. High enantioselectivity was 
achieved by using a chiral diene ligand 187 (Scheme 1.54). The nosyl group of the 
chiral products could be easily removed without erosion of enantiopurity. 
[RhCl(ligand 187)]2 (2.5 mol%)
MeOH (3 equiv)






















Scheme 1.54: Rhodium-catalysed arylation of ketimine 185. 
Furthermore, cyclic imines such as cyclic N-sulfonyl ketimines are also a very good 
source of prochiral substrates for the rhodium-catalysed asymmetric arylation with 
arylboroxines.76 Utilising chiral diene ligand 191, the triarylsubstituted stereogenic 
carbon centre of the resultant benzosultam 192 was produced with high yield and high 
enantioselectivity. Importantly, the chiral benzosultam 192 was easily transformed into 




Scheme 1.55: Rhodium-catalysed asymmetric arylation of the cyclic imine 189. 
Concurrently, Hayashi reported the rhodium-diene complex catalysed asymmetric 
arylation of cyclic N-carbonyl ketimines resulting in isoindolin-1-ones bearing a triaryl-
substituted stereogenic carbon centre (Scheme 1.56). The cyclic ketimines were 
generated in situ by the dehydration of hemiaminols with arylboroxines. Arylboroxine 
158 was used with a dual propose; as a dehydrating reagent to generate ketimine 197, 
and as an arylating reagent.77 
 
Scheme 1.56: Rhodium-catalysed arylation of 3-aryl-3-hydroxyisoindolin-1-ones. 
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Two weeks later the Xu group published the rhodium-catalysed asymmetric arylations of 
cyclic ketimines using simple sulphonamide-based olefin ligands. Both 5- and 
6-membered N-sulfonyl ketimines containing ester, CF3 or aryl substitutents were 
successfully arylated to generate benzosultams and benzosulfamidates. This is the first 
example of the use of a sulphur-olefin ligand 201 in asymmetric nucleophilic addition of 
imine substrates (Scheme 1.57).78 
 
Scheme 1.57: Rhodium-catalysed arylation of cyclic imines using sulfonamide-based 
branched olefin ligand. 
The scope of cyclic substrates for the rhodium-catalysed arylation was expanded from 
N,N- or N,O-5-membered ring ketimines. The results showed that the asymmetric 
arylation proceeded smoothly in the presence of a rhodium catalyst coordinated with 
chiral diene ligands to give high yields and stereoselectivities of sulfamidates and 




Scheme 1.58: Rhodium-catalysed arylation of cyclic imines. 
Recently, Lin and co-workers developed the enantioselective rhodium-catalysed 
1,2-addition of arylboronates to cyclic N-sulfamidate alkylketimines.80 Despite low 
yields, high enantioselectivities and broad functional group tolerance were observed for 
this reaction. Furthermore, the resulting sulfamidates could easily be reduced, providing 




 Scheme 1.59: Rhodium-catalysed arylation of cyclic imines using ligand 215. 
1.3.2 Rhodium-Catalysed Alkenylation 
Following the report by Brak and Ellmann the rhodium-catalysed asymmetric 
alkenylation of chiral auxiliary imine substrates,74 there has been no further discription 
of this reaction employing chiral catalysts to control stereoselectivity. However, in 2011, 
Hayashi and co-workers demonstrated a rhodium-catalysed asymmetric addition of 
potassium organotrifluoroborates to both N-tosyl and N-nosyl ketimines. In terms of 
arylation high enantioselectivity was achieved by using a chiral diene ligand 187 
(Scheme 1.54). Importantly, one example of an alkenylation reaction was revealed with 
high yield and enantioselectivity (Scheme 1.60).75 
 




Enantioselective alkenylation of imines using potassium alkenyltrifluoroborates was 
investigated by Lam and co-workers in 2012.81 With the use of rhodium-chiral diene 
catalysts, both acyclic and cyclic imine substrates were alkenylated and it was found that 
acyclic imines gave low yields and enantioselectivities. Fortunately, high yields and 
excellent enatioselectivities were observed when cyclic imines were employed 
(Scheme 1.61). Moreover, it was reasonalised that the cyclic structure of these imines, in 
which the C=N bond is constrained in the Z geometry, is crucial for the success of the 
reactions. 
 
Scheme 1.61: Rhodium-catalysed asymmetric alkenylation of 5- and 6- membered 
cyclic imines. 
A year later, Wu and co-workers investigated a rhodium-catalysed enantioselective 
addition of various potassium alkenyltrifluoroborates to acyclic aryl aldimines in the 
hope that the problem of using acyclic imines will be resolved. This is the first 
preparation of chiral allylic N-tosyl amines via the asymmetric 1,2-addition of potassium 
alkenyltrifluoroborates to N-tosyl arylaldimines. Generally, the enantioselective 
alkenylation reaction proceeded smoothly in a highly enantioselective manner to provide 
optically active allylic N-tosyl amines in good yields. The reaction was tolerant of 
unprotected alcohol and ester functionality in the nucleophile as well as various 




Scheme 1.62: Rhodium-catalysed asymmetric alkenylation of acyclic imine 61. 
 
Scheme 1.63: Rhodium-catalysed asymmetric alkenylation of acyclic imine using ligand 
215. 
Recently, an enantioselective rhodium-catalysed addition of potassium 
alkenyltrifluoroborates to N-nosylaldimines was reported by Lin and co-workers.83 The 
reaction displayed a broad scope with respect to both imine substrates and alkenylborate 
partners (Scheme 1.63). This provided a simple, reliable, and scalable method for the 
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modular synthesis of chiral α-branched allylic amines. To demonstrate the utility of this 
method the concise formal synthesis of (−)-aurantioclavine was achieved (233). 
1.3.3 Rhodium-Catalysed Methylation 
Hayashi and co-workers demonstrated the first example of an asymmetric 
rhodium-catalysed methyl-transfer reaction of N-tosylimines with dimethylzinc.84 The 
methylation reaction proceeded with reasonable yield and high enantioselectivity in the 
presence of a chiral diene-rhodium catalyst (Scheme 1.64). The proposed mechanism 
was that the reaction of [Rh(diene)Cl]2 with dimethylzinc generates a methylrhodium 
species, which then adds to the C=N bond to form an aminorhodium species. This 
aminorhodium species undergoes the σ-bond metathesis with Me2Zn to regenerate the 
methylrhodium species and to produce the methylated product as a zinc amide. 
 
Scheme 1.64: Rhodium-catalysed methylation of acyclic imines. 
Six years later, the same research group reported the rhodium-catalysed asymmetric 
methylation of N-sulfonylarylimines using trimethylboroxine 237 as a methylating 
agent.85 The result showed that a hydroxorhodium complex coordinated with the chiral 
diene ligand 195 had a high catalytic activity, and chiral 1-aryl-1-ethylamines were 




Scheme 1.65: Rhodium-catalysed asymmetric methylation of the N-tosylate imine 157. 
The first enantioselective rhodium-catalysed 1,2-addition of methyl- and arylaluminum 
reagents to cyclic α,β-unsaturated N-tosyl ketimines was developed by von Zezschwitz 
and co-workers (Scheme 1.66).86 Depending on the solvent and substituted groups on 
the ring of the imines, the reaction occurred in either 1,2- or 1,4-manner. In terms of 
1,4-addition, 3-substituted cycloalkyl amines were obtained in modest to high yields and 
excellent enantioselectivities after subsequent reduction of addition products. 
 
Scheme 1.66: Rhodium-catalysed asymmetric methylation of cyclic imines. 
In summary, a number of rhodium-catalysed enantioselective additions of nucleophiles 
to prochiral imines have been developed. With the use of organoboron reagents, chiral 
amines are generated with high yields and high levels of selectivities. Although this 
research area is widely studied by many research groups it is still challenging to find a 
new mode of catalysis for rhodium. The most recent contribution to the field from the 
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Lam group: the enantioselective addition of allylboron reagents to imines under rhodium 
catalyst, is presented in Section 1.5. 
1.4 Aims and Approach 
For decades, numerous examples of using rhodium-catalysts in asymmetric synthesis 
have been reported.87,88 Furthermore, plenty of work mentioned in the previous sections 
outlines the advantages of rhodium and organoboron reagents in generating 
enantioenriched chiral amines. However, to date, the field of rhodium-catalysed 
enantioselective nucleophilic addition to imines has been dominated by the addition of 
arylboron reagents, although there are some reports of additions of alkenylboron and 
methylboron reagents. Regardless the crucial importance of nucleophilic allylations in 
synthesis,8a,89 the rhodium(I)-catalysed enantioselective additions of allylboron reagents 
to electrophiles have not been described before.  
To the best of our knowledge, enantioselective rhodium-catalysed nucleophilic 
allylations are limited to additions of allylstannanes to aldehydes (where a chiral 
rhodium(III) complex functions as a Lewis acid), and cyclisations of allylrhodium 
species generated by additions to allenes.90 Also there are a number of examples of the 
rhodium-catalysed isomerisation of alkenylboron reagents into allylboron reagents 
followed by in situ racemic allylation of aldehydes,91 and the rhodium-catalysed redox 
allylation of ketones with allyl acetate and bis(pinacolato)diboron.92  
This chapter will focus on using rhodium as an asymmetric catalyst to allylate both 
acyclic and cyclic imines and using allylboron as an allylating reagents. Hopefully, the 
homoallylic chiral amines will be achieved in high yield and high enantioselectivity. 
Also, the applications of this chemistry will be conducted to demonstrate the utility of 
this new area of rhodium catalysis. 
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1.5 Results and Discussions 
Rhodium catalysed enantioselective allylation to imine is a new concept in asymmetric 
synthesis using rhodium catalysts. Therefore, in order to achieve our goal, several 
acyclic and cyclic imine starting materials; allyltrifluoroborates in combination with 
chiral ligands were investigated in Section 1.5.1. The reaction mechanism will be 
discussed in Section 1.5.2, followed by the manipulations of allylation products which 
will be demonstrated in Section 1.5.3. 
1.5.1 The rhodium-Catalysed Enantioselective Allylation of Cyclic 
Imines 
In order to attempt to realise the goal of developing a rhodium-catalysed asymmetric 
allylation of imine, a range of imine substrate were screened to analyse whether any 
allylation reaction would occur with a rhodium catalyst. The first attempts were focussed 
on the allylation of various benzaldehyde-derived imines using 2 equivalents of 
potassium allyltrifluoroborate (243)93 in the presence of 2.5 mol% of [{Rh(cod)Cl}2] 
and 5 equivalents of MeOH in dioxane at 80 ºC (Table 1.1). Unfortunately, satisfactory 
results were not obtained, with N-phenyl and N-diphenylphosphinoyl imines 96 and 138, 
more than 95% of starting material was recovered (Table 1.1, entries 1 and 2), whereas 
with dimethylsulfamyl imine 244 trace quantities of the allylation product were observed 
(Table 1.1, entry 3). With reactive N-sulfonylimines 61 and 150a, more than 25% of 
homoallylic sulfonamides were obtained, but significant quantities of starting cyclic 
imine remained, along with benzaldehyde (246) resulting from imine hydrolysis 
especially from the more reactive N-Ns imine the benzaldehyde (246) was observed up 






Table 1.1: Rhodium-catalysed allylation of benzaldehyde-derivative imines 
 
Entry R S (%)[b] 245 (%)[b] 246 (%)[b] 
1 Ph (96) >95 <5 <5 
2 P(O)Ph2 (138) >95 <5 <5 
3 SO2NMe2 (244) 85 5 10 
4 Ts (61) 60 25 15 
5 Ns (150a) 42 28 30 
[a] Reactions were conducted by Hamish B. Hepburn using 0.10 mmol of S. [b] Determined by 1H NMR 
analysis of the crude reaction mixtures.  
In accordance with a recent discovery by Lam and co-workers,81 cyclic imines (which 
has a constrained geometry) were found to be highly effective substrates for 
enantioselective rhodium-catalysed alkenylations, the allylation of benzoxathiazine-2,2-
dioxide 202a was investigated (Table 1.2) using the same reaction conditions employed 
in Table 1.1. The results showed that the imine was consumed completely after 3 h to 
afford a desired product in 87% yield upon isolation (Table 1.2, entry 1). Several chiral 
ligands (Figure 1.3) were examined and it was found that the use of (R)-binap 160 was 
totally ineffective showing only less than 5% conversion (Table 1.2, entry 2). Chiral 
diene 247,73 however, provided a superior result with 60 % conversion and 67 % ee 
(Table 1.2, entry 3). In terms of the other five chiral dienes, fortunately, most of them 
produced reasonable yields and selectivities (Table 1.2, entries 4-8). Especially the use 
of 2.5 mol % of [{Rh(221)Cl}2],81,94 the percent conversion was greater than 95% and 
homoallylic amine 251a was obtained with excellent enantioselectivity (Table 1.2, 
entry 8). These results from both Tables 1.1 and 1.2 clearly demonstrated that both the 
cyclic imine and diene ligand 221 was required to facilitate an efficient allylation 
reaction. To highlight the importance of potassium allyltrifluoroborate (243) for this 
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reaction, allylboronic acid pinacol ester (106) (with the addition of aqueous 0.5 
equivalents of K3PO4), was used instead. It showed that this allylboronic acid pinacol 
ester (106) had no effect on the reaction conversion but adversely affected the 
enantioselectivitiy. The reasons for this diminished enantioselectivity are not clear but a 
non-rhodium-catalysed alternative pathway is most likely to be the cause of such a loss 
of stereoselectivity. 
 







Table 1.2: Rhodium-catalysed allylation of imine 202a.[a]
 
Entry [Rh] (2.5 mol%) Ligand (5 mol%) Conv (%)[b] ee (%)[c] 
1 [{Rh(cod)Cl}2] None >95[d] - 
2 [{Rh(C2H4)Cl}2] 160 <5 - 
3 [{Rh(C2H4)Cl}2] 247 60 67 
4 [{Rh(C2H4)Cl}2] 248 85 50 
5 [{Rh(C2H4)Cl}2] 249 35 55 
6 [{Rh(C2H4)Cl}2] ent-159 95 −82 
7 [{Rh(C2H4)Cl}2] 250 89 87 
8 [{Rh(221)Cl}2] None >95 93 
9[e] [{Rh(221)Cl}2] None >95 28 
[a] Reactions were conducted by Hamish B. Hepburn using 0.10 mmol of 202a. [b] Determined by 
1H NMR analysis of the crude reaction mixtures. [c] Determined by HPLC analysis on a chiral stationary 
phase. [d] rac-251a isolated in 87 % yield. [e] AllylBPin 106 with K3PO4 was used instead of allylBF3K 
243. 
With an effective ligand identified, the scope of this process was investigated under 
slightly modified reaction conditions. Both 5 and 6-membered cyclic imines, namely 
benzoxathiazine 2,2-dioxides, 1,2,6-thiadiazine 1,1-dioxides, 1,2,5-thiadiazolidine 
1,1-dioxides, cyclic sulfamidates and cyclic N-sulfonylketimines, underwent 
enantioselective allylation as shown in the following sections. 
Firstly, for the use of 1.5 mol % of [{Rh(221)Cl}2] and MeOH (5 equivalents) in a 
THF/dioxane mixture at 55 °C, a wide range of 6-membered ring N,O-aldimines 
underwent allylation in generally good yields (79-97%) and good enantioselectivities 
(91-98%). Although, in some cases such as halogen- or cyano-substituted 
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benzoxathiazine-2,2-dioxides, longer reaction times and the use of i-PrOH 
(13 equivalents) in toluene/dioxane rather than MeOH in THF/dioxane were required for 
the yields and enantioselectivities to be high (Table 1.3). 
Table 1.3: Enantioselective rhodium-catalysed allylation of 6-membered ring 
N,O-aldimines.[a] 
 
[a] Reactions were conducted by Dr Yunfei Luo and Hamish B. Hepburn. [b] Using i-PrOH 
(13 equiv) in toluene/dioxane for a reaction time of 18 h. 
N,N-Cyclic aldimines such as 1,2,6-thiadiazine-1,1-dioxides 252a-252c, also underwent 
allylation. Although the stereoselectivities were high (90-95%) in all cases studied, the 
yields were disappointingly modest (45-69%). Moreover, chiral adduct 254a was not 
bench-stable and exhibited signs of decomposition after ca. 2 h. The allylation of 
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ketimine 253c was also carried out, which did not undergo allylation to generate 255c 
due to the steric hindrance of the methyl group (Table 1.4). 
Table 1.4: Enantioselective rhodium-catalysed allylation of 6-membered ring 
N,N-imines. 
 
  [a] the reaction was set at 0.1 mmol scale and run for 24 h. 
Surprisingly, 1,2,6-thiadiazine-1,1-dioxide 253a can be allylated and the allylation 
occurred at the β-position of this α,β-unsaturated imine. The yield was low (33%) and 
enantioselectivity was modest (65% ee). The reason why the nucleophile attacked at this 
position is unclear, but it could be because compound 253a can isomerise to aldimines 
253d and 253e which can possibly undergo nucleophilic allylation to form the product 
255a (Scheme 1.67). This hypothesis was supported by the allylation of benzyl 
protected imine 253b by using the standard reaction conditions. Unsurprisingly, as this 
substrate is unable to generate aldimine isomers, no allylated product 255b was observed 





Scheme 1.67: Rhodium-catalysed allylation of an imine 253a. 
Not only 6-membered ring cyclic ketimine 253c but 5-membered ring cyclic ketimines 
such as 1,2,5-thiadiazolidine-1,1-dioxides (256a-256c), cyclic N-sulfonylketimines 
(219a-219c) and a cyclic sulfamidate imines (213a and 213f) were  also investigated 
(Table 1.5). Most of N,N- and N,O-5-membered ring cyclic ketimines underwent 
allylation to give homoallylic amines with high yields and enantioselectivities. However, 
bulky ketimines 256c and 213f did not convert to products 257c and 259b under the 
same conditions. All cyclic N-sulfonylketimines (219a-219c) were effective substrates. 
Methyl- and butyl-substituted ketimines underwent allylation with potassium 
allyltrifluoroborate (243) to give benzosultams 258a and 258b, respectively, with 
moderate yields (57% and 64%) and with high enantioselectivities (96% ee). It was clear 
that the allylations of sulfonylketimine 219c containing electron-withdrawing substituent 







Table 1.5: Enantioselective rhodium-catalysed allylation of 5-membered ring imines. 
 
[a] Reactions were conducted by Hamish B. Hepburn. [b] With reaction time of 12 h. [c] Reaction 
was conducted by Dr Yunfei Luo using dioxane in place of THF. [d] Using [RhCl((ent-221)]2 in 
place of [RhCl((R)-221)]2  with reaction time of 15 h. 
As previously discussed in Table 1.3, benzoxathiazine 2,2-dioxides containing 
electron-withdrawing substituents on the benzene ring were allylated with higher 
enantioselectivities when i-PrOH in toluene/1,4-dioxane was used instead of MeOH in 
THF/1,4-dioxane. However, application of this modified condition to the synthesis of 
product 258c did not improve the enantioselectivity. 
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The allylation of cyclic imines 202a and 256b with E-and Z-crotyltrifluoroborates were 
also studied (Table 1.6). Under the standard reaction conditions, the results showed that 
a new carbon-carbon bond formation took place at the more substituted γ carbon atom of 
the allyltrifluoroborates. E-Crotyltrifluoroborate 260 underwent highly 
diastereoselective allylations to 202a and 256b to afford anti products 261a and 262a, 
respectively, with reasonable yields. Importantly, Z-crotyltrifluoroborate (260) resulted 
in the corresponding syn products 261b and 262b with high yields and 
enantioselectivities. Unfortunately, the diastereomeric ratio in the case of 261b was 
reduced to 6:1. 
 Table 1.6: Allylation of cyclic imines with various E- and Z-crotylltrifluoroborates.[a]  
 
[a] Reactions were conducted by Hamish B. Hepburn. [b] Yield of an isolated inseparable mixture of 





Table 1.7: Reaction of imines with the monosubstituted allyltrifluoroborates.[a] 
 
[a] Reactions were conducted by Hamish B. Hepburn. [b] Using [RhCl((R)-221)]2 in place of 
[RhCl(ent-221)]2. [c] Reaction conducted using i-PrOH (5 equiv) in toluene-1,4-dioxane instead of 
MeOH in THF-1,4-dioxane  
Similar to E-crotyltrifluoroborates, γ-n-propyl-substituted allyltrifluoroborate (263) and 
γ-phenyl-substituted allyltrifluoroborate (264) generally afforded products with high 
yields, diastereo- and enantioselectivities except with products 269 and 272 that gave 
moderate yields (61% and 48% respectively). Exploiting the results mentioned in the 
previous section, the use of i-PrOH (5 equiv) in toluene/1,4-dioxane provided higher 
enantioselectivities compared with the standard reaction conditions of MeOH (5 equiv) 
in THF/1,4-dioxane, products 267-268 were synthesised with high yields and high 
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enantioselectivities. β-Methyl-substituted allyltrifluoroborate (265) reacted with both 
aldimines 202a and ketimine 256b as well as ketimine 219a to give products with high 
enantioselectivities, the yield were lower in the reaction with aldimines 202a and 
ketimine 219a (65% and 56%), although product 268 was generated via the use of 
i-PrOH in toluene/1,4-dioxane (Table 1.7). 
In order to gain some insight into the mechanism of these processes, ketimine 256b was 
allylated by dideuterated potassium allyltrifluoroborate 243a (Scheme 1.68).95 It was 
found that products 257d and 257e (1:1 mixture) were obtained in 88% yield. This result 
suggests that allylation proceeds via an allylrhodium(I) species which undergoes rapid 
interconversion between the two σ-allyl haptomers 275a and 275b.96. If the rhodium did 
not form an allyrhodium species and the reaction proceed via another mechanism, then 
only product 257e would be formed.8a,89 
 
[a] Reaction was conducted by Dr Yunfei Luo. 
Scheme 1.68: Deuterium-labelling experiment.[a] 
Previously, all of the allylboron reagents that had been studied featured the boron atom 
connected to a primary carbon atom. In all cases it was clear that C−C bond formation 
occurred exclusively at the γ-carbon of the allyltrifluoroborates. It was important, 
therefore, to examine the reactions using racemic α-methyl-substituted 
allyltrifluoroborate (276), where the boron is bonded to a secondary carbon atom. 
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Through deuterium experiments, it was speculated that these allylations proceed via the 
intermediacy of allylrhodium species. In agreement with this hypothesis, transmetalation 
of rac-276 with the chiral rhodium complex could therefore, in principle, lead to several 
interconverting isomeric allylrhodium species (277a-277c). Reactions of these reactive 
species with imine 219a would provide three different products (Scheme 1.69). 
However, it was unclear whether the γ-selectivity observed previously would be 
maintained using rac-276. 
 
Scheme 1.69: Possible outcomes of reactions using α-methyl-substituted 
allyltrifluoroborate (276). 
 
[a] The reaction was conducted by Hamish B. Hepburn. 




After the reaction was conducted using imine 219a and rac-276 under standard reaction 
conditions, it was found that diastereomeric products 278b and 278c were obtained with 
excellent enantioselectivities. Surprisingly, C−C bond formation only occurred at the 
α-carbon of rac-276 and other isomeric products such as 278a where C−C bond was 
formed at γ-carbon of rac-276 were not observed (Scheme 1.70). 
The above result not only provided further evidence that these allylations proceeded via 
allylrhodium intermediates, but also indicated that the contributions of these three 
allylrhodium species to the allylation of imine are different. Clearly, the greatest 
contribution is by E-crotylrhodium species 277b, followed by Z-277c, while the 
contribution of 277a is negligible. If there is a rapid interconversion between the 
different allylrhodium species compared with the imine allylation rates, the product ratio 
will only depend upon the relative rates of allylation from E-277b, 277a, and Z-277c, 
and not upon their equilibrium distribution (Curtin–Hammett-type kinetics).97 However, 
the allylations of imine 202a using E- and Z-crotyltrifluoroborates (260) brought about 
the high degrees of stereochemical transfer (see Table 1.6). This result suggests that the 
isomerisation between E-277b and Z-277c is slow compared with the rate of imine 
allylation. Therefore, regarding the allylation of imine 219a with rac-276 in similar 
scenario it is likely that the ratio of 278b and 278c obtained relies significantly on the 
ratio of E-277b and Z-277c formed in the initial transmetallation. 
In addition to providing further evidence that the ratio of allyation products from imine 
219a is dependent on the ratio of allylrhodium species, allylations of imines 202a and 
256b with rac-276 were investigated. It was found that similar outcomes were observed, 
in the case of imine 202a, two diastereomers ent-279a and ent-279b were obtained as an 
inseparable 2.3:1 mixture with 60% combined yield, and with 93% ee and 97% ee, 
respectively. With imine 256b, the two separable products 280a and 280b were isolated 




Table 1.8: Reaction of cyclic imines with the α-methyl-substituted allyltrifluoroborate 
276.[a]  
[a] Reactions were conducted by Hamish B. Hepburn. 
To show an example of a disubstituted allyltrifluoroborate containing substituent at both 
the α- and γ-carbons, allylation with cyclohexenyltrifluoroborate 281 was studied. The 
result showed that the reaction between this reagent and aldimine 202a provided a 
product 284 with only 36% yield, though with good diastereo- and enantioselectivity. 
Moreover, with ketamine 256b the allylation was unsuccessful, and provided a complex 
mixture of unidentified products (note it was known that substrate 256b is unstable 
under the reaction conditions, and if rhodium-catalysed allylation does not occur, it was 
found that no starting material or product was present in the resultant reaction mixture). 
In terms of γ,γ-dimethyl-substituted allyltrifluoroborate 282, the allylation with both 
imines 202a and 256b delivered reverse prenylation products with high yields and 
excellent selectivities. Similarly, allylation of α,α-dimethyl-substituted 
allyltrifluoroborate (283) with imines 202a and 256b, resulted in reverse prenylation 
products 286b and 287b with reasonable yields and with high enantioselectivities, where 
the C−C bond formed exclusively at the α-carbon (Table 1.9).  
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Table 1.9: Reaction of imines with the disubstituted allyltrifluroborates[a] 
 
[a] Reactions were conducted by Hamish B. Hepburn. [b] Using [RhCl((R)-221)]2 in place of 
[RhCl(ent-221)]2. [c] Reaction conducted using i-PrOH (5 equiv) in toluene/1,4-dioxane instead 
of MeOH in THF-1,4-dioxane. 
According to the interesting result mentioned above, for both allyltrifluoroborates 283 
(α-selectivity) and 282 (γ-selectivity) the reverse prenylation products were isolated. 
This result suggests that allylation proceeds via the reactive allylrhodium species 288a 




Scheme 1.71: Allylrhodium species from allyltrifluoroborates 282 and 283. 
Other Reactive Substrates 
In addition to the imine substrates described in the previous sections, ketimine 203 
containing a trifluoromethyl group was also investigated. This imine underwent 
allylation with allyltrifluoroborate (243) in 85% yield, but unfortunately the product 289 
was obtained as a racemate (Scheme 1.72). 
 
Scheme 1.72: Allylation of imine 203. 
Under the standard reaction conditions imine 290 did not react with allyltrifluoroborate 
(243). However, when substoichiometric amount of t-BuOK base was added imine 290 
underwent full conversion to provide homoallylic amine 257d with 80% yield 
(Scheme 1.73). Again, disappointingly, it was obtained as a racemate. Presumably under 
strong basic conditions imine 256d is generated in situ by de-ethoxylation of 
pro-diimine 290. Then, the resulting imine 256d is allylated by allyltrifluoroborate (243) 
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to afford 257e, which can easily undergo tautomerisation to provide racemic compound 
257d. 
 
Scheme 1.73: Rhodium-catalysed allylation of an imine 290. 
Other Unreactive Substrates 
Although most substrates underwent allylation very well, some of these compounds such 
as acyclic imines and cyclic enamides shown in Figure 1.4 were unreactive under 
standard allylation conditions. 
 
Figure 1.4: Unreactive substrates. 
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1.5.2 Mechanistic Discussion 
Owing to the fact that E- and Z-crotyltrifluoroborates (260) provided anti- and 
syn-allylation products (261a and 261b respectively), with good to high 
diastereoselectivities (Table 1.6), it is likely that the reaction proceeds via 6-membered 
cyclic transition states. The corresponding allylrhodium(I) intermediates have 
appreciable configurational stability during their lifetime in the reaction mixture despite 
the possibility of rapid interconversion between the two σ-allyl isomers, a process which 
could erode E/Z stereochemistry.96,98 On the basis of these features, a plausible catalytic 
cycle of the allylation reaction has been proposed (Scheme 1.74). Presumably, in the 
presence of MeOH, potassium allyltrifluoroborate (243) can undergo reversible 
methanolysis to generate an ate-complex 297, which transmetallates with the rhodium 
complex 298a to form the allylrhodium species 298b. This species can then coordinate 
with imine 299 in a manner that gives less steric hindrance to afford complex 298c. 
Allylation of the bound imine in 298c through a cyclic chair-like transition state would 
give 298e, which is then protonated with HX to release the product 300 and regenerate 
298a. 
 
Scheme 1.74: Possible catalytic cycle. 
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1.5.3 Derivatisation of the Resultant Enantioenriched Homoallylic 
Amines 
To demonstrate the utility of this methodology, representative transformations of 
allyation products were conducted as shown below. For example, removal of the 
sulfonyl group of compound 251a was readily accomplished over two steps. Firstly, the 
treatment of cyclic compound 251a with LiAlH4 generated the amine adduct. This was 
followed by the in situ protection of the resultant amine with Boc2O to provide 
Boc-protected amine 301 in 85% overall yield with retained stereochemistry 
(Scheme 1.75). 
 
Scheme 1.75: Removal of the sulfonyl group of homoallylic amine 251a. 
 
[a] Reaction was conducted my Hamish B. Hepburn. 
Scheme 1.76: Conversion of ent-251a into amine 304. 
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The hydroboration of the alkene of ent-251a (prepared in the same way as compound 
251a but using chiral diene ent-221) using 9-BBN provided primary alcohol 302 with 
reasonable yield. Further transformations provided tricyclic sulfamate 303 via a 
Mitsunobu cyclisation (Scheme 1.76). The resulting tricyclic sulfamate 303 then 
underwent a nickel-catalysed Kumada coupling with hexylmagnesium bromide, using 
the sulfamide moiety as a pseudo-halide to provide chiral 2-substituted pyrroldine 304 
with 78% yield. 
Alternatively, treatment of 302 with LiAlH4 to remove the sulfonyl group followed by 
Boc protection provided carbamate 305 in 75% yield. This compound was successfully 
converted into the tetrahydrobenzoxepine 306 by a Mitsunobu cyclisation. Interestingly, 
amino-substituted tetrahydrobenzoxepines have been found to exhibit interesting 
biological activities. A study by Fescal and co-workers,99 for example, showed that 
compound 307 is a strong ACAT (acyl coenzyme A, cholesterol O-acyltransferase) 
inhibitor (Scheme 1.77). 
 
Scheme 1.77: Conversion of 302 into amino-substituted tetrahydrobenzoxepine 306. 
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A diastereoselective reduction of imine ent-257b (prepared as the same way as 
compound 257b but using chiral diene ent-221 instead of (R)-221) was investigated. A 
range of different reducing agents was screened to enable good diastereomeric ratios to 
be achieved (Table 1.10). Pleasingly, with the use of DIBAL-H at –20 °C, chiral adduct 
308 was obtained in 90% yield as a single observable diastereomer with no erosion of 
enantioselectivity (entry 8). 












1 NaBH4 THF 0 15 100 3:1 
2 LiAlH4 THF 0 15 100 6:1 
3 LiBHEt3 THF 0 15 100 2:1 
4 DIBAL-H THF 0 15 100 15:1 
5 DIBAL-H THF –5 to r.t. 15 100 18:1 
6 DIBAL-H THF –78 to r.t. 15 30 - 
7 DIBAL-H THF –20 to r.t. 15 100 36:1 
8[b] DIBAL-H THF –20 to r.t. 15 100(90) 36:1 
[a] Reactions were conducted using 0.05 mmol of ent-257b and 0.2 mmol of reducing agent which 
% conversions were determined by 1H NMR analysis of the unpurified reaction mixtures. [b] Reaction 
was conducted using 0.8 mmol of ent-257b to give product 308 in 90% isolated yield. 
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Finally, the removal of the sulfonyl group of compound 308 by heating in hydrazine 
solution was unsuccessful. Fortunately, when ethylenediamine (10 equiv) in 1,4-dioxane 
was used, 1,2-diamine 309 was achieved with 88% yield (Table 1.11, entry 3). 
Table 1.11: Removal of sulfonyl group of compound 308.[a] 
 






1 NH2NH2·H2O - 100 15 100[b] 
2 NH2CH2CH2NH2 1,4-dioxane 100 15 100 
3[c] NH2CH2CH2NH2 1,4-dioxane 100 15 100(88) 
[a] Reactions were conducted using 0.1 mmol of 308 and 1 mmol of reducing agent, % conversions were 
determined by 1H NMR analysis of the unpurified reaction mixtures. [b] 1H NMR result of crude mixture 
was very messy. [c] Reaction was conducted using 0.4 mmol of 308 to give product 309 in 88% isolated 
yield. 
1.6 Conclusion and Future Studies 
In summary, rhodium-catalysed enantioselective allylation of imines has been studied 
and developed.100 Acyclic imines where imine-enamine tautomerisation takes place 
provide products in poor yields.  In contrast, cyclic imines where the C=N bond is 
constrained in the Z geometry, allow the reactions to proceed in generally good yields 
and high levels of diastereo- and enantioselectivities using chiral diene ligand. E- and 
Z-allyltrifluoroborates generate exclusively different stereoisomers possibly because the 
use of the chiral allylrhodium(I) intermediates have appreciable E/Z configurational 
stability during the time scale of allylation. Moreover C−C bond formation preferably 
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occurs at the more highly substituted end of the allyl fragment of the trifluoroborate, 
regardless of the position of the boron atom. To the best of our knowledge, these 
reactions represent the first rhodium-catalysed enantioselective nucleophilic allylations 
of π electrophiles with allylboron reagents. The utility of the allylation products was 
demonstrated by several transformations. 
In the future, the scope of nucleophilic boron reagents will be expanded in order to 
obtain complex and useful chiral products which are difficult to synthesise and also to 
understand more about the role of this rhodium catalyst in synthesis. For example, using 
potassium acyltrifluoroborate as nucleophilic reagents would result in chiral aminoacyl 
compounds (Scheme 1.78). 
 









2. Enantioselective Nickel-Catalysed Michael 
Additions of 2-Acetylazaarenes to 
Nitroalkenes 
2.1 Introduction to Azaarenes 
Azzaarenes; nitrogen-containing aromatic heterocycles, are ubiquitous structures in 
many chiral molecules.101 These important chemical units can be featured in naturally 
occurring compounds102 with biological properties such as Fuzanin D (310), Pateamine 
A (311) and Terezine A (312), drugs103 such as Viagra (313), Telaprevir (314) and 
Topotecan (315) or even pesticides104 such as Benzthiazuron (316) and nicotine (317) 
(Figure 2.1). Due to the exceptionally high significance of azaarenes, worldwide efforts 
have been made by many researchers to design and develop strategies for their synthesis. 
 
Figure 2.1: Biologically active compounds containing azaarenes. 
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There are many well established approaches for the synthesis of functionalised azaarenes 
such as transition metal-catalysed cross-coupling reactions,105 Friedel−Crafts 
alkylations106 and C−H functionalisation,107 which are robust and often high yielding. 
However, most of them frequently lead to achiral or racemic products (Scheme 2.1). 
Therefore, the catalytic asymmetric functionalisation of azaarenes to generate optically 
active compounds is significantly challenging in organic synthesis and of great 
importance. 
 
Scheme 2.1: Non-asymmetric functionalisation of azaarenes. 
In this regard, a huge number of organic compounds have been studied in terms of 
biological activities especially those containing chiral carbon stereocentres.  However, to 
the best of our knowledge, chiral molecules containing both azaarenes and all-carbon 
quaternary stereocentres are rarely synthesised or explored. Signifying its importance; 
more than 12% of the top 200 prescription drugs sold in the US in 2011 comprised of 
pharmaceutically active molecules containing a quaternary stereocentre.108 This suggests 
that molecules bearing quaternary carbons may be useful in terms of medicinal 
properties and synthesising them in a controlled manner is a significant challenge. Thus, 
in the next Section 2.2, the synthesis of chiral compounds containing all-carbon 
quaternary stereogenic centre is discussed. 
2.2 Chiral All-Carbon Quaternary Stereocentre Synthesis by 
Michael Reaction 
For several decades, impressive progress have been made in the field of enantioselective 
synthesis of all-carbon quaternary stereocentres.109 According to comprehensive reviews 
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by Overman110 and others111 there are many categories of these transformations; 
cycloaddition reactions, polyene cyclisations, metal-catalysed insertions, reaction of 
carbon nucleophiles, reaction of carbon electrophiles and desymmetrisation etc. 
However, it is too broad to cover all of these approaches here. In this section, only some 
important examples of all-carbon quaternary stereocentre syntheses by Michael reactions 
will be discussed. 
The Michael addition is one of the most important carbon-carbon bond-forming 
reactions in organic synthesis.112 Historically, the pioneering study of the transition 
metal-catalysed Michael reaction to generate chiral quaternary carbons was studied by 
Ito and co-workers in 1992.113 Utilising a catalytic complex generated in situ from 
trans-chelating chiral diphosphine ligand 320 and [RhH(CO)(PPh3)3], vinyl ketones and 
acroleins reacted with α-cyanoesters to obtain chiral products containing all-carbon 
quaternary stereocentres in high yields and enantioselectivities (Scheme 2.2). 
 
Scheme 2.2: Rhodium-catalysed enantioselective Michael addition of 
α-cyanocarboxylate 318 to vinyl ketones. 
Sodeoka and co-workers described the generation of chiral palladium enolates of 
1,3-dicarbonyl compounds and its application to the efficient catalytic enantioselective 
Michael reaction with α,β-unsaturated ketones.114 With a novel palladium aqua complex 
catalyst 324, 1,3-dicarbonyl compounds were transformed to chiral dicarbonyl adducts 
with all carbon quaternary centres (Scheme 2.3). The unique mechanism proposed that 
the palladium aqua complex allows successive supply of a Brønsted base and a Brønsted 
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acid. The former activates the dicarbonyl compound to give the chiral palladium enolate 
and the latter cooperatively activates the enone. 
 
Scheme 2.3: Palladium-catalysed enantioselective Michael reaction with enones. 
Jacobsen and co-workers115 reported asymmetric Michael additions of electron-deficient 
nitrile derivatives to acyclic α,β-unsaturated carbonyl compounds catalysed by a chiral 
(salen)-aluminum complex 328. This catalyst tolerated a large variety of α-aryl and 
heteroaryl cyanoacetates with substituted enones or imides. Although the reaction of 
methyl cyanoacetate gave chiral products in a roughly 1:1 mixtures of diastereomers 
because α-cyanoester stereocentre undergoes epimerisation, the use of substituted 
cyanoacetates provided adducts containing carbon- and heteroatom-substituted 
quaternary stereocentres in high enantio- and diastereoselectivities (Scheme 2.4). 
Moreover, the authors believed that a simple one-point binding of carbonyl compounds 




Scheme 2.4: Enantioselective Michael additions to α,β-unsaturated carbonyls catalysed 
by a salen-Al complex 328. 
In recent years, organocatalysed Michael reactions have also been broadly studied to 
generate chiral all-carbon quaternary stereogenic centres. For example, Melchiorre and 
co-workers116 reported an intermolecular vinylogous Michael addition of unmodified 
cyclic β-substituted ketones to nitroalkenes promoted by diamine catalysts. Notably, the 
two stereocentres at the γ and δ positions of the carbonyl moiety were formed with very 
high levels of diastereo- and enantioselectivities (Scheme 2.5(a)). The reaction 
proceeded smoothly via γ-site-selective addition of β-substituted cyclohexanone 
derivatives to nitroalkene acceptors. When β-substituted nitroacrylate 338a was used the 





Scheme 2.5: Direct asymmetric vinylogous Michael addition of cyclic enones to 
nitroalkenes via dienamine catalysis. 
Kwiatkowski and co-workers developed an efficient high-pressure enantioselective 
organocatalytic 1,4-conjugate addition of nitroalkanes to prochiral β,β-enones.117 This 
approach worked successfully with various acyclic and cyclic enones to afford 
γ-nitroketones containing chiral all-carbon quaternary stereogenic centres (Scheme 2.6). 
The loading of simple chiral primary amine catalysts was only 1-5 mol%. This work 
demonstrates the significant effect of hydrostatic pressure on the rate of an 
organocatalytic reaction while the enantioselectivity was retained. 
 
[a] using a direct, single-stage piston-cylinder apparatus with a hydraulic press. 
Scheme 2.6: Organocatalytic asymmetric Michael reaction of enone 340. 
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In 2012, the asymmetric Michael addition of nitromethane to β-disubstituted 
α,β-unsaturated aldehydes was investigated using a resin-supported peptide catalysts.118 
The use of an aqueous solvent system was found to be essential for effective reactions in 
comparison with running the reaction in THF which afforded products with poor 
conversions. Moreover, the hydrophobic helical part of the peptide significantly affected 
the reaction rate and enantioselectivity. With the optimised peptide catalyst 344, highly 
enantioenriched products with all-carbon quaternary stereocentres were obtained with 
reasonable yields (Scheme 2.7). The report demonstrates the high potential of peptide 
catalysis for organocatalytic reactions, in which a conventional low molecular weight 
catalyst such as diphenylprolinol silyl ether (346) is ineffective. 
 
Scheme 2.7: Peptide-catalysed asymmetric Michael addition of nitromethane to 
β-disubstituted α,β-unsaturated aldehyde 343. 
As discussed above, there are many different approaches to obtain chiral compounds 
containing all-carbon quaternary stereocentres, either by using metal catalysts or 
organocatalysts. However, in terms of azaarenes bearing chiral all-carbon quaternary 
substituents, they are rarely investigated and explored. These compounds may serve as 
intermediates for the synthesis of complex target molecules. In order to highlight the 
importance of azaarenes in asymmetric Michael reactions, the use of azaarenes as 
activating groups in stereoselective transformations is discussed in Section 2.3. 
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2.3 Introduction to Heteroarenes as Activating Groups in 
Enantioselective Reactions 
Generally, chiral compounds containing azaarenes can be synthesised by using either 
catalytic asymmetric reactions or chiral auxiliaries.119-121 However, within most of those 
reports the azaarene acts as a nonparticipating bystander in a reaction. Therefore the 
development of methods that exploit or utilise the unique chemical properties of the 
azaarene itself to promote the reaction should provide powerful, complementary tools 
for synthesis. Interestingly, if the structure of an azaarene is considered carefully, it is 
found that this functional group is isoelectronic with respect to the carbonyl motif. For 
example, the C=N bond of azaarenes could mimic carbonyl (C=O) containing groups 
such as α,β-unsaturated carbonyl, 1,2-dicarbonyl and 1,3-dicarbonyl (Scheme 2.8). 
Therefore this section will provide an overview of the relevant literature demonstrating 
that azaarenes can activate both electrophiles and nucleophiles as shown below. 
 
Scheme 2.8: Azaarenes mimic carbonyl compounds. 
2.3.1 Azaarenes as Activating Groups for Electrophilic Additions 
The conjugate addition of a nucleophile to a C=C bond electrophile normally requires 
the alkene be activated by a range of π-electron withdrawing groups. Theoretically, C=N 
containing azaarenes can activate adjacent conjugated π-systems by withdrawing 
electron density from those unsaturated double bonds (Scheme 2.9). Using this concept, 
82 
 
several research groups have functionalised alkenylazaarenes with various nucleophiles 
although most of these works produced only achiral products.122 
 
Scheme 2.9: Electronic homology concept between α,β-unsaturated carbonyl motives 
and alkenylazaarenes. 
Conjugate Additions of Nucleophiles to Alkenylazaarenes 
In 1998, Houpis and co-workers123 reported a nickel catalysed conjugate addition of 
Grignard reagents to substituted alkenylpyridines (Scheme 2.10). Yields of the reaction 
were improved by the gentle heating from room temperature to 45 °C. Unfortunately, 
when the asymmetric version of these reactions were investigated by using chiral ligands 
such as bis-phosphines, diamines, bis-sulfonamides, aminoalcohols, and diols, 
unsatisfactory results were received (<15% ee). These results highlight the possibility 
the catalytic asymmetric conjugate addition of nucleophiles to alkenylazaarenes. 
 
Scheme 2.10: Nickel-catalysed conjugate addition of Grignard reagents to 
alkenylazaarene 347. 
A few years later, Lautens and co-workers124 developed an aqueous rhodium-catalysed 
coupling reaction of arylboronic acids and olefins. The aqueous conditions were crucial 
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for reactivity since the reaction was unsuccessful in organic solvents. Moreover, sodium 
dodecyl sulfate (SDS) and water soluble phosphine ligand were used as a phase transfer 
catalyst to generate products in high yield (Scheme 2.11). 
 
Scheme 2.11: Rhodium-catalysed conjugate addition of vinylazaarenes. 
In 2011, Yorimitsu and Oshima125 developed a cobalt-catalysed addition of 
alkenylboronic acids to 2-vinyl heteroarenes. It was found that the C=N of azaarenes 
adjacent to the vinyl group was crucial to promote the reaction. It is possible that the 
nitrogen accelerated the addition of the styrylcobalt species, generated by 
transmetalation, onto the vinyl double bond to give alkenylation products in modest 
yields. The reactions of other azaarenes or other heteroarenes were unsuccessful 
(Scheme 2.12). 
 
Scheme 2.12: Cobalt-catalysed conjugate alkenylation of 2-vinylazaarenes. 
Regarding an asymmetric conjugate addition, in 2009, Bernardi and Adamo126 reported 
an enantioselective Michael addition of nitroalkanes to 5-styrylisoxazoles such as 355 
with Cinchona alkaloid-derived organocatalyst 356. This work demonstrated a novel 
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family of nitroisoxazoles with dual activating groups in asymmetric Michael reaction of 
various nitroalkanes and 3-methyl-4-nitro-5-styrylisoxazoles (Scheme 2.13). 
 
Scheme 2.13: Organocatalysed asymmetric conjugate addition of nitroalkanes to 
β-substituted alkenylnitroisoxazoles. 
 
Scheme 2.14: Organocatalysed asymmetric conjugate addition of anthrone 359 to 
β-substituted alkenylnitroisoxazole 360. 
Similar to the work reported by Bernardi and Adamo, a simple and efficient method for 
the enantioselective 1,6-Michael addition reaction of anthrone 359 to a series of 
3-methyl-4-nitro-5-alkenyl-isoxazoles was reported by Yuan and co-workers127 
(Scheme 2.14). With the use of bifunctional thiourea-tertiary amine 360 as the catalyst, 
the transformation proceeded smoothly and resulted in Michael adducts with high yields 
(up to 99%) and enantioselectivities (up to 96% ee). 
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In 2010, Lam and co-workers studied an enantioselective rhodium-catalysed addition of 
arylboronic acid 363 to β-monosubstituted alkenylheteroarene 362.128 Chiral products 
containing heterocycles were obtained with modest to high yields and high 
enantioselectivities when employing a secondary amide-containing chiral diene ligand 
364a (Scheme 2.15). Following that report, a comprehensive investigation of 
second-generation ligands showed that a simpler novel chiral ligand 364b provided 
results superior to those obtained using the first generation ligand.129 
 
Scheme 2.15: Enantioselective rhodium-catalysed addition of arylboronic acids to 
alkenylheteroarenes. 
Lautens and co-workers130 subsequently developed the time-resolved domino reaction of 
3-chloro-2-vinylpyridine (366) with 2-hydroxy-phenylboronic ester (367) to give chiral 
aza-dihydrodibenzoxepine 370 (Scheme 2.16). This domino process composed of 
2-catalytic systems in one pot. The first step is the rhodium-catalysed arylation which is 
similar to the one previously reported by Lam.128,129 The second step is the Pd-catalysed 




Scheme 2.16: Domino synthesis of chiral aza-dihydrodibenzoxepine 370. 
Reductive Couplings and Conjugate Reductions 
Krische and co-workers132 reported the first metal-catalysed reductive couplings 
between vinyl azines and N-sulfonylaldimines. Employing the use of a 
rhodium−phosphine catalyst, branched products were obtained with modest to high 
yields and diastereoselectivities as single regioisomers. However, pyridines bearing a 
6-substituent and quinolines seemed to be privileged substrates while other azines had 
low reactivity. Fortunately, this coupling process tolerated a wide range of imine 
substituents especially when Na2SO4 was added to prevent their hydrolysis 
(Scheme 2.17). 
 
Scheme 2.17: Rhodium-catalysed reductive coupling of alkenylazaarenes with imines. 
In 2009, copper-catalysed asymmetric conjugate reductions of β,β′-disubstituted 
2-alkenyl heteroarenes were reported by Lam and co-workers.133 This work 
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demonstrated that nitrogen-containing aromatic heterocycles could provide effective 
activation of an adjacent alkene for highly enantioselective catalytic conjugate addition 
reactions (Scheme 2.18). Furthermore, to prove the hypothesis that C=N is crucially 
important for electrophilic activations, the reduction of 3- and 4-alkenylpyridines were 
attempted. Interestingly, it was found that 4-alkenylpyridine provided chiral adduct 374a 
with 60% yield and 94% ee, even though the reaction time was longer than the standard 
condition. This result suggests that the copper hydride reduction process can occur 
without assistance of a directing effect from the nitrogen atom. In contrast, 
3-alkenylpyridine 374b was unreactive. This indicates the importance of conjugation of 
the alkene to a C=N moiety for reactivity. 
 
Scheme 2.18: Enantioselective copper-catalysed reduction of 2-alkenylheteroarenes. 
In addition to the trapping chemistry reported by Krische in which rhodium catalyst was 
used,132 Lam and co-workers134 reported copper-catalysed enantioselective reductive 
coupling reactions of alkenylazaarenes with ketones. The idea is the combination of the 
utility of copper hydride catalysis133 with the ability of C=N-containing azaarenes to 
activate adjacent alkenes toward nucleophilic additions. By the use of chiral biphosphine 
ligands, aromatic heterocycles bearing stereogenic tertiary alcohols were obtained with 
high levels of diastereo- and enantioselectivity. Both acyclic and cyclic ketones were 
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effective substrates and β-substitution on the alkene was also tolerated under standard 
reaction conditions (Scheme 2.19). 
 
Scheme 2.19: Copper-catalysed asymmetric reductive coupling of alkenylazaarene 377 
with ketone 378. 
Electrophilic Activation with Two-Point Binding to Catalysts 
Azaarenes have been used as an electrophilic activating group for over a decade, 
especially in a homology of 1,2-dicarbonyl compounds. There are many examples 
showing that α,β-unsaturated acylazaarenes are potential electrophiles for 
enantioselective processes that rely upon two-point binding of these azaarenes to chiral 
metal complexes for activation and enantioinduction.135 For example, in 2005, Evans 
and co-workers reported an enantioselective Friedel−Crafts alkylation of α,β-unsaturated 
2-acyl imidazoles catalysed by chiral bis(oxazolinyl)pyridine (PyBox)-scandium(III) 
triflate complex 383.120c Reactions proceeded smoothly with furan, pyrrole and indole 





Scheme 2.20: Scandium-catalysed enantioselective Friedel−Crafts alkylations of 
α,β-unsaturated 2-acyl imidazole 381. 
 
Scheme 2.21: Rhodium-catalysed enantioselective reductive coupling of 1,3-enynes to 
heterocyclic aromatic aldehydes and ketones. 
In 2006, Komanduri and Krische136 studied an enantioselective rhodium-catalysed 
reductive coupling of 1,3-enynes to heterocyclic aromatic aldehydes and ketones. It was 
speculated that heteraromatic aldehydes and ketones might be viable electrophilic 
partners for hydrogen-mediated alkyne couplings because they are isoelectronic with 
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vicinal dicarbonyl substrates. By using chiral rhodium catalysts, chiral alcohols were 
obtained with high yields and enantioselectivities (Scheme 2.21). 
Two years later, Hoveyda and co-workers137 developed protocols for catalytic 
enantioselective aluminium-catalysed alkylations of alkynones bearing a pyridyl 
substituent with Et2Zn and Me2Zn reagents. The reactions were promoted by amino 
acid-based chiral ligands, which were easily prepared on gram-scale (Scheme 2.22). 
However, there was <2% conversion when aryl ketone 395 and furyl ketone 396 were 
employed. It was believed that the two point chelation, which involved Lewis acidic Al 
and the Lewis basic carbonyl and N atom of the pyridine, is crucial. 
 
Scheme 2.22: Aluminium-catalysed asymmetric alkylations of pyridyl-substituted 
alkynyl ketones with dialkylzinc reagents. 
The reaction mechanism was proposed to proceed via model 397a (cationic complex) or 
397b (neutral complex) as illustrated in Figure 2.2. The Lewis acidic Al associates with 
and activates the substrate molecule. Then the dialkylzinc adds to the Al-bound pyridyl 
ketone to afford chiral tertiary propargyl alcohols. The authors also suggested that the 
strongly Lewis basic phosphoramidate additive increases Al Lewis acidity and catalytic 
activity. This activation involves the amide carbonyl interaction with the dialkylzinc 
reagent. Moreover, molecular mechanics calculations suggest that a zinc bridge leads to 
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a high degree of rigidity in complexes 397a and 397b, resulting in the enhanced 
enantioselectivity. 
 
Figure 2.2: Mechanistic model. 
2.3.2 Azaarenes as Activating Groups for Nucleophilic Additions 
In addition to acting as an activating group for electrophiles, azaarenes can alternatively 
be used as an activating group for nucleophiles. Similar to C=O, the electron deficient 
C=N of azaarenes withdraws electron density facilitating α-deprotonation adjacent alkyl 
pronucleophile. This enolate-equivalent anion can then undergo either direct (1,2-) or 
conjugate (1,4-) nucleophilic addition to a suitable electrophile (Scheme 2.23). 
 
Scheme 2.23: Electronic homology concept between enolisable carbonyl motifs and 
alkylazaarenes. 
Previously, most reports of this type of activation rely upon Lewis acids together with 
harsh conditions such as high pressure and temperatures in order to achieve useful 
reactivity. For example, in 2010, Huang and co-workers138 reported the racemic 
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palladium-catalysed benzylic addition of 2-methyl azaarenes to aldimines. The mixture 
of substrates, palladium catalyst and THF was heated at 120 °C in a sealed vessel for 
24-30 h to obtain racemic amines with reasonable yields (Scheme 2.24). 
 
Scheme 2.24: Palladium-catalysed direct benzylic addition of 398 to imine 399. 
 
Scheme 2.25: Proposed mechanism. 
The proposed mechanism involves coordination between the azaarene and Pd(OAc)2 to 
form complex 402a. This complex then undergoes C−H bond cleavage via a 
three-centre-two-electron interaction to form the intermediate 402b or 402c, which then 
coordinates with imine 399a, resulting in intermediate 402d or 402e. This complex 
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undergoes nucleophilic addition to obtain addition product 401a after protonolysis 
(Scheme 2.25). Moreover, closely related reactions were then reported by the groups of 
Huang,139 Rueping140 and Matsunaga and Kanai141 using various metalcatalysts such as 
Cu(OTf)2, Sc(OTf)3, Y(OTf)3 and Fe(OAc)2 as well as other electrophiles such as 
α,β-unsaturated carbonyls and α,β-unsaturated nitriles. 
Alkylazaarenes Activated by Boron Additives 
Apart from the metal-based Lewis acid catalysts mentioned above, non-metallic Lewis 
acids such as dialkylboryl triflates can also promote the deprotonation of alkylazaarenes 
under relatively mild conditions. For example, Hamana and Sugasawa142 investigated 
the diastereo- and regioselective reaction of alkylpyridines with benzaldehyde (246) in 
the presence of 9-BBN triflate and triethylamine. This racemic, aldol-like process gave 
alcohol adducts with reasonable yields and modest to high diastereoselection 
(Scheme 2.26). 
 
Scheme 2.26: Mild aldol type reaction of alkylpyridines and benzaldehyde 246. 
In 2008, Trost and Thaisrivongs143 reported a palladium-catalysed enantioselective 
allylic alkylation of 2-alkylpyridines. Employing the use of a BF3 promoter, soft carbon 
nucleophiles such as 2-methylazaarenes underwent allylation with five-, six- and 
seven-membered endocyclic allylic carbonates to generate chiral products with high 
yields and stereoselectivities (Scheme 2.27(a)). A year later,144 they investigated an 
analogous reaction with higher 2-alkylpyridines. This idea originated from the 
hypothesis that the coordination of the pyridyl nitrogen atom with BF3 followed by 
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benzylic deprotonation leads to a nucleophile existing as a single geometric isomer 
(Scheme 2.27(c)). Using optimised reaction conditions, with chiral ligand 408 and 
[(η3-C3H5)PdCl]2, chiral products were obtained with high level of regio-, diastereo-, and 
enantioselectivities (Scheme 2.27(b)). 
 
Scheme 2.27: Palladium-catalysed regio-, diastereo-, and enantioselective benzylic 
allylation of 2-substituted pyridines. 
In order to expand the scope of substrates, Trost and co-workers145 subsequently 
investigated the asymmetric allylic alkylation under the previously optimised conditions 
discussed above. Unfortunately, higher azines such as pyrazine and pyrimidine were 
unreactive. It was believed that complexation of these substrates to BF3 rendered them 
too electron-deficient to undergo nucleophilic attack to the allyl carbonates. However, 
when the reaction was repeated without adding Lewis acid, the desired product was 
observed with low yields. Moreover, when allylic mesitylate esters were used as 
95 
 
electrophiles the reaction yields improved significantly (Scheme 2.28). The reason 
behind this was that bulky leaving groups such as mesitylate esters prevents the 
competitive elimination of the acyl group of the electrophile. 
 
Scheme 2.28: Palladium-catalysed asymmetric allylic alkylation of 
polynitrogen-containing aromatic heterocycles. 
Nucleophilic Addition of Electron-Deficient Alkylazaarenes 
Alternatively, electron-deficient substituents are able to activate alkylazaarene 
pronuclephiles (Scheme 2.29). This strategy relies upon the additional inductive or 
mesomeric effect of an electron-withdrawing group either on the azaarene rings or on 
the alkyl group. Thus, the proton at the alkyl α-position becomes more acidic and more 
easily deprotonated by weakly basic anions. Recently, there are some examples 
demonstrating the use of this mode of activation as shown below. 
 
Scheme 2.29: Alkylazaarenes activated by an additional electron-withdrawing groups. 
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In 2011, the asymmetric Michael addition of nitrobenzyl pyridines to α,β-unsaturated 
aldehydes was reported by Melchiorre and co-workers.146 This transformation 
demonstrated the use of dually activated methylene nucleophiles in which the methylene 
group is not activated by classical electron-withdrawing substituents (such as a carbonyl 
moiety). Interestingly, the mode of activation is the combination of electronic effects of 
a p- or o-nitro-substituted aromatic and a pyridine system (Scheme 2.30). 
 
Scheme 2.30: Asymmetric Michael addition of nitrobenzyl pyridines to enals via 
iminium catalysis. 
Similarly, Wang and co-workers147 reported an organocatalytic enantioselective Michael 
reaction of 4-methyl-3-nitropyridine to enals. In the presence of an analogous chiral 
amine catalyst under mild reaction conditions, various α,β-unsaturated aldehydes were 
converted to chiral adducts with modest to high yields and high enantioselectivities 
(Scheme 2.31). These reactions were developed based on a hypothesis that a methyl 
substituent of pyridine pronucleophiles was activated by a strongly electron-withdrawing 





Scheme 2.31: Organocatalysed conjugate addition of 4-methyl-3-nitropyridine (420) to 
α,β-unsaturated aldehyde 421. 
Fallan and Lam148 studied the catalytic enantioselective Michael additions of azaaryl 
carboxylic acid derivatives to nitroalkenes using a chiral nickel(II)-bis(diamine) 
complex catalyst.149 With pronucleophiles containing a wide variety of azaarenes, 
enantioenriched chiral azaarene-containing building blocks were obtained with high 
yield and enantioselectivities (Scheme 2.32). The authors also suggested that the 
analogy between the C=O group and the C=N moiety in azaarenes may serve as a rich 
platform for the development of additional catalytic enantioselective reactions. 
 
Scheme 2.32: Enantioselective nickel-catalysed Michael additions of azaarylacetamides 
to nitroalkenes. 
It was believed that the reaction mechanism is similar to a mechanism of the Michael 
addition of 1,3-dicarbonyls to nitoalkenes, originally proposed by Evans and co-workers 
(see Scheme 2.48).149 Firstly, the catalyst 426 releases one diamine ligand to generate 
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the catalytically active species. This active nickel species binds to the amide oxygen and 
the azaaryl nitrogen atoms to generate a reactive nickel enolate after deprotonation. 
Subsequently, the nickel enolate undergoes Michael addition to a coordinated 
nitroalkene to afford a chiral product. The anti-selectivity observed was explained by the 
four plausible transition states (Scheme 2.33). The unfavoured transition states 428b and 
428c showed steric interactions between nitroalkenes and the benzyl groups of ligand. In 
transition 428d, there is a steric interaction between the nitro group and the benzene ring 
of the azaarene, while in 428a, the nitro group is relatively free from unfavourable steric 
repulsions. 
 
Scheme 2.33: Stereochemical model. 
The first palladium-catalysed diastereo- and enantioselective addition of alkylazaarenes 
to N-Boc aldimines and nitroalkenes was reported by Lam and co-workers.150 The 
reactions were promoted by a chiral palladium(II)-bis(oxazoline) complex at mild 
temperature in undried solvent under an air atmosphere. By exploiting the acidifying 
effect of nitro, cyano, or ester groups on the azaarenes, chiral adducts were synthesised 




Scheme 2.34: Diastereo- and enantioselective palladium(II)-catalysed additions of 
2-alkylazaarenes to N-Boc imines and nitroalkenes. 
Simpson and Lam also developed an enantioselective nickel-catalysed Michael additions 
of 2-acetylazaarenes to nitroalkenes.151 This process was tolerant of a range of azaarenes 
in the pronucleophilic component, and the reactions proceeded under mild conditions. 
Although the enantioselectivities were modest with β-alkyl-substituted nitroalkenes, a 
range of β-(hetero)aryl-substituted nitroalkenes reacted smoothly to result in Michael 
products with much higher enantiopurity (Scheme 2.35). 
 
Scheme 2.35: Enantioselective nickel-catalysed Michael additions of 2-acetylazaarenes 
to nitroalkenes. 
The result mentioned above demonstrated the utilisation of the C=N moiety for 
participating in the activation of adjacent alkenyl or alkyl groups by mimicking a 
1,2-dicarbonyl compound. This reactivity was confirmed by the attempted reaction of 
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4-acetylpyridine (436) with β-nitrostyrene (425a), which gave no Michael product under 
the same conditions (Scheme 2.36). 
 
Scheme 2.36: Enantioselective nickel-catalysed Michael additions of 4-acetylpyridine 
(436) to β-nitrostyrene (425a). 
Azaarenes have been used as activating groups in enantioselective transformations. The 
utility of the electronic analogy between C=N bond of azaarenes and C=O bond of 
carbonyls provides access to novel azaarene-containing compounds, and allows 
alternative modes of catalytic activation to be explored. The Lam group has reported in 
detail the most recent contribution to the field; the enantioselective Michael addition of 
2-acetylazaarenes to β,β-disubstituted nitroalkenes (Section 2.7). Therefore, in the next 
Section 2.4, an overview of previously reported Michael additions of 1,2-dicarbonyls 
and 2-acetylheteroarenes to nitroalkenes is discussed. 
2.4 Michael Addition of 1,2-Dicarbonyl Compounds and 
2-Acetylheteroarenes to Nitroalkenes 
1,2-Dicarbonyl compounds are important in the eyes of both biochemists and organic 
chemists. Pyruvic acid, for example, is one of the simple 1,2-dicarbonyl compounds 
believed to be involved in biosynthesis by nature.152 In terms of synthetic utility, 
1,2-dicarbonyls are less developed than 1,3-dicarbonyl compounds because they are less 




Sodeoka and co-workers154 reported a diastereo- and enantioselective Michael addition 
of 1,2-dicarbonyl compounds to nitroalkenes catalysed by a chiral Ni(OAc)2 complex. 
The reaction was applicable to various α-ketoester pronucleophiles and proceeded well 
in very mild reaction conditions. It was expected that acetate counteranion is sufficient 
to produce a chiral metal enolate 440b with a Z-enolate geometry. This enolate is then 
trapped by the nitroalkene in a stereoselective manner (Scheme 2.37). 
 
Scheme 2.37: Nickel-catalysed diastereo- and enantioselective conjugate addition of 
α-ketoesters to nitroalkenes. 
In 2010, Shibasaki and co-workers reported a syn-selective catalytic asymmetric 
Michael addition of α-ketoanilides to nitroalkenes using a dinuclear Ni-Schiff base 
catalyst (442).155 Under optimised reaction conditions, chiral products were obtained 
with 61-92% yields, 8-20:1 syn-selectivity, and 72-98% ee. A stereoselective 
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transformation of the 1,4-adduct 443 to a pyrrolidine derivative 444 was performed to 
demonstrate the utility of this methodology (Scheme 2.38). 
 
Scheme 2.38: Syn-selective catalytic asymmetric 1,4-addition of α-ketoanilides to 
nitroalkenes under dinuclear nickel catalysis. 
Although nickel is a good metal for enantioselective Michael reaction of 1,2-dicarbonyl 
compounds to nitroalkenes, copper is also a useful catalyst for this transformation. For 
example, Huang and co-workers156 demonstrated the copper-catalysed asymmetric 
formal [2+2+2] annulation between α-ketoesters and nitroalkenes (Scheme 2.39). This 
high efficiency domino process resulted in six stereocentres under mild and 
environmentally friendly reaction conditions. The reason for the high stereoselectivity 
was the use of a chiral copper catalyst derived from the rigid chiral diamine which 
produced a highly diastereo- and enantioselective adduct in the first Michael addition. 





Scheme 2.39: Copper-catalysed Michael/Michael/Henry domino annulation. 
Wang and co-workers157 reported a catalytic asymmetric Michael-Henry reaction of 
1,2-diones with substituted nitroalkenes. With the use of a highly efficient catalyst 
system derived from Ni(OAc)2 and chiral diamine ligands under aprotic conditions, a 
series of polyfunctionalised bicycle compounds containing four consecutive stereogenic 
centres were obtained with generally excellent enantio- and diastereoselectivities with 
reasonable yields (Scheme 2.40). Moreover, when the reaction time was prolonged from 
six hours to 48 hours the diastereomeric outcome of a product was maintained. This 
result suggested that the base-induced epimerisation could be minimised. 
 
Scheme 2.40: Ni-catalysed Michael/Henry domino annulation. 
In comparison to transition metal-catalysed Michael addition of 1,2-dicarbonyl 
compounds to nitroalkenes, the corresponding organocatalysed additions have been 
more widely studied. Rodriguez and co-workers were the first to investigate the 
organocatalysed enantio- and diastereoselective conjugate additions of α-ketoamides to 
nitroalkenes.158 Using a bifunctional amino thiourea catalyst, the Michael anti-adducts 
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were synthesised in high yields and stereoselectivities (Scheme 2.41). Notably, the 
substrate amide proton was believed to play a critical role in the formation of product 
with anti-selectivity. The bifunctional catalyst activates the nitroolefin via a bidentate 
H−bond interaction and the tertiary amine group deprotonates the amide nucleophile, 
resulting in the ion pair transition state 454. In the transition state, the Si face of the 
Z-enolate is preferentially delivered to the Re face of the nitroalkene to give the 
observed stereochemistry. Moreover, the described method was applied to α-ketoester 
substrates.159 
 
Scheme 2.41: Organocatalysed asymmetric Michael addition of α-ketoamide 451 to 
nitroalkene 425d. 
Although aromatic ketones are very common substrates for organocatalysed asymmetric 
Michael reactions to nitroalkenes, the corresponding heteroaromatic ketones are rarely 
investigated. In 2009, Wang and co-workers160 designed and synthesised a new class of 
bifunctional primary amine-thiourea catalysts. The new catalysts were applied for the 
asymmetric Michael addition of ketones containing heteroaryl groups such as furyl, 
thienyl and thiazolyl to nitroalkenes to afford γ-nitro heteroaromatic ketones with 




Scheme 2.42: Organocatalysed asymmetric Michael addition of 2-acetylthiophene (455) 
to nitrodiene 425e. 
In addition to the potential of bifunctional thiourea catalysts as mentioned above, Ma 
and co-workers161 reported the Michael addition of ketones to conjugated nitrodienes by 
using catalysts derived from commercially available saccharides and chiral diamines. 
Not only akyl- and arylketones, but heteroaryl ketones, were also investigated 
(Scheme 2.43). Moreover, in all cases, 1,4-addition selectively occurred without any 
trace of the 1,6-adducts. 
 
Scheme 2.43: Organocatalysed asymmetric Michael addition of 2-acetylpyridine (458) 
to nitrodiene 425f. 
Barbas and co-workers162 developed an organocatalytic asymmetric Michael reaction 
through the rational design of pyrazoleamides as Michael donors. In contrast to the 
works reported by Ma and Wang in which the heteroaryl rings behaved as simple 
substituents, the study by Barbas demonstrated a rare example of the use of 
pyrazoleamides as an ester equivalent, an activating group, and a directing group, as 
well as a good leaving group for further transformation. In general, amides are 
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considered to be challenging substrates due to their relatively low acidity. However, in 
this study, the authors demonstrated that pyrazoleamide derivatives could undergo the 
Michael addition to nitroalkenes in the presence of Cinchona alkaloid-based urea 
catalyst 462 (Scheme 2.44). 
 
Scheme 2.44: Organocatalysed asymmetric Michael addition of pyrazoleamide 461 to 
nitroalkene 425g. 
Asymmetric Michael additions of 1,2-dicarbonyls to nitroalkenes have been 
investigated. Most of these transformations relied upon organocatalysts. Only some 
examples used transition metal catalysts and nickel is amongst the most popular metals, 
presumably, because nickel has good catalytic properties. To justify this claim, in 
Section 2.5, nickel-catalysed enantioselective nucleophilic addition of nucleophiles to 
nitroalkenes will be discussed. 
2.5 Introduction to Nickel-Catalysed Enantioselective 
Addition of Nucleophiles to Nitroalkenes 
Nickel is one of the most widely studied transition metals in organic synthesis. It is 
comparatively cheaper than other transition metals such as Ru, Rh, Pd, Ir, Pt and Au etc. 
Moreover, nickel has very unique catalytic properties that make it very useful for the 
chemical industries. For example, nickel has been used as a catalyst in chemical 
processes such as Kumada coupling and Negishi coupling. It has been shown to be 
highly effective in enantioselective transformations of nitroalkenes as discussed below. 
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2.5.1 Friedel−Crafts alkylations 
In 2013, Jia and co-workers163 reported an enantioselective nickel-catalysed 
Friedel−Crafts alkylation reaction of indoles with β-trifluoromethyl-β-disubstituted 
nitroalkenes. Under the optimised reaction conditions, a wide range of substituted 
indoles and nitroalkenes were investigated. Indole-bearing chiral compounds with 
all-carbon quaternary stereocentres were obtained with good yields and good 
enantioselectivities. In order to demonstrate the utility of this methodology, the synthesis 
of a tetrahydro-β-carboline was carried out by the reduction of chiral nitro product 467 
to trifluoromethylated tryptamine (468), followed by Pictet−Spengler cyclisation of this 
amine to afford 469 with complete preservation of enantiopurity (Scheme 2.45).  
*
 
Scheme 2.45: Nickel-catalysed Friedel−Crafts alkylation of nitroalkene 465a toward the 
synthesis of compound 469. 
To expand the scope of nitroalkenes in the previous work,163 Jia and co-workers studied 
an enantioselective Friedel−Crafts alkylation reaction of indoles with acyclic 
α-substituted β-nitroacrylates using Ni(ClO4)2-bis(oxazoline) complex catalyst.164 Chiral 
β-nitroesters bearing all-carbon quaternary stereocentres were obtained with excellent 
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yields and enantiopurities. It should be noted that this result was obtained with a very 
low catalyst loading of 0.1 mol % (Scheme 2.46), which represents a rare case of highly 
active Lewis acid catalyst in the asymmetric Friedel−Crafts reaction. 
 
Scheme 2.46: Asymmetric Friedel−Crafts alkylation of α-substituted β-nitroacrylate 
470a. 
2.5.2 Michael Additions 
The Michael reactions of nucleophiles to nitroalkenes have been broadly investigated. 
There are many reported examples of Ni-catalysed Michael addition of nucleophiles to 
nitroalkene receptors. Apart from 1,2-dicarbonyl pronucleophiles (Section 2.4), there are 
several examples of the use of 1,3-dicarbonyl compounds as a Michael donors.165 For 
example, Evans and co-workers149 screened various types of cyclohexanediamine 
ligands and Ni(II), and it was found that the complex 426 showed the best results. 
Moreover, the reaction was conveniently performed under mild conditions at room 
temperature without the need to exclude air or moisture. Under the optimised reaction 
conditions, chiral products were obtained with high yields and enantioselectivities from 




Scheme 2.47: Nickel-catalysed enantioselective Michael additions of 1,3-dicarbonyl 
compounds to conjugated nitroalkenes. 
The results from an NMR experiment, together with an X-ray structure analysis of 
complex 474a suggested that the two diamine ligands in this system each play a distinct 
role. The first one serves as a chiral ligand to provide stereoinduction in the addition 
step. The second diamine functions as a base to deprotonate the metal-bond substrate to 
generate the chiral enolate nucleophile. The resulting chiral enolate subsequently adds 
enantioselectively to a range of nitroalkenes (Scheme 2.48). 
Scheme 2.48: Proposed mechanism. 
Chen and co-workers investigated an enantioselective Michael reaction of 
1,3-dicarbonyl compounds to 3-nitro-2H-chromenes catalysed by chiral nickel 
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complexes.166 After extensive ligand screening, they found that the chiral nickel 
complex 426 exhibited high stereoselectivity and catalytic activity to generate 
corresponding enantioenriched products (Scheme 2.49). To demonstrate the utility of 
this procedure, Michael product 477 was transformed to chiral cyclo γ-amino butyric 
acid derivative 479. 
 
Scheme 2.49: Enantioselective Michael reaction of 1,3-dicarbonyl compounds to 
3-nitro-2H-chromenes catalysed by chiral nickel complex 426. 
Shibasaki and co-workers developed a catalytic asymmetric vinylogous Michael reaction 
of α,β-unsaturated γ-butyrolactam 480 to nitroalkenes under homodinuclear nickel 
catalysis (Scheme 2.50).167 It was shown that the reactions proceeded selectively at the 
γ-position, giving vinylogous Michael adducts in high diastereoselectivities (16-30:1 dr) 




Scheme 2.50: Catalytic asymmetric vinylogous Michael reactions of α,β-unsaturated 
γ-butyrolactams to nitroalkenes under dinuclear nickel catalysis. 
Liu and co-workers reported the first diastereoselective Michael reaction of chiral 
nickel(II) glycinate with nitroalkenes.168 The reactions proceeded smoothly under mild 
conditions in the presence of TBAB (tetrabutyl ammonium bromide). A broad range of 
aryl-, heteroaryl-, and alkyl-substituted nitroalkenes were transformed to chiral 
β-substituted α,γ-diaminobutyric acid derivatives in a single reaction step with high yield 
and excellent stereoselectivity (Scheme 2.51). 




Arai and Yamamoto studied a tandem asymmetric Michael/Henry reaction between 
2-mercaptobenzaldehydes and β-nitrostyrenes using an imidazoline-aminophenol-nickel 
complex catalyst.169 Using the optimised reaction conditions, the corresponding 
(2S,3R,4R)-2-aryl-3-nitrothiochroman-4-ols were obtained with up to 99% dr with 
95% ee. (Scheme 2.52). 
 
Scheme 2.52: Stereochemically divergent synthesis of thiochromanes using an 
imidazoline-aminophenol-nickel catalysed Michael/Henry reaction. 
In summary, many research groups have developed stereoselective Michael additions of 
1,2-dicarbonyls to nitroalkenes using transition metal catalysts or organocatalysts. Under 
the very mild reaction conditions, both methods of catalysis allow selective access to 
chiral products with impressive results. However, for the organocatalysed Michael 
reactions the amount of catalyst loadings are normally higher than that of the 
metal-catalysed process. 
Additionally, in terms of the Michael addition of 2-alkylazaarenes to nitroalkenes, the 
challenge is the weaker activation property of C=N bound in comparison with C=O. 
Therefore, only some examples of enantioselective Michael additions of 
acetylheteroarenes to nitroalkenes have been reported recently and most of them rely 
upon organocatalysis. In the Lam group,151 we investigated nickel-catalysed Michael 
addition of 2-acetylazaarenes to nitroalkenes with the exploitation of the activation 
properties of azaarene units (Section 2.3.2). However, it is currently unclear whether 
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this mode of activation could be applied to the more complex substrates. To address this 
issue, the enantioselective Michael addition of 2-acylazaarenes to sterically 
β,β-disubstituted nitroalkenes will be discussed in detail in Section 2.7. 
2.6 Aims and Objectives 
As shown in the previous sections, molecules containing chiral all-carbon quaternary 
stereocentres are useful in terms of their biological properties. However, chiral 
compounds containing both azaarenes and an all-carbon quaternary centre in the same 
molecule are rarely explored and studied. Moreover, it should be noted that the Michael 
reaction is one of the most practical approaches to obtain all-carbon quaternary 
stereocentres. Thus, constructing azaarenes bearing chiral all-carbon quaternary 
substituents by the Michael addition reaction would be a promising and challenging 
idea.  
Importantly, the use of azaarenes as activating groups in enantioselective 
transformations is one of the main research goals in the Lam group. Since the first report 
of the copper-catalysed enantioselective reduction of 2-alkenylazaarenes in 2009,133 
many novel methods for the asymmetric functionalisation of azaarene-containing 
compounds have been investigated in our group.128,129,133,134,148,150,151 Besides, according 
to the recent work by Simpson and Lam,151 the Michael reaction between 2-acetyl 
azaarenes and β-substituted nitroalkenes afforded chiral products containing 
heteroarenes with reasonable yields and selectivities (Scheme 2.35). This report 
demonstrates the ability of C=N group to stabilise a negative charge and activate the 
nucleophilicity of 2-acetylazaarenes. Therefore, following the same concept, the aim of 
our research was to apply this novel mode of activation for the asymmetric 
functionalisation of 2-acyl substituted azaarenes using the more sterically hindered 
electrophiles, β,β-disubstituted nitroalkenes to generate azaarene derivatives containing 
chiral all-carbon quaternary stereocentres. It was envisaged that employing 
α,α-disubstituted 2-acetyl heteroarenes instead of 2-acetyl azaarenes, chiral products 
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with vicinal all-carbon quaternary stereocentres could be obtained as shown in 
Scheme 2.53. 
 














2.7 Results and Discussions 
As discussed in Scheme 2.35, the Lam group had developed the enantioselective 
nickel-catalysed Michael addition of 2-acetylazaarenes to β-substituted nitroalkenes by 
exploitation of the mode of activation of azaarenes.151 However, the use of 
β,β-disubstituted nitroalkenes as electrophiles is very challenging due to the sterically 
hindered nature of these substrates. In order to fulfil our goal (see Scheme 2.53) of 
generating azaarenes featuring a chiral all-carbon quaternary stereocentre, initially, the 
Michael addition of 2-acetylpyridine (458) to a β,β-disubstituted nitroalkene 490 was 
studied by Alain J. Simpson (a former PhD student in Lam group) using the same 
reaction conditions as in our previous report.151 Unfortunately, no Michael product was 
observed, only the isomerisation of alkene 490 was formed (Scheme 2.54).170,171 
 
[a] Reaction was conducted by Alain J. Simpson (a former PhD colleague). 
Scheme 2.54: Attempted Michael addition with a β-methy-β-phenyl nitroalkene (490). 
The low reactivity of nitroalkene 490 was ascribed to its more hindered β-position. To 
overcome the increased steric crowding and gain sufficient activation,172 the methyl 
group of β,β-substituted nitroalkene 490 was replaced by electron-withdrawing 
substituents, such as carbonyl,173 phosphonate174 and CF3163 groups. The 
nickel-catalysed Michael addition of 2-acetylazaarenes to these activated nitroalkenes 
will be featured in the following sections. 
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2.7.1 The Michael Addition of 2-Acetylazaarenes to Aromatic 
α-Substituted β-Nitroacrylates 
As discussed in Scheme 2.54, the Michael addition of 2-acetylpyridine (458) to 
nitroalkene 490 was unsuccessful presumably due to the low reactivity of this hindered 
nitroalkene. However, it was anticipated that electron deficient substituted nitroalkenes 
could be compatible substrates. To continue this work, Alain J. Simpson investigated the 
Michael addition of 2-acetylpyridine (458) to nitroalkene 338a under the reported 
optimal reaction conditions (the complex composed of Ni(OAc)2·4H2O (5 mol %) and 
the bis-oxazoline ligand 431 in i-PrOH/CH2Cl2 at room temperature).151 Gratifyingly, it 
was found that the Michael adduct 496a was obtained with 93% yield and 95% ee 
(Table 2.1). Various other 2-acetylazaarenes containing quinoline, pyrazine, thiazole, 
benzothiazole, or N-methylimidazole groups also reacted smoothly with 338a to provide 
chiral products, with all-carbon quaternary stereocentres, with 78-89% yield and 95-99% 
ee. Unfortunately, the use of 2-acetylpyrimidine (492) as the nucleophilic partner was 
problematic, giving product with poor yield (46%) and selectivity (49% ee). The origin 
of the detrimental effect of pyrimidine ring is still unclear; although this dinitrogen-
containing ring may lead to an alternative binding mode, resulting in diminished 
catalytic activity.  
To expand the substrate scope, the Michael additions of various azaarenes to other 
aromatic or heteroaromatic β-acylnitroalkenes were also studied. For m- and 
p-substituted aromatic β-acylnitroalkenes (Table 2.2) with both electron rich and poor 
substituents such as methyl, methoxy and chloro groups the reactions proceeded 
smoothly providing chiral products with high yields (80-96%) and excellent 





Table 2.1: Enantioselective nickel-catalysed Michael additions of 2-acetylazaarenes to 
phenyl β-acylnitroalkene 338a.[a] 
 







Table 2.2: Enantioselective nickel-catalysed Michael additions of 2-acetylazaarenes to 
aryl β-acylnitroalkenes. 
 





In the case of o-substituted aromatic β-acylnitroalkenes with either electron-rich or -poor 
groups such as methoxy or chloro substituents, the reaction was unsuccessful leading to 
recovering only the starting materials (Table 2.3). This result suggested that substituents 
at the o-position of aromatic nitroalkenes render the system too bulky to react with 
azaarenes. This kind of steric effect has also been observed by Jia and co-workers in the 
nickel-catalysed enantioselective Friedel−Crafts alkylation of indoles with nitroalkenes: 
although m- and p-substituted aromatic nitroacrylate esters were successfully reacted 
(see Scheme 2.45), the reaction of nitroalkene 465b containing an o-tolyl substituent 
gave no product (Scheme 2.55).163  
Table 2.3: Enantioselective nickel-catalysed Michael additions of 2-acetylazaarenes to 
phenyl β-acylnitroalkenes. 
 




Scheme 2.55: Enantioselective nickel-catalysed Friedel−Crafts alkylation of 
indole (464) with β-CF3-β-disubstituted nitroalkene 465b.163 
Table 2.4: Enantioselective nickel-catalysed Michael addition of 2-acetyl azaarenes 
with heteroaromatic β-substituted nitroalkenes and aromatic β-acylnitroalkene. 
 
[a] Reactions were conducted by Alain J. Simpson. 
Further investigations were made using heteroaromatic instead of aromatic β-substituted 
nitroalkenes. Notably, it was revealed that 2-thiophenyl β-substituted nitroalkene 338h 
underwent Michael addition with satisfactory results. Both 2-acetylbenzothiazole (495) 
and 2-acetylpyridine (458) afforded heteroaromatic adducts with high yields and 
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enantioselectivities. Moreover, the ester substituent could be varied as well. For 
example, the nitroalkene containing a bulky tert-butyl ester 470b afforded chiral 
product 497a with 87% yield and 97% ee (Table 2.4).  
In light of these encouraging results with aromatic α-acyl-β-nitroacrylates, the Michael 
addition of 2-acetylazaarenes to α-alkyl-β-nitroacrylates appeared to be a promising 
avenue for future research. Therefore in the following section, the Michael reaction of 
aliphatic α-substituted β-nitrocrylates was investigated. 
2.7.2 The Michael Addition of 2-Acetylazaarenes to Aliphatic 
α-Substituted β-Nitroacrylates 
Ligand Screening 
Initial attempts (Table 2.5) focused on the Michael addition between 2-acetylpyridine 
(458) and α-octyl β-nitroacrylate (510a) using the same catalyst as was used for 
aromatic α-substituted β-nitroacrylates. The result showed that both yield and 
enantioselectivity were modest (79% NMR yield, 74% ee, entry 1). In order to improve 
enantioselectivity, a number of Box and PyBox ligands (Figure 2.3) were investigated. 
Firstly, 2,2-dimethylmalonic acid-derived bis-oxazoline ligands (498, 499 and 500) were 
screened, however, inproved results were not observed (entries 2-4). Ligand 501, 
derived from unsubstituted malonic acid, was also screened and the reaction remained 
incomplete after 48 h (it gave only 27% yield and 8% ee; entry 5).  
At this point, bis-oxazoline ligands with a different central linker, for example PyBox 
ligands with aliphatic or aromatic substituents at the oxazoline ring, were investigated. 
Fortunately, the use of ligand 503 gave superior result; 83% yield and 78% ee (entry 7). 
Thus, pyridinyl oxazoline (PyOx) ligand 507 was also tested; however, it was found to 
give a modest yield (74%) and a low level of selectivity (14% ee, entry 11). 
Nickel−diamine catalyst 426, which is a very good catalyst for the Michael addition of 
1,3-dicarbonyl compounds, azaarylacetates and acetamides to nitroalkenes,148,149,166 gave 
low yield and racemic product (entry 12). This catalyst seemed to behave as a stronger 
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base than oxazoline ligands because an isomerised nitroalkene 512 was observed in a 
significant amount (34%) (this is consistent with the requirement for loss of one diamine 
ligand to generate a reactive nickel enolate, see Scheme 2.35 and Scheme 2.48).148,149 
Ligands 508 and 466 (having substituents pointing in opposite directions) were then 
evaluated, as this type of ligand has been previously reported as an effective ligand for a 
nucleophilic addition to nitroalkenes.163,164 However, neither improved the yield or 
selectivity (entries 13 and 14). A bis-oxaxoline ligand 509 was then studied and it was 
found that this ligand gave low yield and enantioselectivity as well (entry 15). Other 
classes of ligands such as biphosphines were not investigated because they tended to be 
unreactive to this chemistry.151 
 
[a] Commercial ligands. [b] This catalyst was prepared by Alain J. Simpson. 
Figure 2.3: Bis-oxazoline ligands and catalyst for screening. 
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Table 2.5: Ligand screening. 
 









1 431 96 100 79 18 −74 
2 498 96 73 46 22 −24 
3 499 96 61 22 13 0 
4 500 96 64 31 27 12 
5 501 96 48 27 10 −8 
6 502 48 100 78 22 −70 
7 503 40 100 83 15 78 
8 504 48 67 53 11 −50 
9 505 68 100 82 15 68 
10 506 96 80 57 19 −50 
11 507 40 100 74 19 14 
12[c] Catalyst 426 40 100 60 34 0 
13 508 62 95 81 13 54 
14 466 96 37 24 12 5 
15 509 72 78 59 18 12 
[a] Determined by NMR analysis of the crude product using 1,3,5-tetramethoxybenzene as an internal 
standard. [b] Enantiomeric excess were determined by chiral HPLC analysis. [c] Catalyst 426 was used 
in place of Ni(OAc)2·4H2O and ligand. 
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Table 2.6: Solvent screening 
 




NMR Yield (%)[a] ee 
(%)[b] 511a E-512 
1 CH2Cl2 48 34 16 14 74 
2 CHCl3 48 43 27 7 70 
3 MeOH 48 94 55 7 22 
4 i-PrOH 48 100 82 15 32 
5 BuOH 48 100 84 14 52 
6 Et2O 48 18 8 7 30 
7 THF 48 97 84 7 58 
8 dioxane 48 31 22 4 60 
9 MeCN[d] 48 100 35 44 54 
10 toluene 48 20 11 6 65 
11 EtOAc 48 19 13 4 58 
12 DMF[d] 48 100 44 28 38 
13 BuOH:CH2Cl2 (1:1) 40 100 79 12 75 
14 THF:CH2Cl2 (1:1) 96 74 55 12 70 
15[c]  i-PrOH:CH2Cl2 (1:1) 40 100 83 15 78 
[a] Determined by NMR analysis of the crude product using 1,3,5-tetramethoxybenzene as internal 
standard. [b] Enantiomeric excess were determined by chiral HPLC analysis. [c] The result from 
Table 2.5. [d] starting materials were possibly degraded to generate unidentified compounds which 




With the best ligand 503 revealed, a range of solvents was screened (Table 2.6). 
Halogenated solvents such as dichloromethane and chloroform gave modest conversion, 
with the highest enantioselectivities (entries 1-2). Protic solvents or alcohols such as 
methanol, isopropanol and butanol resulted in high to complete conversion (maybe 
because of a good solubility of catalyst) but low selectivities were observed and larger 
alcohols gave higher enantioselectivities (entries 3, 4 and 5). Most ether solvents showed 
low reactivity except THF, which underwent 97% conversion, but disappointingly, with 
only 58% ee (entry 7). Although toluene and ethyl acetate brought about a moderate ee, 
these solvents afforded very low conversions (entries 10-11). Acetonitrile and DMF 
were also investigated and gave complete conversion; however, very high levels of 
isomerised nitroalkene were observed (entries 9 and 12). Apart from single solvents, 
which produced poor results, mixed solvents were also tested. However, both 
BuOH:CH2Cl2 and THF:CH2Cl2 mixtures were poor in comparison with the use of 
i-PrOH:CH2Cl2 (entries 13-15). 
According to the result in Table 2.6, a mixed i-PrOH:CH2Cl2 solvent system afforded 
the best result. Notably, this resulted in higher enantioselectivity than the use of pure 
i-PrOH or CH2Cl2. This result suggested a synergistic phenomenon between i-PrOH and 
CH2Cl2. Thus, different ratios of these two solvents were investigated (Table 2.7). 
Undoubtedly, a synergistic effect was observed when 40% and 50% of dichloromethane 
in isopropanol were used as a mixed solvent giving product in 78% ee (entries 5 and 6). 
However the yields of these reactions were unsatisfactory. A possible reason for this 
problem would be the isomerisation of the nitroalkene starting material. To solve this 
issue, the Z-nitroalkene 510a was added in excess (1.5 equiv) and 2-acetylpyridine (458) 
was used as the limiting substrate. Gratifyingly, the result showed that Michael adduct 
511a, with all-carbon quaternary stereogenic centre, was achieved with excellent yield 
(>99% NMR yield) and retained a reasonable enantioselectivity (78% ee, entry 12). 
Therefore these conditions were considered as the optimal conditions for this reaction. 
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Table 2.7: Cosolvent proportion screening. 
 




NMR Yield (%)[a] ee 
(%)[b] 511a E-512 
1[d] 10 : 0 48 100 82 15 32 
2 9 : 1 40 100 84 16 56 
3 8 : 2 40 100 81 13 68 
4 7 : 3 40 100 83 14 68 
5 6 : 4 40 100 78 17 78 
6[c] 5 : 5 40 100 83 15 78 
7 4 : 6 40 100 81 18 74 
8 3 : 7 48 91 70 19 73 
9 2 : 8 48 72 40 17 74 
10 1 : 9 48 63 34 19 73 
11[d] 0 : 10 48 34 16 14 74 
12[e] 5 : 5 40 100 >99 - 78 
[a] Determined by NMR analysis of the crude product using 1,3,5-tetramethoxybenzene as internal 
standard. [b] Enantiomeric excess were determined by chiral HPLC analysis. [c] The result from 
Table 2.5. [d] The results from Table 2.6. [e] 0.1 mmol of 2-acetylpyridine (458) and 0.15 mmol of 




Scope of Azaarenes and Nitroalkenes 
With the optimised reaction conditions in hand, several aliphatic substituted nitroalkenes 
were investigated using 2-acetylpyridine (458) as a model pronucleophile (Table 2.8). 
Firstly, for 2Z-2-(nitromethylidene)octanoates with methyl-, ethyl- or tert-butyl- 
substituents at ester group, the results indicated that the bulkier the substituents, the 
lower enantioselectivities of products were obtained (81%, 78%, and 52% ee 
respectively). Next, ethyl β-nitroacrylates with different substituents at the α-position 
were studied. Both methyl and 3-butenyl substituted nitroalkenes gave products with 
modest percent enantiomeric excess. However, substrates with larger substituents 
resulted in products with higher yields than substrates with smaller substituents. 
Table 2.8: Enantioselective nickel-catalysed Michael addition of 2-acetylpyridine (458) 




The scope of both azaarenes and nithroalkenes were further investigated. In addition to 
2-acetylpyridine (458), other 2-acetylazaarenes with different heterocyclic cores (namely 
thiazole, benzothiazole, pyrazine, N-methylimidazole and quinolone) were studied 
whilst varying the aliphatic nitroalkene partners (Table 2.9). The results showed that 
most of these azaarenes were significantly less reactive than 2-acetylpyridine (458). 
Moreover, nitoalkene 510f reacted with azaarenes 494 and 495 to afford chiral products 
511d and 511e with high enantioselectivities but modest yields even though the reaction 
time was extended to four days. The more reactive 2-acetylpyrazine (386) underwent 
Michael addition to nitroalkene 510d and 510g giving products 511f and 511g with 
reasonable yields and selectivities. Fortunately, nitroalkene 510e containing two ester 
groups also reacted with 2-acetylthiazole (390) to give product 511h with 63% yield and 
78% ee. The least reactive 2-acetylquinoline (493) could react with nitroalkenes 510a 
and 510c generating Michael adducts 511i and 511j with moderate ee, however, the 
yields of these reactions were very low. 
To demonstrate the versatility of this methodology, three other electron deficient 
substituted-nitroalkenes were investigated, namely keto-substituted, phosphonate 
ester-substituted and trifluoromethyl-substituted nitroalkenes (Table 2.10). Extending 
the reaction time to seven days, keto-substituted nitroalkene 515 reacted slowly with 
2-acetylpyrazine (386), 2-acetyl N-methyl imidazole (494) and 2-acetylbenzothiazole 
(495) to give products in reasonable yields (67-82%) and excellent enantioselectivities 
(97-99% ee). Regarding the synthesis of the chiral compounds 518a and 518b from 
phosphonate ester-substituted nitroalkene 516, a number of PyBox and Box ligands as 
well as solvents were screened (data not show). The best result was the use of ligand 502 
in a mixture of dioxane and CH2Cl2. Although the enantioselectivities were very high, 
the yields were disappointingly low. The reaction did not go to completion even with 
extension of the reaction time to 96 h. Pleasingly, using ligand 502 in THF, 














Table 2.10: Enantioselective nickel-catalysed Michael addition of 2-acetylazaarenes 
with other β-substituted nitroalkenes. 
 
[a] Ligand 502 was used. [b] Reactions were run in 1:1 dioxane:CH2Cl2 for 96 h. [c] Reactions were 
run in THF for 72 h and using 1.5 equivalent of 2-acetylazaarenes. 
2.7.3 Unsuccessful Heteroarenes and Nitroalkenes 
To investigate the scope of both Michael donors and Michael acceptors, a number of 
azaarenes and nitroalkenes were studied (Figure 2.4). The result showed that acyl 
pyridine derivatives in which the alkyl substituent is bigger than methyl group such as 
ethyl, isopropyl or bromomethyl were unsuccessful. This result suggested that steric 
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effects have a crucial role in this catalytic process. Also other heteroaromatic group 
apart from azaarenes, for example, 2-acetylthiophene (455) or 2-acetylfuran (523), were 
incompatible substrates. If the carbonyl group was derivatised to an imine group such as 
in compound 524, the reaction was also unsuccessful. The reason for this would be 
because of the steric effect of the bulky p-methoxy phenyl substituent. Also this 
substrate would behave like a Schiff base ligand and slow the rate of this reaction. 
 
Figure 2.4: Unreactive heteroarenes. 
As mentioned in Table 2.3, o-substituted aromatic β-acylnitroalkenes were unreactive. 
Aliphatic nitroalkenes with bulky substituents such as isopropyl or cyclohexyl groups 
were also unreactive (Figure 2.5), it could be rationalised that having a massive 
substituent on the nitroalkenes renders the system too bulky to react with azaarenes. Last 
but not least, as mentioned in Scheme 2.54, the nitroakene without an ester group such 
as nitroalkene 490 could not undergo Michael addition either. From NMR analysis of a 
crude mixture, this nitroalkene seems to isomerise to alkene 491.170,171  
 
[a] The reaction was conducted by Alain J. Simpson. 
Figure 2.5: Unsuccessful nitroalkenes. 
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Absolute Configuration Determination 
The absolute configurations of Michael products 511e, 517b, 518a and 519a were 
determined by X-ray crystallography (Figure 2.6). The relative stereochemistry of the 
remaining products was assigned by analogy with the observed sense of 
enantioinduction in the representative products. 
 




Figure 2.6: Crystal structures of Michael adducts 511e, 517b, 518a and 519a 
(Continued). 
2.7.4 Mechanistic Discussion  
It was shown that the catalyst might cause an isomerisation of α-alkyl-β-nitroacrylates. 
This resulted in a low yield of the Michael adducts (Table 2.5). To investigate this 
problem, Z-nitroalkene 510a was mixed with the nickel catalyst without an 
acetylazaarene substrate. After 40 h of continuous stirring, four nitroalkenes were found 
in a crude mixture. There were 56% of E-510a, 24.5% of Z-510a, and 16% and 3.5% of 
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alkenes E-512 and Z-512 respectively (Scheme 2.56). This result demonstrated that 
Z-nitroalkene 510a undergoes isomerisation over the course of the reaction. 
 
[a] yields were relative to total nitroalkene signals. 
Scheme 2.56: Isomerisation of Z-nitroalkene 510a.[a] 
The four alkenes were determined by the 1H-1H NOESY experiments. For the E-510a, 
there was no cross peak observed between CH2 and =CHNO2. However, a strong 
correlation was detected between CH2 and =CHNO2 of Z-510a. Regarding Z-alkene 
512, there was a strong NOE correlation between =CH and CH2NO2. However, for 
E-alkene 512 there was a cross peak between CH2 and CH2NO2 instead (Figure 2.7). 
 
Figure 2.7: 1H-1H NOESY experiments of 510a and 512. 
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As shown in Table 2.5 (entry 7), the NMR yield in the presence of azaarene 458 was 
only 83%, and the isomerised alkene E-512 was about 15% (entry 7). This result 
indicated that alkene E-512 could not isomerise back to nitroalkene 510a to generate a 
higher quantity of chiral product 511a. To test this hypothesis, the isomerised alkene 
E-512 was investigated by putting this alkene in the same catalytic system as shown 
above with or without 2-acetylpyridine (458) (Scheme 2.57). Michael product 511a, 
isomerised alkene Z-512 or nitroalkenes 510a were not observed in the reaction mixture 
apart from the starting material E-512. This result proved that alkene E-512 does not 
undergo isomerisation in this reaction medium. 
 
Scheme 2.57: Reaction of alkene E-512. 
It was therefore decided to investigate the effect of nitroalkene configuration on the 
yield and stereochemical outcome of the reaction. Usually, in most asymmetric reactions 
involving activated alkenes as electrophiles, E- and Z-olefins provide stereodivergent 
products or products with opposite absolute configurations.175 For example, in the 
enantioselective nickel-catalysed Friedel−Crafts alkylation reaction of indoles with 
β-methylnitrostyrenes investigated by Jia and co-workers,163 E- and 
Z-β-methylnitrostyrenes gave opposite stereoisomers with significantly lower ee values 




Scheme 2.58: Enantioselective nickel-catalysed Friedel−Crafts alkylation of indole 
(464) to E- and Z-nitroalkenes 490.163 
Moreover, in the study of organocatalytic asymmetric transfer hydrogenations of 
β-nitroacrylates by List and co-workers173 it was shown that the stereochemical outcome 
of nitroolefin reduction strongly depends on the substrate olefin geometry, with E- and 
Z-nitoalkenes 510b giving products with opposite enantiomers (Scheme 2.59). The 
authors proposed that the addition of triphenylphosphine creates a rapid equilibrium 
between E-510b and Z-510b via a conjugate addition/elimination pathway and 
E-starting material dominates the equilibrium of the two olefin isomers resulting in 




Scheme 2.59: Organocatalytic asymmetric transfer hydrogenation of β-nitroacrylates 
510b.173 
In the present chemistry, if Z- and E-nitroalkenes reacts with 2-acetylazaarene in a 
similar manner, opposite enantiomers would be obtained. Moreover, if one nitroalkene 
isomer reacts faster than the other, the enantiomeric excess obtained would be different 
for the two nitroalkene isomers. To test this hypothesis, the Michael reactions of both 
Z- and E-nitroalkenes 510a with 2-acetylpyridine (458) were investigated. Surprisingly, 
both Z- and E-nitroalkenes 510a gave the same enantiomer of 511a (78% ee) which 
suggests that one isomer is either much more reactive than the other, or maybe the 




Scheme 2.60: Nickel-catalysed enantioselective Michael addition of 2-acetylpyridine 
(458) to Z- and E-nitroalkenes 510a. 
In order to determine which is the more reactive nitroalkene, two stoichiometric 
reactions were set up separately using Z- and E-nitroalkenes 510a as starting materials. 
The reaction using Z-510a generated Michael adduct 511a with only 25% yield 
(78% ee) for the reaction time of 24 h. In addition, there were two isomerised alkenes, 
E-512 and Z-512, observed at 61% and 14% respectively in the reaction mixture. In the 
reaction using E-510a, a quantitative yield of the same product was obtained with the 
same enantioselectivity as with Z-510a, in only 20 minutes (Scheme 2.61). This result 




[a] Determined by NMR analysis of the crude product using 1,3,5-tetramethoxybenzene as internal 
standard 
Scheme 2.61: Stoichiometric reactions of Z- and E-510a. 
Although stereoconvergent reactions of E- and Z- alkenes are rare, a few examples of 
metal-catalysed stereoconvergent enantioselective addition of nucleophiles to alkenes 
have been reported.176 For example, in 1996, Koch and Pfaltz177 studied the 
intramolecular Pd-catalysed allylic alkylations of 1,3-dicarbonyl compounds using chiral 
phosphinooxazoline ligands (Scheme 2.62). It was proposed that the reaction pathway 
involves a rapid equilibration of allylpalladium intermediates, with the enantioselectivity 




Scheme 2.62: Palladium-catalysed intramolecular allylic alkylations of 1,3-dicarbonyl 
compound 529.177 
McQuade and co-workers178 reported the enantioselective synthesis of chiral 
α-substituted allylboronates from allylic ethers using a 6-NHC-Cu(I) catalyst 
(Scheme 2.63). Both trans- and cis-alkenes or a trans-/cis-alkene mixture provided 
chiral products with the same absolute configuration (without showing trans-cis 
isomerisation by NMR analysis of cis-starting material). Moreover, this 
stereoconvergent reaction occurred with high yields, high ee, high SN2′ selectivity, and 
exhibited wide functional group tolerance. After monitoring the reaction by GC and 
1H NMR spectroscopy using a 1:1 trans-/cis- mixture of alkenes, they observed that the 
reaction of trans-532 was faster than that of cis-532. On the basis of this result, they 
speculated that the trans-532 has a lower-barrier transition state than the cis-532 and that 




Scheme 2.63: Stereoconvergent synthesis of chiral α-substituted allylboronates from 
allylic ethers using a 6-NHC-Cu(I) catalyst 533.178 
Organocatalysis has also been reported in stereoconvergent reactions of alkene 
electrophiles.179 MacMillan and co-workers180 developed the first enantioselective 
organocatalytic hydride reduction of enal-olefins with chiral amine catalysts using 
Hantzsch esters as a hydride source (Scheme 2.64). It was suggested that the origin of 
stereoconvergence arises from catalyst accelerated E-Z isomerisation prior to selective 
hydride reduction of the E-olefin. 
 
Scheme 2.64: Organocatalytic hydride reduction of E-and Z-enals 535.180 
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At this point, it was clear that the isomerisation of the nitroalkene is problematic for the 
reaction yield. Another question regarding this result was whether the catalyst 
(metal−ligand complex) causes unwanted isomerisation, or only base (AcO−). To 
determine this, a weak base, NaOAc, was used instead of the nickel catalyst and the 
reaction was run for 40 h (Scheme 2.65). As before, four compounds were detected in 
the crude mixture in a different ratio from the use of nickel-ligand complex catalyst in 
Scheme 2.56. The result suggested that this is a base-mediated isomerisation. 
 
[a] yields were relative to total nitroalkene signals. 
Scheme 2.65: NaOAc mediates isomerisation of nitroalkene Z-510a.[a] 
NaOAc gave a higher ratio of nitroalkenes Z-510a and E-510a (67.3% and 25.9% 
respectively) and a lower ratio of alkenes E-512 and Z-512 (5.1% and 1.7%) than when 
Ni(OAc)2·4H2O was used. From this observation, it was postulated that NaOAc would 
improve the reaction yield because it generates the more reactive nitroalkene Z-510a 
in situ. To test this hypothesis, compound 511e was resynthesised by adding 5.0 mol% 
of NaOAc in the reaction in addition to the catalyst. Fortunately, the yield was improved 




Scheme 2.66: NaOAc as a yield-improving compound for enantioselective Michael 
reaction. 
On the basis of the results mentioned above, a possible catalytic cycle for these 
reactions, using 2-acetylpyridine (458) and nitroalkene 510a for illustrative purposes, is 
shown in Scheme 2.67. Presumably, coordination of 2-acetylpyridine (458) to the nickel 
catalyst allows acetate anion (AcO−) to deprotonate the α-proton of the acetyl group to 
generate the nucleophile nickel enolate complex 539c. In the presence of base (AcO−), 
Z-nitroalkene 510a undergoes isomerisation to generate E-nitroalkene 510a, which is the 
reactive electrophile. This electrophile engages in ligand exchange with the complex 
539c. It is believed that the Michael addition proceeds in a way that minimises 
unfavourable steric interactions between the alkene and ligand to give complex 539e, 
which is then protonated through proton transfer from AcOH to release the product and 




Scheme 2.67: Proposed mechanism. 
2.8 Conclusion and Future Studies 
In summary, Michael additions of azaarenes to nitroalkenes have been investigated by 
using a chiral nickel(II)−bis(oxazoline) complex. The process is tolerant of a range of 
azaarene pronucleophiles and nitroalkene electrophiles, and the reactions proceed under 
mild, experimentally convenient conditions. Aromatic nitroacrylates react smoothly to 
give products bearing all carbon quaternary stereocentres with high yields and excellent 
enantioselectivities. However, aliphatic nitroacrylates only give products with moderate 
to high yields and selectivities. Although nitroalkenes with acyl and trifluoromethyl 
substituents give products with reasonable yields and enantioselectivities, the 
nitroalkene with phosphonate ester generates product in very low yield. 
Further investigations of this isomerisation chemistry will be a Michael addition of 
azaarenes containing unsaturated groups in order that varieties of new products can be 
explored. For instance, with α,β-unsaturated carbonyl compound 540 as starting 
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material, the complex product 543 could be accessed (Scheme 2.68(a)). Interestingly, 
this product has two contiguous stereogenic centres. Moreover, one carbon is a 
quaternary carbon having four different functional groups (pyridyl, vinyl, carbonyl and 
alkyl) attached. The other two azaarenes 541 and 542 are also interesting because they 
could generate chiral all-carbon quaternary adducts containing α,β-unsaturated carbonyl 
and azaarene in their structures (Scheme 2.68(b)). 
 
Scheme 2.68: New potential heteroarenes. 
Not only new azaarenes, but also new nitroalkenes will receive considerable attention. 
As mentioned in the previous section, β-methyl β-phenyl-nitroalkene 490 was 
unsuccessful (see Scheme 2.54). However, β-heteroaryl β-alkylnitroalkene 545 and 
β,β-diarylnitroalkene 546 could give chiral products. Also nitrodiene 547 is worth 
studying as it could afford an interesting product as well as pyridine-N-oxide substrate 
548. 
 





Unless otherwise stated, all commercially available reagents were used without further 
purification. Solvents were dried and purified by passage through activated alumina 
columns using a solvent purification system. Unless specified otherwise, all of 
non-aqueous reactions were carried out under a nitrogen atmosphere in oven-dried 
glassware. Microwave-assisted reactions were carried out in thick-wall glass vials using 
a Biotage Initiator. Thin layer chromatography (TLC) was performed on Merck 
DF-Alufoilien 60F254 0.2 mm precoated plates. Product spots were visualised by UV 
light at 254 nm, and subsequently developed using potassium permanganate, vanillin or 
ninhydrin solution as appropriate. Flash column chromatography was carried out using 
silica gel (Fisher Scientific 60 Å particle size 35-70 micron) employing the method of 
Still and co-workers.181 Melting points were recorded on a Gallenkamp or Griffin 
melting point apparatus and are uncorrected. Infra-red spectra were recorded on a 
Shimadzu IRAffinity-1 instrument. All 1H NMR spectra were recorded on a Bruker 
AVA400 (400 MHz), a Bruker AVA500 (500 MHz) or a Bruker AVA600 (600 MHz). 
Chemical shifts (δ) are quoted in parts per million (ppm) downfield of tetramethylsilane, 
using residual protonated solvent as internal standard (Acetone-d6 at 2.05 ppm, CDCl3 at 
7.27 ppm, CD3OD at 3.31 ppm and DMSO-d6 at 2.50 ppm). Abbreviations used in the 
description of resonances are: s (singlet), d (doublet), t (triplet), q, (quartet), app 
(apparent), br (broad), m (multiplet). Coupling constants (J) are quoted to the nearest 
0.1 Hz. Proton-decoupled 13C NMR spectra were recorded on a Bruker AVA400 
(100.6 MHz) spectrometer, a Bruker AVA500 (125.8 MHz) spectrometer or a Bruker 
AVA600 (150.8 MHz) spectrometer. Assignments were made using the DEPT sequence 
with secondary pulses at 90º and 135º. For proton-decoupled 19F NMR spectra, chemical 
shifts (δ) are quoted in parts per million (ppm) downfield of CFCl3. For 
proton-decoupled 31P NMR spectra, chemical shifts (δ) are quoted in parts per million 
(ppm) downfield of tetramethylsilane, using residual protonated solvent as internal 
standard (aqueous 85% H3PO4 at 161.9 MHz with respect to tetramethylsilane at 
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400.00 MHz). Optical rotations were performed on an Optical Activity POLAAR 20 
polarimeter. Chiral HPLC analysis was performed on an Agilent 1100 instrument using 
4.6 x 250 nm columns. Authentic racemic samples of products for chiral HPLC assay 
determinations were obtained using [Rh(cod)Cl]2 (2.5 mol%) as an achiral precatalyst 
(or Ni(OAc)2·4H2O/ rac-498 for the nickel catalysed Michael addition project). 
High-resolution mass spectra were recorded using electrospray ionisation (ESI) or 
electron impact (EI) techniques at the EPSRC National Mass Spectrometry Service 
Centre, University of Wales, Swansea, or on a Finnigan MAT 900 XLTspectrometer at 
the School of Chemistry, University of Edinburgh. 
3.1 Enantioselective Rhodium-Catalysed Addition of 
Allylboron Reagents to Cyclic Imines 




Compounds E-260,182 Z-260,182a,183 263,182a,184 264,184,185 265,185 243a,182a 276,185 
281,184,185 282182a,184 and 283185 were prepared by Hamish B. Hepburn and Dr Yunfei 
Luo following a slight modification of previously reported procedures. Yields and 





Potassium allyltrifluoroborate (243) 
 
In a modification of a previously reported procedure,186 to a solution of B(OMe)3 
(6.44 g, 62.0 mmol) in THF (42 mL) was added dropwise allylmagnesium chloride 
(2.0 M in THF, 25 mL, 50.0 mmol) at –78 ºC. The mixture was stirred at this 
temperature for 30 min then the ice bath was removed. The yellow solution with a white 
precipitate was allowed to reach room temperature over a 1 h period. Then, it was cooled 
to 0 ºC and KHF2 (19.5 g, 250 mmol) was added in one portion. This was followed by 
the dropwise addition of H2O (27 mL). The mixture was stirred at room temperature for 
30 min and then concentrated in vacuo until no water remains. The crude solid was 
extracted with hot acetone (4 x 100 mL). The extracts were filtered through a Celite pad. 
The filtrate was concentrated to afford a white solid. This solid was purified by 
dissolving in the minimum amount of hot acetone (5 mL), followed by cooling to room 
temperature and precipitation with Et2O. The precipitate was collected and dried under 
high vacuum to yield 2.56 g (35%) of a powdery white solid. 1H NMR (500 MHz, 
Acetone-d6) δ (1H, dq, J = 10.0, 7.9 Hz, CH=), 4.70-4.62 (1H, m, CH2=), 4.55 (1H, dd, 
J = 10.0, 2.6 Hz, CH2=), 1.15-1.02 (2H, m, CH2); 13C NMR (125.8 MHz, Acetone-d6) 








Chiral Ligands and Rhodium-Catalysts 
 
(R)-Binap 160 was purchased from Acros. Diene ent-159 was purchased from 
Manchester Organics. Dienes 247,73 248,73 and ent-22194 were prepared by Hamish B. 
Hepburn according to previously reported procedures. Diene 249129 was prepared by 
Iain D. Roy according to previously reported procedure. Diene 221,94 250,187 Catalysts 
[Rh((R)-221)Cl]294 and [Rh(ent-221)Cl]294 were were prepared by Dr. Yunfei Luo 
according to previously reported procedures. Yields and reaction times reported in this 
Section are unoptimised. 
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3.1.2 The Synthesis of Imines and Related Substrates 
 
Compounds 61,188 150a,189 and 202b-202j81 were prepared by Dr Yunfei Luo according 
to previously reported procedures. Compounds 244188 and 138190 were prepared by 
Dr Daneil Best according to previously reported procedures. Compounds 256a191 and 
213a192 219a,193 219b,194 219c78 were prepared by Hamish B. Hepburn according to 






General Procedure A: Synthesis of 1,2,3-Benzoxathiazine-2,2-dioxides 
 
In a modification of a previously reported procedure,195 to a solution of chlorosulfonyl 
isocyanate (21.14 g, 150 mmol) in dry dichloromethane (100 mL) at 0 ºC was added 
solution of formic acid (6.87 g, 150 mmol) in dry dichloromethane (40 mL) dropwise 
(Caution: the apparatus should be well vented as gas evolution ensues upon addition of 
formic acid). The mixture was stirred for 1 h at 0 ºC. The cold dichloromethane was then 
removed with the aid of cannula. The resulting solid was dried in vacuo to give sulfamyl 
chloride (H2NSO2Cl) in quantitative yield. Then, to a solution of appropriate aldehydes 
or ketones (50 mmol) in DMA (150 mL) at 0 ºC was transferred solid sulfamyl chloride 
(150 mmol) (Caution: a mild exotherm is generally noted upon combination of these 
reagents). The mixture was allowed to warm up to ambient temperature and stirred 
overnight. The reaction was quenched by a pH 7 NaH2PO4/NaOH aqueous buffer 
solution (100 mL) and extracted with Et2O (3 x 50 mL). The combined organic layers 
were washed successively with H2O (2 x 20 mL) and saturated NaCl (aq) (40 mL), dried 
(MgSO4), filtered and concentrated in vacuo. The crude product was purified by flash 
chromatography to afford the imine substrates. 
1,2λ6,3-Benzoxathiazine-2,2-dione (202a). The title compound was 
prepared according to General Procedure A from salicylaldehyde (6.11 g, 50 
mmol) and was purified by column chromatography (20-60% 
EtOAc/Hexane) to afford the imine 202a as a white solid (8.31 g, 91%). 
Rf = 0.40 (40% EtOAc/Hexane); 1H NMR (500 MHz, CDCl3) δ 8.68 (1H, s, CH=N), 
7.77 (1H, ddd, J = 8.4, 7.5, 1.6 Hz, ArH), 7.70 (1H, dd, J = 7.7, 1.5 Hz, ArH), 7.44 (1H, 
td, J = 7.6, 1.0 Hz, ArH), 7.32-7.29 (1H,m, ArH); 13C NMR (125.8 MHz, CDCl3) 
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δ 167.6 (CH), 154.2 (C), 137.6 (CH), 130.8 (CH), 126.2 (CH), 118.6 (CH), 115.4 (C). 
The NMR data were in agreement with the literature.195b 
2,2,2-Trifluoro-2-methoxyacetophenone (551) 
 
In a modification of a previously reported procedure,196 to a solution of phenyltrifluoro 
acetate (549) (15 g, 80 mmol) in THF at –78 ºC (40 mL) was dropwise added a THF 
solution of 4-methoxyphenylmagnesium bromide (550) (1.0 M, 53 mL, 53 mmL). After 
stirring for 1 h at this temperature, the reaction was quenched with sat. NH4Cl (50 mL) 
and the whole mixture was extracted with EtOAc (3 x 100 mL). The obtained organic 
layers were washed with brine, dried (MgSO4), filtered and concentrated in vacuo. The 
residue was purified by column chromatography (4-12% EtOAc/hexane) and distilled to 
give product 551 as a colourless oil (5.26 g, 49%). Rf = 0.26 (10% EtOAc/Hexane); 
1H NMR (500 MHz, CDCl3) δ 7.70-7.64 (1H, m, ArH), 7.63-7.56 (1H, m, ArH), 
7.09-6.96 (2H, m, ArH), 3.92 (3H, s, OCH3); 13C NMR (125.8 MHz, CDCl3) δ 183.0 
(q, J = 36.4 Hz, C), 159.8 (C), 135.9 (CH), 131.3 (CH), 121.7 (C), 120.7 (CH), 116.2 (q, 
J = 291.0 Hz, CF3), 112.1 (CH), 55.8 (CH3); 19F NMR (376 MHz, CDCl3) δ –74.1 ppm. 
The NMR data were in agreement with the literature.196 
2-Trifluoroacetylphenol (552) 
 
In a modification of a previously reported procedure,195b to a solution of ketone 551 
(5.26 g, 25.77 mmol) in 20 mL of dichloromethane cooled to –78 ºC was added 
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dropwise of a solution of BBr3 (1.0 M, 24 mL, 24 mmol). The mixture was warmed 
slowly to ambient temperature and stirred for 10 h. The mixture was then cooled to 0 ºC 
and carefully quenched by the slow addition of H2O (15 mL). The mixture was extracted 
with dichloromethane (3 x 50 mL). The combined organics were dried (MgSO4), filtered 
and concentrated in vacuo. The crude product was purified by flash chromatography 
(10% EtOAc/Hexane) to afford the corresponding ketone 552 as a colourless oil (2.29 g, 
47%). Rf = 0.46 (30% EtOAc/Hexane); 1H NMR (500 MHz, CDCl3) δ 11.08-11.07 (1H, 
m, OH), 7.86-7.82 (1H, m, ArH), 7.67-7.62 (1H, m, ArH), 7.10 (1H, dd, J = 8.5, 0.8 Hz, 
ArH), 7.02 (1H, ddd, J = 8.3, 7.2, 1.1 Hz, ArH); 13C NMR (125.8 MHz, CDCl3) δ 184.4 
(q, J = 35.3 Hz, C), 164.6 (C), 139.0 (CH), 130.7 (q, J = 3.8 Hz, CH), 120.0 (CH), 119.1 
(CH), 116.4 (q, J = 289.9 Hz, CF3), 113.9 (C); 19F NMR (376 MHz, CDCl3) δ –70.3 
ppm. The NMR data were in agreement with the literature.195a 
4-Trifluoromethyl-1,2,3-benzoxathiazine-2,2-dioxide (203). The title 
compound was prepared according to a slight modification of General 
Procedure A from 2-trifluoroacetylphenol (552) (2.03g, 10.68 mmol) to 
afford a yellow solid (1.72 g, 64%). Rf = 0.25 (30% EtOAc/hexane);  
1H NMR (500 MHz, CDCl3) δ 7.98-7.40 (1H, m, ArH), 7.87 (1H, ddd, J = 8.9, 7.6, 1.5 
Hz, ArH), 7.54-7.49 (1H, m, ArH), 7.44 (1H, dd, J = 8.4, 0.8 Hz, ArH); 13C NMR 
(125.8 MHz, CDCl3) δ 162.1 (dd, J = 75.3, 37.6 Hz, C), 155.1 (C), 138.8 (CH), 128.5 
(q, J = 3.2 Hz, CH), 126.7 (CH), 119.6 (CH), 118.3 (q, J = 281.4 Hz, CF3), 111.7 (C); 










In a modification of a previously reported procedure,197 a mixture of 3-hydroxy-3-
methyl-2-butanone (553) (2.12 g, 20.75 mmol), benzaldehyde (246) (4.4 g, 41.52 mmol) 
and LiOH (96 mg, 4 mmol) in methanol (60 mL) and H2O (20 mL) was stirred overnight 
at room temperature. Methanol was then removed under reduced pressure and H2O 
(80 mL) was added. The mixture was extracted with dichloromethane (3 x 50 mL). The 
combined organics were dried (MgSO4), filtered and concentrated in vacuo. The crude 
product was purified by flash chromatography (5% EtOAc/Hexane) to afford a yellow 
oil (2.83 g, 72%). Rf = 0.30 (30% EtOAc/Hexane); 1H NMR (400 MHz, CDCl3) δ 7.86 
(1H, d, J = 15.7 Hz, CH=), 7.64-7.58 (2H, m, ArH), 7.47-7.38 (3H, m, ArH), 7.06 
(1H, d, J = 15.7 Hz, CH=), 4.01 (1H, s, OH), 1.48 (6H, s, 2 x CH3); 13C NMR (100.6 
MHz, CDCl3) δ 202.4 (C), 145.5 (CH), 134.2 (C), 131.0 (CH), 129.0 (2 x CH), 128.6 
(2 x CH), 118.4 (CH), 75.5 (C), 26.4 (2 x CH3). The NMR data were in agreement with 
the literature.197 
5,5-Dimethyl-4-[(E)-2-phenylethenyl]-5H-1,2λ6,3-oxathiazole-2,2-
dione (213f). The title compound was prepared according to a slight 
modification of General Procedure A (in that pyridine (4.5 equiv) was 
added and the solvent was acetonitrile instead of DMA) from 554 (515 mg, 2.7 mmol) 
and was purified by column chromatography (20% EtOAc/hexane) to give a white solid 
(162 mg, 24%). m.p. 146-148 ºC (EtOAc/Hexane); Rf = 0.34 (30% EtOAc/Hexane); 
IR (film) 2954, 1629, 1560, 1360, 1197, 1178, 1111, 966, 862, 656 cm−1; 1H NMR 
(500 MHz, CDCl3) δ 8.16 (1H, d, J = 15.7 Hz, CH=), 7.65-7.62 (2H, m, ArH), 7.54-7.45 
(3H, m, ArH), 6.63 (1H, d, J = 15.7 Hz, CH=), 1.75 (6H, s, 2 x CH3); 13C NMR 
(125.8 MHz, CDCl3) δ 180.7 (C), 149.5 (CH), 133.5 (C), 132.2 (CH), 129.3 (2 x CH), 
129.0 (2 x CH), 112.0 (CH), 93.8 (C), 25.0 (2 x CH3); HRMS (ESI) Exact mass calcd. 





1,2,6-Thiadiazine-1,1-dioxide potassium salt (556) 
 
In a modification of a previously reported procedure,198 to stirred ethanol (30 mL) was 
gently dropped acetyl chloride (0.5 mL) and the mixture was stirred for 30 min. To this 
solution, sulfamide (431 mg, 4.48 mmol) and 1,1,3,3-tetramethoxypropane (555) 
(1.1 g, 6.72 mmol) were added. The mixture was heated at reflux for 3 h. and then 
evaporated to dryness in vacuo. The residue was dissolved in ethanol (30 mL). 
Potassium tert-butoxide (502 mg, 4.50 mmol) was added at ambient temperature before 
the reaction mixture was heated at 80 ºC for 10 min, filtered whilst hot, cooled and 
partially evaporated. The solution was kept in refrigerator for 24 h and the precipitated 
product 556 was filtered and washed with diethyl ether (10 mL) to afford the salt 
product 556 as a pale yellow solid (494 mg, 65%). 1H NMR (500 MHz, CD3OD) δ 7.56 
(2H, d, J = 5.3 Hz, NCH and CH=N), 5.54 (1H, t, J = 5.3 Hz, NCH=CH); 13C NMR 
(125.8 MHz, CD3OD)  159.0 (2 x CHN), 98.4 (CH). The NMR data were in agreement 
with the literature.198 
2-Benzyl-1,2,6-thiadiazine-1,1-dioxide (252a) 
 
In a modification of a previously reported procedure,198 benzyl bromide (1.14 g, 6.64 
mmol) was added to the solution of 1,2,6-thiadiazine-1,1-dioxide potassium salt (556) 
(564 mg, 3.32 mmol) in acetonitrile 40 mL. The mixture was stirred at room temperature 
for 3 h and then the solvent was evaporated to give a crude product. The residue was 
purified by silica gel chromatography (40% EtOAc/hexane) to afford 252a as a white 
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solid (544 mg, 74%). Rf = 0.21 (40% EtOAc/hexane); 1H NMR (500 MHz, CDCl3) 
δ 7.95 (1H, dd, J = 4.4, 2.5 Hz, CH=N), 7.44-7.37 (5H, m, ArH), 7.13 (1H, dd, J = 7.2, 
2.5 Hz, NCH=), 5.82 (1H, dd, J = 7.2, 4.4 Hz, NCH=CH), 4.95 (1H, s, CH2); 13C NMR 
(125.8 MHz, CDCl3)  162.4 (C=N), 147.7 (CH), 133.6 (C), 129.3 (2 x CH), 129.1 




In a modification of a previously reported procedure,198 sulfuryl chloride (267 mg, 
1.98 mmol) was added to a solution of 2-benzyl-1,2,6-thiadiazine-1,1-dioxide (252a) 
(398 mg, 1.80 mmol) in dichloromethane (8 mL). The mixture was heated at reflux for 
3 h, and then the solvent was evaporated to give a crude product. The residue was 
purified by silica gel chromatography (40% EtOAc/hexane) to afford 252b as a pale 
yellow solid (391 mg, 85%). Rf = 0.54 (40% EtOAc/hexane); 1H NMR (500 MHz, 
CDCl3) δ 7.95 (1H, d, J = 3.1 Hz, CH=N), 7.47-7.37 (5H, m, ArH), 7.18 (1H, d, J = 3.1 
Hz, NCH=), 4.93 (2H, s, CH2); 13C NMR (125.8 MHz, CDCl3)  161.8 (CH=N), 144.7 
(CH), 133.0 (C), 129.5 (3 x CH), 128.8 (2 x CH),  107.5 (C), 53.6 (CH2). The NMR data 











In a modification of a previously reported procedure,198 bromine in dichloromethane 
(1 M, 3.6 mL, 3.60 mmol) was added dropwise to a solution of 2-benzyl-1,2,6-
thiadiazine-1,1-dioxide (252a) (800 mg, 3.56 mmol) in dry dichloromethane (10 mL). 
The mixture was stirred at ambient temperature for 30 min before the solvent was 
evaporated. The residue was purified by silica gel chromatography (40% EtOAc/hexane) 
to afford the pure product 252c as a white solid (837 mg, 78%). Rf = 0.59 
(40% EtOAc/hexane); 1H NMR (500 MHz, CDCl3) δ 7.97 (1H, d, J = 2.9 Hz, CH=N), 
7.47-7.37 (5H, m, ArH), 7.24 (1H, d, J = 2.9 Hz, NCH=), 4.93 (1H, s, CH2); 13C NMR 
(125.8 MHz, CDCl3)  163.1 (C=N), 146.9 (CH), 133.0 (C), 129.5 (2 x CH), 129.4 
(CH), 128.8 (2 x CH), 92.3 (C), 53.6 (CH2). The NMR data were in agreement with the 
literature. 198 
General Procedure B: Synthesis of 1,2,6-Thiadiazine 1,1-Dioxides and 
1,2,5-Thiadiazole 1,1-Dioxides 
 
In a modification of a previously reported procedure,191,199 to stirred ethanol (10 mL) 
was gently dropped acetyl chloride (0.50 mL). After stirring at room temperature for 
10 min sulfamide (192 mg, 2.00 mmol) and dicarbonyl compound (3.00 mmol) were 
added. The mixture was heated at reflux for 3 h and then concentrated in vacuo. The 
residue was triturated with several portions of hexane and filtered to afford 1,2,6-
thiadiazine 1,1-dioxides or 1,2,5-thiadiazole 1,1-dioxides. 
5-Phenyl-3-methyl-(2H)-1,2,6-thiadiazine 1,1-dioxide (253c). The 
title compound was prepared according to General Procedure B from 
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1-phenyl-1,3-butanedione (485 mg, 3.00 mmol) to obtain a pale yellow solid (431 mg, 
98%). m.p. (EtOH) 173-175 ºC (lit. 174 ºC); Rf = 0.28 (CH2Cl2; 1H NMR (500 MHz, 
DMSO-d6) δ 7.95 (2H, d, J = 7.6 Hz, ArH), 7.59 (1H, t, J = 7.3 Hz, ArH), 7.52 (2H, t, 
J = 7.6 Hz, ArH), 6.55 (1H, s, CH=), 3.85 (1H, s, NH), 2.55 (3H, s, CH3); 13C NMR 
(125.8 MHz, DMSO-d6)  166.0 (C=N), 161.4 (=CN), 135.0 (C), 132.8 (CH), 129.4 




In a modification of a previously reported procedure,201 acetophenone (557) (2.41 g, 
0.02 mol) was dissolved in dry toluene 80 mL and the mixture was cooled to 0 ºC. 
Sodium hydride (1.20 g, 0.03 mol) was added to the solution and the mixture was stirred 
for 30 min. Ethyl formate (2.22 g, 0.03 mol) was then added dropwise to the reaction 
mixture which was maintained at <5 ºC, after the addition the reaction mixture was 
stirred for another 2 h then allowed to warm to room temperature, and stirred for 15 h. 
Water (100 mL) was added to the slurry, and the reaction was stirred for an additional 
30 min and then partitioned between organic layer and aqueous. The aqueous layer was 
extracted with dichloromethane (2 x 50 mL). This organic extract was discarded. The 
aqueous phase was then acidified with 5% hydrochloric acid and extracted with 
dichloromethane (3 x 50 mL). This extract was washed with water and brine, dried 
(Na2SO4), filtered and concentrated in vacuo to give compound 558 as a yellow oil 
(1.61 g, 54 %). Rf = 0.49 (40% EtOAc/hexane); 1H NMR (500 MHz, CDCl3) δ 15.33 
(1H, br s, J = 1.8 Hz, OH), 8.29 (1H, d, J = 4.2 Hz, CH=), 7.93-7.90 (2H, m, ArH), 
7.58-7.54 (1H, m, ArH), 7.49-7.45 (2H, m, ArH), 6.23 (1H, d, J = 4.2 Hz, CH=). 
13C NMR (125.8 MHz, CDCl3):  = 187.8 (C=O), 178.6 (CH), 134.9 (C), 132.8 (CH), 
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128.6 (2 x CH), 127.3 (2 x CH), 98.2 (CH). The NMR data were in agreement with the 
literature.201 
5-Phenyl-(2H)-1,2,6-thiadiazine 1,1-dioxide (253a). The title compound 
was prepared according to a slight modification of General Procedure B 
from 3-oxo-3-phenylpropanol (558) (240 mg, 1.62 mmol) to obtain a 
yellow solid (145 mg, 64%). m.p. (EtOAc/hexane) 130-132 ºC; Rf = 0.18 (EtOAc); 
IR (film) 3132 (NH), 1600, 1506, 1489, 1433, 1398, 1328, 1172, 761, 740 cm−1; 
1H NMR (500 MHz, DMSO-d6) δ 7.98-7.95 (2H, m, ArH), 7.81 (1H, d, J = 7.0 Hz, 
NCH=), 7.63-7.58 (1H, m, ArH), 7.55-7.51 (2H, m, ArH), 6.57 (1H, d, J = 7.0 Hz, 
CH=), 3.76 (1H, s, NH); 13C NMR (125.8 MHz, DMSO-d6) δ 167.3 (C=N), 149.3 
(=CHN),   135.0 (C), 133.1 (CH), 129.5 (2 x CH), 128.1 (2 x CH), 96.6 (CH); HRMS 
(ESI) Exact mass calcd. for C9H8N2O2SNa [M+Na]+: 231.0199, found 231.0202. 
3-Ethoxy-4-phenyl-1,2,5-∆2-thiadiazolidine 1,1-dioxide (290).The title 
compound was prepared according to a slight modification of General 
Procedure B from phenylglyoxal monohydrate (484 mg, 3.18 mmol) to 
obtain a pale yellow solid (476 mg, 94%). m.p. (EtOAc/hexane) 106-108 ºC; Rf = 0.24 
(40% EtOAc/hexane); IR (film) 3310 (NH), 1597, 1570, 1450, 1352, 1176, 1097, 982, 
810, 739 cm−1; 1H NMR (500 MHz, CDCl3) δ 8.10-8.07 (2H, m, ArH), 7.68-7.64 (1H, 
m, ArH), 7.53-7.48 (2H, m, ArH), 6.22 (1H, d, J = 5.2 Hz, NH), 5.95 (1H, d, J = 5.2 Hz, 
CH), 3.77-3.70 (1H, m, CH2), 3.55-3.48 (1H, m, CH2), 1.19 (3H, s, CH3); 13C NMR 
(125.8 MHz, CDCl3)  174.5 (C=N), 135.0 (CH), 130.4 (2 x CH), 129.1 (2 x CH), 
127.9 (C), 88.4 (CH), 62.9 (CH2), 14.7 (CH3); HRMS (ESI) Exact mass calcd. for 
C10H13N2O3SNa [M+Na]+: 241.0641, found 241.0652. 
3-Phenyl-4-methyl-1,2,5-thiadiazole 1,1-dioxide (256b). The title 
compound was prepared according to a slight modification of General 
Procedure B from 1-phenyl 1,2-propanedione ( 208 mg, 1.40 mmol) to obtain 
a pale yellow solid (186 mg, 96%). m.p. (EtOAc/hexane)138-140 ºC (lit. 135 ºC); 














ArH), 7.73 (1H, t, J = 7.5 Hz, ArH), 7.61 (2H, t, J = 7.8 Hz, ArH), 2.78 (3H, s, CH3); 
13C NMR (125.8 MHz, CDCl3)  167.7 (C=N), 165.7 (C=N), 134.3 (CH), 130.2 
(2 x CH), 129.4 (2 x CH), 127.3 (C), 18.8 (CH3). The data were in agreement with the 
literature.191,199 
3,4-Diphenyl-1,2,5-thiadiazole 1,1-dioxide (256c). The title compound was 
prepared according to a slight modification of General Procedure B from 
1,2-diphenylethane 1,2-dione (710 mg, 3.38 mmol) to obtain a white solid 
(228 mg, 84%). m.p. (EtOH) 246-248 ºC (lit. 248 ºC) Rf = 0.58 (40% EtOAc/hexane); 
1H NMR (500 MHz, CDCl3) δ 7.69-7.66 (2H, m, ArH), 7.59-7.57 (4H, m, ArH), 
7.49-7.45 (4H, m, ArH); 13C NMR (125.8 MHz, CDCl3)  165.6 (2 x C=N), 134.0 
(2 x CH), 130.8 (4 x CH), 128.7 (4 x CH), 128.0 (2 x C). The data were in agreement 
with the literature.199,202  
2-Benzyl-5-phenyl-(2H)-1,2,6-thiadiazine 1,1-dioxide (253b) 
 
5-Phenyl-(2H)-1,2,6-thiadiazine 1,1-dioxide (253a) (41 mg, 0.20 mmol) and potassium 
carbonate (84 mg, 0.60 mmol) were dissolved in acetonitrile (12 mL) and the mixture 
was stirred at room temperature for 30 min. Benzyl bromide (68 mg, 0.40 mmol) was 
added to the solution and the mixture was stirred overnight and then concentrated 
in vacuo. The residue was recrystallised (hexane/EtOAc) to afford the pure product 253b 
as a white solid (52 mg, 87%). m.p. 144-146 ºC (CH2Cl2); Rf = 0.27 
(40% EtOAc/hexane); IR (film) 3095, 1599, 1575, 1508, 1485, 1337, 1277, 1227, 1173, 
744 cm−1; 1H NMR (500 MHz, CDCl3) δ 8.0-7.97 (2H, m, ArH), 7.58-7.54 (1H, m, 
ArH), 7.50-7.45 (2H, m, ArH), 7.44-7.37 (5H, m, ArH), 7.21 (1H, d, J = 7.6 Hz, 
NCH=), 6.38 (1H, d, J = 7.6 Hz, CH=CHN), 5.0 (2H, s, CH2); 13C NMR (125.8 MHz, 
CDCl3)  168.8 (C=N), 147.1 (CH), 134.5 (C), 133.9 (C), 132.9 (CH), 129.3 (2 x CH), 
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129.0 (CH), 128.8 (4 x CH), 128.2 (2 x CH), 97.9 (CH), 52.5 (CH2); HRMS (ESI) Exact 
mass calcd. for C16H15N2O7S [M+H]+: 299.0849, found 299.0858. 
(E)-N-(1,3-Diphenylallylidene)-4-methylbenzenesulfonamide (291) 
 
In a modification of a previously reported procedure,203 to a solution of trans-chalcone 
(559) (4.16 g, 20 mmol) in dichloromethane (40 mL), was added p-toluene 
sulphonamide (560) (3.42 g, 20 mmol), triethylamine (5.6 mL, 40 mmol) and TiCl4 
(2.2 mL, 20 mmol) at 0 ºC under N2 (g). The reaction mixture was heated at reflux for 
16 h. Then it was cooled to room temperature and quenched with brine (20 mL). The 
aqueous phase was extracted with dichloromethane (3 x 40 mL) and the combined 
organic layers were dried (MgSO4), filtered and concentrated in vacuo. Purification of 
the residue by column chromatography on silica gel (20% EtOAc/hexane) to afford 291 
as a white solid (4.44 g, 61%). Rf = 0.65 (40% EtOAc/hexane); 1H NMR (400 MHz, 
CDCl3) δ 8.20-8.10 (1H, m, ArH), 7.95 (2H, d, J = 7.2 Hz, ArH), 7.72-7.38 (10H, m, 
ArH and CH=), 7.33 (2H, d, J = 8.1 Hz, ArH), 7.08 (1H, d, J = 16.1 Hz, CH=), 2.43 
(3H, s, CH3); 13C NMR (100.6 MHz, CDCl3) δ 177.5 (C), 148.8 (CH),  143.4 (C), 
138.7 (C), 137.2 (C), 134.5 (C), 131.9 (CH), 131.1 (CH), 130.2 (2 x CH), 129.4 
(2 x CH), 129.0 (2 x CH), 128.7 (2 x CH), 128.3 (2 x CH), 127.2 (2 x CH), 122.5 (CH), 





In a modification of a previously reported procedure,204 to a solution of benzaldehyde 
(246) (0.73g, 6.86 mmol) and N-aminophthalimide (561) (1.06 g, 6.54 mmol) in 
1,4-dioxane (20 mL) was added conc. HCl (2 drops) at room temperature. After the 
mixture was stirred for 5 min, the solvent was evaporated under reduced pressure and 
the residue was purified by silica gel chromatography to afford the pure product 292 as a 
white solid (1.45 g, 88%). Rf = 0.53 (40% EtOAc/hexane); 1H NMR (500 MHz, CDCl3) 
δ 9.41 (1H, s, CH=N), 7.95-7.89 (4H, m, ArH), 7.79 (2H, dd, J = 5.5, 3.0 Hz, ArH), 
7.52-7.44 (3H, m, ArH); 13C NMR (125.8 MHz, CDCl3) δ 165.1 (2 x C), 158.6 (CH), 
134.6 (2 x CH), 133.6 (C), 131.7 (CH), 130.3 (2 x C), 128.8 (2 x CH), 128.4 (2 x CH), 
123.8 (2 x CH). The NMR data were in agreement with the literature.204 
(Z)-N-Benzylidinebenzenamide oxide (293) 
 
In a modification of a previously reported procedure,205 to a stirred mixture of 
nitrobenzene (562) (6.2 mL, 60 mmol) and NH4Cl (3.9 g, 72 mmol) in H2O 60 mL was 
slowly added zinc dust (7.8 g, 120 mmol) while maintaining the temperature below 
60 ºC. After stirring for 15 min, the reaction mixture was filtered while still warm and 
the solid was washed with hot water (20 mL). The filtrate was saturated with NaCl and 
cooled to 0 ºC and the resulting solid was collected and dried. This crude 
N-phenylhydroxylamine was recrystallised from hexane-diethyl ether to give the pure 
product 563 as a white solid (3.3 g, 30 mmol, 50%). To a stirred solution of 
N-phenylhydroxylamine (563) in EtOH was added benzaldehyde (246) (3.1 mL, 
30 mmol). After overnight stirring at room temperature, the mixture was cooled in 
ice−water bath and filtered. The collected solid was recrystallised from EtOH to give the 
title compound 293 (3.1 g, 53 %). Rf = 0.34 (40% EtOAc/hexane); 1H NMR (500 MHz, 
CDCl3) δ 8.50-8.47 (2H, m, ArH), 7.50-7.48 (2H, m, ArH), 7.39 (1H, s, CH=N), 
7.23-7.18 (2H, m, ArH), 7.14-7.10 (1H, m, ArH), 6.96-6.93 (3H, m, ArH); 13C NMR 
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(125.8 MHz, CDCl3) δ 149.9 (C), 133.0 (CH), 131.9 (C), 130.4 (CH), 129.5 (CH), 129.0 
(2 x CH), 128.9 (2 x CH), 128.7 (2 x CH), 128.4 (CH), 122.1 (CH). The NMR data were 
in agreement with the literature.205 
2-Acetylpyridyloxime (294) 
 
In a modification of a previously reported procedure,206 to a stirred solution of 
2-acetylpyridine (458) (1.23 g, 10.15 mmol) and hydroxylamine hydrochloride (0.84 g, 
12 mmol) in 60 mL of ethanol was added pyridine (2 g, 25 mmol). The reaction mixture 
was heated at reflux for 3 h and then cooled down to room temperature. The reaction 
mixture was evaporated to dryness. The residue was purified by silica gel 
chromatography (30% EtOAc/hexane) to afford the pure product 294 as a white solid 
(1.21 g, 90%). Rf = 0.46 (60% EtOAc/hexane); 1H NMR (500 MHz, CDCl3) δ 9.48 (1H, 
br s, NOH), 8.64 (1H, dd, J = 4.8, 0.6 Hz, ArH), 7.85 (1H, d, J = 8.0 Hz, ArH), 7.70 
(1H, dt, J = 7.9, 7.8, 1.8 Hz, ArH), 7.3-7.26 (1H, m, ArH), 2.42 (3H, s, CH3); 13C NMR 
(125.8 MHz, CDCl3) δ 156.7 (C=NOH), 154.3 (C=N), 148.9 (CH), 136.5 (CH), 123.7 
(CH), 120.6 (CH), 10.8 (CH3). The NMR data were in agreement with the literature.206 
1-Benzyl-1,2-dihydropyridin-2-one (295) 
 
In a modification of a previously reported procedure,207 a solution of sodium salt of 
2-hydroxypyridine in tetrahydrofuran (40 mL) was prepared by the use of 
2-hydroxypyridine (564) (2.85 g, 30 mmol) and NaH (1.80 g, 45 mmol). To this 
164 
 
solution, benzyl bromide (7.70 g, 45 mmol) was added and the mixture was heated at 
reflux under N2. After 1 h, the reaction mixture was cooled, poured into aq. NH4Cl 
solution (30 mL), and then extracted with EtOAc. The organic layer was dried (MgSO4), 
filtered and concentrated in vacuo. The residue was purified by silica gel 
chromatography (pure EtOAc) to afford the product 295 as a white solid (4.48 g, 81%). 
Rf = 0.24 (EtOAc); 1H NMR (500 MHz, CDCl3) δ 7.36-7.21 (7H, m, ArH, 2 x CH), 
6.57 (1H, d, J = 9.1 Hz, CH), 6.10 (1H, td, J = 6.7, 1.3 Hz, CH), 5.11 (2H, s, CH2); 
13C NMR (125.8 MHz, CDCl3) δ 162.4 (C), 139.2 (CH), 137.1 (CH), 136.2 (C), 128.6 
(2 x CH), 127.9 (2 x CH), 127.8 (CH), 120.9 (CH), 106.0 (CH), 51.6 (CH2). The NMR 
data were in agreement with the literature.207 
3-Methyl-1,4-benzoxazepin-5(4H)-one (296) 
 
In a modification of a previously reported procedure,208 to a stirred solution of 
salicylamide (565) (428 mg, 3.12 mmol) in acetone (25 mL) were added K2CO3 
(862 mg, 6.24 mmol) and chloroacetone (0.5 mL, 6.24 mmol). The reaction mixture was 
heated at reflux for 2 h and then cooled down to room temperature. After the precipitate 
was removed by filtration, the filtrate was concentrated in vacuo and the residue was 
washed with Et2O (15 mL) to give a white solid. A mixture of the white solid and 
p-toluenesulfonic acid monohydrate (8 mg, 0.04 mmol) in toluene (20 mL) was heated at 
reflux overnight with removal of water with a Dean-Stark trap. The reaction mixture was 
diluted with EtOAc (20 mL), washed with water (20 mL) and brine (20 mL), dried 
(MgSO4), filtered and concentrated in vacuo. The residue was then chromatographed 
over silica gel (40% EtOAc/hexane) to give the title compound 296 as a white solid 
(264 mg, 48%). Rf = 0.36 (40% EtOAc/hexane); 1H NMR (500 MHz, CDCl3) δ 7.89 
(1H, dd, J = 7.8, 1.7 Hz, ArH), 7.80 (1H, br s, NH), 7.47 (1H, ddd, J = 8.1, 7.4, 1.8 Hz, 
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ArH), 7.20 (1H, dt, J = 7.7, 1.1 Hz, ArH), 7.00 (1H, dd, J = 8.1, 1.0 Hz, ArH), 6.13-6.12 
(1H, m, =CHO), 1.80 (3H, d, J = 1.4 Hz, 3 x CH3); 13C NMR (125.8 MHz, CDCl3) 
 167.9 (C=O), 160.6 (=CN), 134.2 (CH), 132.1 (CH), 132.0 (CH), 125.5 (C), 124.5 
(CH), 123.7 (C), 120.2 (CH), 15.9 (CH3). The NMR data were in agreement with the 
literature.208 
3.1.3 Enantioselective Allylation of imines 
General Procedure C: Allylation of Imine Substrates 
 
A Schlenk tube containing the appropriate cyclic imine substrate (0.30 mmol) and 
potassium allyltrifluoroborate (243) (0.45 mmol) was flushed with nitrogen before 
anhydrous THF (3 mL) was added. To this solution was added a stock solution of the 
rhodium–chiral diene complex (11.5 mM in anhydrous dioxane (Prepared by dissolving 
270 mg of [Rh((R)-221)Cl]2 in 27 mL of anhydrous dioxane) 0.39 mL, 0.0045 mmol = 3 
mol % Rh), and MeOH (60 µL, 1.5 mmol), and the resulting mixture was heated to 
55 ºC for 15 h. The reaction was cooled to room temperature, diluted with Et2O (50 mL) 
and filtered through a silica plug. The resultant solution was concentrated to yield crude 
product and was purified using flash column chromatography to yield pure products. 
(R)-[Prop-2-en-1-yl]-5,6-dihydro-2-benzyl-1,2,6-thiadiazine-1,1-
dioxide (254a). The title compound was prepared according to a 
slight modification of General Procedure C (in that the reaction time 
was 15 h) from 1,2,6-thiadiazine-1,1-dioxide 252a (67 mg, 0.30 mmol) and was purified 
by column chromatography (2:40:58 Et3N:EtOAc:hexane) to give a yellow oil  (47 mg, 
59%), which was not stable toward long term storage, and exhibited signs of 
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decomposition after ca. 2 h. Rf = 0.59 (40% EtOAc/hexane); [α]
20
D –29.7 (c 0.94, 
CHCl3); IR (film) 3250 (NH), 1641, 1402, 1334, 1217, 1174, 927, 769, 725, 700 cm−1; 
1H NMR (500 MHz, CDCl3) δ 7.39-7.31 (5H, m, ArH), 5.95 (1H, dd, J = 8.5, 2.1 Hz, 
NCH=), 5.74-5.66 (1H, m, CH=CH2), 5.20-5.15 (2H, m, =CH2),  4.88  (1H,  dd, J = 8.5, 
1.8 Hz, NCH=CH), 4.66 (1H, d, J = 15.1 Hz, PhCH2), 4.43 (1H, d, J = 15.1 Hz, 
PhCH2), 4.36-4.31 (1H, m, NCH), 3.78 (1H, d, J = 10.4 Hz, NH), 2.50-2.44 (1H, m, 
CH2CH=), 2.41-2.35 (1H, m, CH2CH=); 13C NMR (125.8 MHz, CDCl3) δ 135.3 (C), 
132.0 (CH), 130.0 (CH), 128.8 (2 x CH), 128.5 (2 x CH), 128.2 (CH), 120.0 (CH2), 
107.0 (CH),  55.2 (CH), 51.9 (CH2), 37.7 (CH2); HRMS (ESI) Exact mass calcd for 
C13H16NO2SNa [M+Na]+: 287.0825, found: 287.0820. Enantiomeric excess was 
determined by HPLC with a Chiralcel OD-H column (90:10 hexane:i-PrOH, 
0.8 mL/min, 230 nm, 25 ºC); tr (major) = 18.9 min, tr (minor) = 22.7 min; 95% ee. 
(R)-(Prop-2-en-1-yl)-5,6-dihydro-2-benzyl-4-chloro-1,2,6-
thiadiazine-1,1-dioxide (254b).The title compound was prepared 
according to a slight modification of General Procedure C (in that the 
reaction time was 15 h) from 1,2,6-thiadiazine-1,1-dioxide 252b (77 mg, 0.30 mmol) 
and was purified by column chromatography (20% EtOAc/hexane) to give a yellow oil 
(59 mg, 65%). Rf = 0.63 (40% EtOAc/hexane); [α]
20
D +72.5 (c 0.80, CHCl3);  IR (film) 
3250 (NH), 1640, 1454, 1408, 1350, 1292 1215, 1180, 923, 761 cm−1; 1H NMR (400 
MHz, CDCl3) δ 7.41-7.30 (5H, m, ArH), 6.15 (1H, d, J = 1.6 Hz, NCH=), 5.61-5.49 
(1H, m, CH=CH2), 5.21-5.13 (2H, m, =CH2), 4.65 (1H, d, J = 14.8 Hz, PhCH2), 4.36 
(1H, d, J = 14.8 Hz, PhCH2), 4.26 (1H, br s, NCH), 4.00 (1H, br d, J = 6.6 Hz, NH), 
2.82-2.72 (1H, m, CH2CH=), 2.48-2.39 (1H, m, CH2CH=); 13C NMR (100.6 MHz, 
CDCl3) δ 134.4 (C), 130.8 (CH), 129.0 (2 x CH), 128.7 (2 x CH), 128.5 (CH), 128.4 
(CH), 121.3 (CH2), 114.6 (C), 57.6 (CH), 52.8 (CH2), 34.4 (CH2); HRMS (ESI) Exact 
mass calcd for C13H15ClN2O2SClNa [M+Na]+: 321.0435, found: 321.0437; 
Enantiomeric excess was determined by HPLC with a Chiralcel IC column (90:10 
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hexane:i-PrOH, 0.8 mL/min, 230 nm, 25 ºC); tr (minor) = 15.3 min, tr (major) = 17.5 
min; 94% ee. 
(R)-(Prop-2-en-1-yl)-5,6-dihydro-2-benzyl-4-bromo-1,2,6-
thiadiazine-1,1-dioxide (254c). The title compound was prepared 
according to a slight modification of General Procedure C (in that the 
reaction time was 15 h) from 1,2,6-thiadiazine-1,1-dioxide 252c (90 mg, 0.30 mmol) and 
was purified by column chromatography (20% EtOAc/hexane) to give a yellow oil 
(45 mg, 45%). Rf = 0.65 (40% EtOAc/hexane); [α]
20
D +40.3 (c 0.74, CHCl3); IR (film) 
3250 (NH), 1640, 1406, 1352, 1292, 1213, 1180, 929, 761, 700, 617 cm−1; 1H NMR 
(500 MHz, CDCl3) δ 7.42-7.32 (5H, m, ArH), 6.28 (1H, d, J = 1.7 Hz, NCH=), 
5.64-5.55 (1H, m, CH=CH2), 5.23-5.16 (2H, m, =CH2), 4.66 (1H, d, J = 14.9 Hz, 
PhCH2), 4.38 (1H, d, J = 14.9 Hz, PhCH2), 4.33-4.28 (1H, m, NCH), 4.09 (1H, d, 
J = 10.0 Hz, NH), 2.86-2.78 (1H, m, CH2CH=), 2.52-2.46 (1H, m, CH2CH=); 13C NMR 
(125.8 MHz, CDCl3) δ 134.5 (CH), 131.0 (C), 130.8 (CH), 129.0 (2 x CH), 128.7 
(2 x CH), 128.5 (CH), 121.3 (CH2), 103.5 (C), 58.4 (CH), 52.6 (CH2), 35.6 (CH2); 
HRMS (ESI) Exact mass calcd for C13H15BrN2O2SNa [M+Na]+: 364.9930, found: 
364.9927. Enantiomeric excess was determined by HPLC with a Chiralcel IC column 
(90:10 hexane:i-PrOH, 0.8 mL/min, 230 nm, 25 ºC); tr (minor) = 14.0 min, tr (major) 
= 16.2 min; 90% ee. 
(R)-(Prop-2-en-1-yl)-3-methyl-4-phenyl-2,3-dihydro-[1,2,5] thiadiazole 
1,1-dioxide (257b). The title compound was prepared according to a slight 
modification of General Procedure C (in that the reaction time was 12 h) 
from 1,2,5-thiadiazole 1,1-dioxide 256b (62 mg, 0.30 mmol) and was 
purified by column chromatography (20% EtOAc/hexane) to give an orange oil (66 mg, 
88%). Rf = 0.45 (40% EtOAc/hexane); [α]
20
D −29.9 (c 0.74, CHCl3); IR (film) 3244 
(NH), 1557, 1315, 1158, 995, 818, 779, 700, 652, 561 cm−1; 1H NMR (500 MHz, 
CDCl3) δ 8.05-8.02 (2H, m, ArH), 7.65 (1H, t, J = 7.5 Hz, ArH), 7.56-7.52 (2H, m, 
ArH), 5.72-5.63 (1H, m, CH=CH2), 5.28 (1H, d, J = 10.1 Hz, =CH2), 5.21 (1H, dd, 
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J = 1.0, 17.0 Hz, =CH2), 4.53 (1H, br s, NH), 2.91 (1H, dd, J = 14.6, 6.5 Hz, CH2), 2.70 
(1H, dd, J = 14.6, 8.0 Hz, CH2), 1.82 (3H, s, CH3); 13C NMR (125.8 MHz, CDCl3) 
δ 181.6 (C), 133.8 (CH), 130.1 (CH), 130.0 (2 x CH), 129.2 (2 x CH), 128.8 (C), 122.4 
(CH2), 72.3 (C), 43.6 (CH2), 26.3 (CH3); HRMS (ESI) Exact mass calcd for 
C12H15N2O2S [M+H]+: 251.0849. found 251.0848; Enantiomeric excess was determined 
by HPLC with a Chiralpak AD-H column (90:10 hexane:i-PrOH, 0.8 mL/min 280 nm, 
25 ºC); tr (minor) = 43.7 min, tr (major) = 48.2 min; 97% ee. 
(Rac)-4-Phenyl-3-(prop-2-en-1-yl)-2,3-dihydro-[1,2,5]thiadiazole 1,1-
dioxide (257d).The title compound was prepared according to a slight 
modification of General Procedure C (in that the reaction time was 2 h 
and potassium tertiarybutoxide (5 mg, 3 mol %) was added) from 3-ethoxy-4-phenyl-
1,2,5-∆2-thiadiazolidine 1,1-dioxide (290) (73 mg, 0.30 mmol) and was purified by 
column chromatography (40% EtOAc/hexane) to give an colourless oil (57 mg, 80%); 
Rf = 0.62 (60% EtOAc/hexane); IR (film) 3245 (NH), 1597, 1566, 1448, 1341, 1306, 
1173, 928, 812, 768 cm−1; 1H NMR (500 MHz, CDCl3) δ 7.88-7.86 (2H, m, ArH), 
7.67-763 (1H, m, ArH), 7.54-7.50 (2H, m, ArH), 5.83-5.74 (1H, m, CH=CH2), 5.20 
(1H, dd, J = 10.2, 1.1 Hz, =CH2), 5.15-5.09 (3H, m, =CH2, CH=N and NH), 2.69 (1H, 
dddd, J = 12.2, 6.1, 3.1, 1.4 Hz, CH2), 2.43 (1H, ddd, J = 14.91, 8.3, 7.6 Hz, CH2); 
13C NMR (125.8 MHz, CDCl3) δ 179.2 (C), 134.4 (CH), 131.5 (CH), 129.4 (2 x CH), 
129.3 (2 x CH), 128.5 (C), 120.2 (CH2), 64.0 (CH), 38.5 (CH2); HRMS (ESI) Exact 
mass calcd for C11H12N2O2S [M+H]+: 237.0698. found 237.0696; Enantiomeric excess 
was determined by HPLC with a Chiralcel OD-H column (90:10 hexane:i-PrOH, 
0.8 mL/min 280 nm, 25 ºC); tr = 39.5 min, 44.4 min; 0% ee. 
5-Phenyl-3-(prop-2-en-1-yl)-(2H)-1,2,6-dihydrothiadiazine 
1,1-dioxide (255a).The title compound was prepared according to a 
slight modification of General Procedure C (in that the reaction time 
was 24 h) from 5-phenyl-(2H)-1,2,6-thiadiazine 1,1-dioxide (253a) (20 mg, 0.10 mmol) 
and was purified by preparative TLC (2:40:58 Et3N:EtOAc:hexane) to give a colourless 








decomposition after ca 2 h.; Rf = 0.78 (60% EtOAc/hexane); [α]
20
D −250 (c 0.04, 
CHCl3); IR (film) 2924, 1597, 1572, 1448, 1348, 1329, 1265, 1170, 789, 744 cm−1; 1H 
NMR (500 MHz, CDCl3) δ 7.98-7.94 (2H, m, ArH), 7.61-7.57 (1H, m, ArH), 7.49-7.44 
(2H, m, ArH), 5.87-5.77 (1H, m, CH=), 5.31 (1H, br s, CH2=), 5.30-5.27 (1H, m, 
CH2=), 4.16 (1H, br s, J = 11.2 Hz, NH), 4.01-3.93 (1H, m, CH=N), 3.06 (1H, dd, J = 
18.8, 4.0 Hz, CH2), 2.56 (1H, dd, J = 18.8, 11.2 Hz, CH2), 2.53-2.45 (2H, m, CH2); 
13C NMR (125.8 MHz, CDCl3)  175.4 (C=N), 135.3 (C), 133.7 (CH), 131.1 (CH), 
128.9 (2 x CH), 127.9 (2 x CH), 120.8 (CH2), 50.0 (CH), 39.0 (CH2), 31.0(CH2); HRMS 
(ESI) Exact mass calcd for C11H12N2O2SNa [M+Na]+: 273.0674. found 273.0676; 
Enantiomeric excess was determined by HPLC with a Chiralpak AD-H column (90:10 
hexane:i-PrOH, 0.8 mL/min 280 nm, 25 ºC); tr (minor) = 66.0 min, tr (major) = 59.6 
min; 65% ee. 
4-(Prop-2-en-l-yl)-4-(trifluoromethyl)-3,4-dihydro-[1,2,3]-
benzoxathiazine-2,2-dione (289). The title compound was prepared 
according to General Procedure C from imine 203 (75 mg, 0.30 mmol) 
and allyltrifluoroborate 243 (but chiral diene ent-221 was used instead of (R)-221) and 
was purified by column chromatography (10% EtOAc/hexane) to give a yellow solid 
(75 mg, 86%). m.p. 76-77 ºC (CH2Cl2/hexane); Rf = 0.30 (10% EtOAc/hexane); 
IR (film)  3285 (NH), 1614, 1489, 1454, 1435, 1377, 1260, 1180, 856, 762 cm−1; 
1H NMR (500 MHz, CDCl3) δ 7.53 (1H, d, J = 8.0 Hz, ArH), 7.48 (1H, dt, J = 7.5, 
5.4 Hz, ArH), 7.34 (1H, td, J = 8.0, 1.2 Hz, ArH), 7.16 (1H, dd, J = 8.2, 1.1 Hz, ArH), 
5.61-5.53 (1H, m, CH=), 5.41-5.36 (2H, m, =CH2), 5.13 (1H, s, NH), 3.05 (1H, dd, 
J = 14.5, 6.5 Hz, CH2), 2.85 (1H, dd, J = 14.5, 8.0 Hz, CH2); 13C NMR (125.8 MHz, 
CDCl3) δ 150.8 (C), 131.5 (CH), 128.4 (CH), 127.0 (CH, q, J = 2.6 Hz), 126.5 (CH), 
124.3 (C, q, J = 286.3 Hz), 124.2 (CH2), 120.0 (CH), 117.9 (C), 65.8 (C, q, J = 29.1 Hz), 
41.3 (CH2); 19F NMR (376 MHz, CDCl3) δ ‒74.7; HRMS (ESI) Exact mass calcd for 
C11H11F3NO3S [M+H]+: 294.0406, found: 294.0408. To facilitate determination of 
enantiomeric excess, 289 was converted into the primary alcohol 566. 
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General Procedure D: Hydroboration of Terminal Alkenes 
 
To a solution of the alkene (0.23 mmol) in THF (3 mL) at 0 ºC was added 9-BBN (0.5 M 
in THF, 1.37 mL, 0.68 mmol) over 2 min. The mixture was warmed to room temperature 
over 1 h and then stirred for a further 23 h. The reaction was cooled to 0 ºC and 3 M 
NaOH (1 mL) and H2O2 (30 wt.% in H2O, 2 mL) were added successively. The resulting 
mixture was stirred for 1 h at room temperature, diluted with H2O (20 mL), neutralised 
with 2 M HCl, and extracted with EtOAc (3 x 20 mL). The combined organic extracts 
were dried (MgSO4), filtered, and concentrated in vacuo. Purification of the residue by 
column chromatography to afford the alcohol products. 
4-(Trifluoromethyl)-3,4-dihydro-[1,2,3]-benzoxathiazine-2,2-
dione (566)The title compound was prepared according to General 
Procedure D from alkene 289 (66 mg, 0.23 mmol) and was purified 
by column chromatography (60% EtOAc/hexane) to obtain the 
alcohol 566 (61 mg, 86%) as a colourless gum. Rf = 0.41 (60% EtOAc/hexane); IR 
(film) 3288 (OH and NH), 2924, 1454, 1375, 1177, 1159, 1115, 1055, 856, 762 cm−1; 
1H NMR (CD3OD, 500 MHz) δ 7.61 (1H, d, J = 8.0 Hz, ArH), 7.55-7.52 (1H, m, ArH), 
7.41-7.38 (1H, m, ArH), 7.19 (1H, dd, J = 8.2, 1.2 Hz, ArH), 3.60-3.52 (2H, m, 
CH2OH), 2.45-2.39 (1H, m, CH2), 2.14-2.08 (1H, m, CH2), 1.76-1.68 (1H, m, CH2), 
1.38-1.26 (1H, m, CH2); 13C NMR (125.8 MHz, CD3OD) δ 152.9 (C), 132.5 (CH), 
125.0 (C, q, J = 286.0 Hz), 127.4 (CH), 126.4 (C, q, J = 286.0 Hz), 120.7 (CH), 119.9 
(C), 68.1 (C, q, J = 28.6 Hz), 62.0 (CH2), 33.1 (CH2), 26.6 (CH2); 19F NMR (CD3OD) 
δ –78.0; HRMS (ESI) Exact mass calcd for C11H12F3NO4SNa  [M+Na]+: 334.0331, 
found: 334.0331; Enantiomeric excess was determined by HPLC with a Chiralpak AD-H 
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column (90:10 hexane:i-PrOH, 0.8 mL/min 280 nm, 25 ºC); tr = 19.3 min, 29.0 min; 
0% ee. 
tert-Butyl N-[(R)-1-(2-hydroxyphenyl)but-3-en-1-yl]carbamate (301) 
 
To a solution of allylation product 251a in THF (1 mL) at room temperature was added 
LiAlH4 (1.0 M in THF, 0.37 mL, 0.37 mmol) over 1 min at room temperature. The 
mixture was heated at 60 ºC for 15 h, allowed to cool to temperature, and then cooled 
with an ice bath. The reaction was quenched carefully with EtOAc (1 mL), followed by 
the addition of EtOH (1 mL) and H2O (2 mL). To the resulting turbid mixture was added 
Boc2O (81 mg, 0.37 mmol) in one portion and the resulting mixture was stirred at room 
temperature for 1 h. The reaction was diluted with EtOAc (20 mL) and acidified with 
2 M HCl until the aqueous layer became clear. The aqueous layer was separated and 
extracted with EtOAc (2 x 20 mL). The combined organic layers were dried (MgSO4), 
filtered, and concentrated in vacuo. Purification of the residue by column 
chromatography (6:1 hexane:Et2O→2:1 hexane:Et2O) gave the carbamate 301 as a 
colourless oil (28 mg, 85%). Rf = 0.54 (30% EtOAc/hexane); [α] 20D  +45.2 (c 1.15, 
CHCl3); IR (film) 3310 (OH), 2925, 1680, 1502, 1456, 1367, 1170, 1043, 918, 860, 750 
cm−1; 1H NMR (500 MHz, CDCl3) δ 8.50 (1H, br s, ArOH), 7.16-7.07 (2H, m, ArH), 
6.88-6.80 (2H, m, ArH), 5.75 (1H, ddt, J = 17.1, 10.2, 6.9 Hz, CH=CH2), 5.27 (1H, br s, 
NH), 5.13 (1H, dd, J = 17.2, 1.0 Hz, =CH2), 5.09 (1H, d, J = 10.4 Hz, =CH2), 4.89 
(1H, br s, CHN), 2.62 (2H, t, J = 7.0 Hz, CH2), 1.47 (9H, s, C(CH3)3); 13C NMR 
(125.8 MHz, CDCl3) δ 157.0 (C), 154.7 (C), 134.6 (CH), 128.5 (CH), 127.9 (C), 126.6 
(CH), 119.8 (CH), 117.8 (CH2), 117.0 (CH), 80.7 (C), 48.9 (CH), 38.6 (CH2), 28.4 
(3 x CH3); HRMS (EI) Exact mass calcd for C15H22O3N [M]+: 264.1594, found: 
264.1599; Enantiomeric excess was determined by HPLC with a Chiralcel AS-H column 
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(98:2 hexane:i-PrOH, 0.8 mL/min, 230 nm, 25 ºC); tr (major) = 23.1 min, tr (minor) 
= 30.6 min; 93% ee. 
(S)-4-(Prop-2-en-1-yl)-3,4-dihydro[1,2,3]benzoxathiazine-2,2-dioxide 
(ent-251a). The title compound was prepared according to General 
Procedure C from benzoxathiazine-2,2-dioxide (202a) (55 mg, 0.30 
mmol) (but chiral diene ent-221 was used instead of (R)-221) and was 
purified by column chromatography (20% EtOAc/hexane) to give an orange oil (59 mg, 
87%). Rf = 0.54 (40% EtOAc/hexane); [α] 20D  +177.9 (c 0.24, CHCl3); IR (film) 3259 (NH), 
1357, 1186, 1157, 1103, 900, 850, 831, 755, 680 cm−1; 1H NMR (500 MHz, CDCl3) 
δ 7.36-7.32 (1H, m, ArH), 7.30-7.28 (1H, m, ArH), 7.24-7.21 (1H, m, ArH), 7.04 (1H, dd, 
J = 8.3, 1.1 Hz, ArH), 5.69 (1H, dddd, J = 17.0, 10.1, 8.5, 5.8 Hz, CH=CH2), 5.34-5.26 
(2H, m, =CH2), 4.93 (1H, ddd, J = 9.0, 7.0, 4.2 Hz, CH), 4.56 (1H, d, J = 9.0 Hz, NH), 
3.01-2.94 (1H, m, CH2), 2.82-2.75 (1H, m, CH2); 13C NMR (125.8 MHz, CDCl3) δ 151.5 
(C), 131.2 (CH), 129.6 (CH), 126.1 (CH), 125.5 (CH), 121.4 (C), 121.4 (CH2), 119.1 (CH), 
55.8 (CH), 37.5 (CH2); HRMS (ESI) Exact mass calcd for C10H10NO3S [M–H]‒: 224.0387, 
found: 224.0388. Enantiomeric excess was determined by HPLC with a Chiralcel OD-H 
column (90:10 hexane:i-PrOH, 0.8 mL/min, 280 nm, 25 ºC); tr (major) = 14.8 min, tr (minor) 
= 18.0 min; 93% ee. 
(S)-4-(3-Hydroxypropyl)-3,4-dihydro-[1,2,3]-benzoxathiazine-
2,2-dioxide (302). The title compound was prepared according to 
General Procedure D from alkene ent-251a (225 mg, 1.00 mmol) 
and was purified by column chromatography (80% EtOAc/hexane) 
to obtain the alcohol 302 as a white solid (182 mg, 75%). m.p. 112-113 ºC (CH2Cl2); 
Rf = 0.36 (30% EtOAc/hexane); [α] 20D  ‒36.7 (c 0.49, CHCl3); IR (film) 3255 (OH), 2880, 
1485, 1452, 1425, 1371, 1175, 1107, 883, 760 cm−1; 1H NMR (500 MHz, CD3OD) 
δ 7.40 (1H, d, J = 7.8 Hz, ArH), 7.36 (1H, J = 8.3, 4.5, 1.1 Hz, ArH), 7.24 (1H, td, 
J = 1.6, 1.2 Hz, ArH), 7.02 (1H, dd, J = 8.2, 1.2 Hz, ArH), 4.70 (1H, dd, J = 10.9, 
3.8 Hz, CHN), 3.70-3.61 (2H, m, CH2OH), 2.26-2.18 (1H, m, CH2CH2CH2OH), 
2.03-1.95 (1H, m, CH2CH2CH2OH), 1.90-1.82 (1H, m, CH2CH2OH), 1.76-1.67 (1H, m, 
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CH2CH2OH); 13C NMR (125.8 MHz, CD3OD) δ 152.8 (C), 130.2 (CH), 127.9 (CH), 
126.1 (CH), 125.0 (C), 119.3 (CH), 62.3 (CH), 57.9 (CH2), 31.3 (CH2), 29.6 (CH2); 




To a solution of the alcohol 302 (61 mg, 0.25 mmol) and PPh3 (85 mg, 0.33 mmol) in 
dichloromethane (4 mL) at 0 ºC was added a solution of DEAD (53 mg, 0.30 mmol) in 
CH2Cl2 (1 mL). The mixture was allowed to warm to room temperature over 1 h and 
then stirred for an additional 9 h. The reaction was quenched with EtOH (1 mL) and 
concentrated in vacuo. Purification of the residue by column chromatography (60% 
EtOAc/hexane) gave the product 303 (56 mg, >95%) as a white solid. m.p. 85-86 ºC 
(CH2Cl2/hexane); Rf = 0.57 (30% EtOAc/hexane); [α] 20D  ‒125.0 (c 0.40, CHCl3); 
IR (film) 2982, 1485, 1450, 1392, 1206, 1175, 1103, 1005, 856, 758 cm−1; 1H NMR 
(500 MHz, CDCl3) δ 7.30 (1H, dddd, J = 8.1, 7.3, 1.7, 0.8 Hz, ArH), 7.21 (1H, td, 
J = 7.5, 1.2 Hz, ArH), 7.15 (1H, dt, J = 7.5, 1.0 Hz, ArH), 7.01 (1H, dd, J = 8.2, 1.2 Hz, 
ArH), 5.20 (1H, dd, J = 7.4, 2.5 Hz, CHN), 3.61-3.56 (1H, m, CH2N), 3.51 (1H, ddd, 
J = 10.1, 8.6, 5.8 Hz, CH2N), 2.59 (1H, ddd, J = 16.5, 12.8, 7.7 Hz, CHCH2CH2), 
2.30-2.24 (1H, m, CHCH2CH2), 2.07-1.99 (1H, m, CHCH2CH2), 1.92-1.83 (1H, m, 
CHCH2CH2); 13C NMR (125.8 MHz, CDCl3) δ 151.0 (C), 129.1 (CH), 126.6 (CH), 
125.6 (CH), 122.5 (C), 118.8 (CH), 62.7 (CH), 49.7 (CH2), 34.0 (CH2), 23.4 (CH2); 
HRMS (EI) Exact mass calcd for C10H12NO3S [M+H]+: 226.0532, found: 226.0529; 
Enantiomeric excess was determined by HPLC with a Chiralpak AD-H column (95:5 




tert-Butyl-N-[(S)-4-hydroxy-1-(2-hydroxyphenyl)butyl] carbamate (305) 
 
To a solution of the cyclic sulfamate 302 (100 mg, 0.41 mmol) in THF (2 mL) at room 
temperature was added LiAlH4 (2.0 M in THF, 0.62 mL, 1.24 mmol) dropwise over 
4 min. The mixture was heated at 60 ºC for 2 h, allowed to cool to room temperature, 
and then cooled with an ice bath. The reaction was quenched carefully with EtOAc 
(2 mL), followed by the addition of EtOH (2 mL) and H2O (2 mL). To the resulting 
turbid mixture was added Boc2O (268 mg, 1.24 mmol) in one portion and the resulting 
mixture was stirred at room temperature for 1 h. The reaction was diluted with EtOAc 
(40 mL) and acidified with 2 M HCl until the aqueous layer became clear. The aqueous 
layer was separated and extracted with EtOAc (2 x 40 mL). The combined organic 
layers were dried (MgSO4), filtered, and concentrated in vacuo. Purification of the 
residue by column chromatography (80% EtOAc/hexane) gave the carbamate 305 
(87 mg, 75%) as a colourless gum. Rf = 0.42 (30% EtOAc/hexane); [α] 20D  ‒33.6 (c 0.24, 
CHCl3); IR (film) 3305 (OH and NH), 2980, 1680 (C=O), 1502, 1456, 1367, 1292, 
1253, 1165, 752, 742 cm−1; 1H NMR (500 MHz, CDCl3) δ 8.28 (1H, br s, OH), 7.18 
(2H, dd, J = 12.1, 4.5 Hz, ArH), 6.93 (1H, d, J = 7.8 Hz, ArH), 6.90 (1H, dt, J = 7.5, 1.1 
Hz, ArH), 5.13 (1H, s, NH), 4.86 (1H, d, J = 6.9 Hz, CHN), 3.72 (2H, dt, J = 6.2, 0.9 
Hz, CH2OH), 2.06-1.95 (2H, m, CHCH2CH2), 1.73-1.58 (2H, m, CHCH2CH2), 1.45 
(9H, s, C(CH3)3); 13C NMR (125.8 MHz, CDCl3) δ 157.3 (C), 154.9 (C), 128.8 (C), 
128.4 (CH), 126.3 (CH), 120.3 (CH), 117.8 (CH), 80.8 (C), 62.3 (CH2), 49.0 (CH), 30.6 
(CH2), 29.5 (CH2), 28.3 (3 x CH3); HRMS (ESI) Exact mass calcd for C15H24NO4 




tert-Butyl N-[(S)-2,3,4,5-tetrahydro-1-benzoxepin-5-yl] carbamate (306) 
 
To a solution of the alcohol 305 (68 mg, 0.24 mmol) and PPh3 (82 mg, 0.31 mmol) in 
dichloromethane (4 mL) at 0 ºC was added a solution of DEAD (51 mg, 0.29 mmol) in 
CH2Cl2 (1 mL). The mixture was allowed to warm to room temperature over 1 h and 
then stirred for an additional 9 h. The reaction was quenched with EtOH (1 mL) and 
concentrated in vacuo. Purification of the residue by column chromatography 
(20% EtOAc/hexane) gave the tetrahydrobenzoxepine 306 as a white solid (43 mg, 
68%). m.p. 105-106 ºC (CH2Cl2/hexane); Rf = 0.40 (30% EtOAc/hexane); [α] 20D  ‒40.0 
(c 0.15, CHCl3); IR (film) 3300 (NH), 2976, 2930, 1713(C=O), 1450, 1366, 1236, 1224, 
1170, 760 cm−1; 1H NMR (500 MHz, CDCl3) δ 7.28-7.26 (1H, m, ArH), 7.20 (1H, td, 
J = 7.7, 1.7 Hz, ArH), 7.05 (1H, td, J = 7.5, 1.3 Hz, ArH), 7.01 (1H, dd, J = 7.5, 1.3 Hz, 
ArH), 5.29 (1H, d, J = 7.8 Hz, NH), 4.91 (1H, t, J = 7.1 Hz, CHN), 4.30 (1H, app d, 
J = 11.9 Hz, OCH2), 3.75 (1H, app t, J = 11.2 Hz, OCH2), 2.30-2.10 (2H, m, CH2), 
1.88-1.81 (1H, m, CH2), 1.79-1.72 (1H, m, CH2), 1.44 (9H, s, C(CH3)3); 13C NMR 
(125.8 MHz, CDCl3) δ 159.3 (C), 155.0 (C), 135.5 (C), 129.3 (CH), 128.9 (CH), 
124.2 (CH), 122.0 (CH), 79.3 (C), 73.8 (CH2), 53.9 (CH), 30.8 (CH2), 28.4 (3 x CH3), 
26.7 (CH2); HRMS (ESI) Exact mass calcd for C15H22NO3 [M+H]+: 264.1594, found: 
264.1595; Enantiomeric excess was determined by HPLC with a Chiralpak AD-H 
column (98:2 hexane:i-PrOH, 0.8 mL/min 280 nm 25 ºC); tr (major) = 12.5 min, 






Screening and Optimisation for Compound 334 (Table 1.10) 
 
To a solution of the imine ent-257b (123 mg, 0.05 mmol, prepared as described in 
General procedure C by the reaction of imine 256b with allyltrifluoroborate (243), but 
chiral diene ent-221 was used instead of (R)-221) in THF (2 mL) at indicated 
temperature was slowly added reducing agents (0.2 mmol, 4 equiv). The mixture was 
stirred at that temperature for 15 h (in case of the reaction was set at 0 °C) or warmed 
gradually to room temperature over 2 h and stirred for a further 13 h (in case of the 
reaction was set at  −5, −20 and −78 °C). The reaction was then quenched carefully with 
1 M HCl solution until the pH value of the mixture reached 3. The mixture was diluted 
with H2O (3 mL) and EtOAc (3 mL), and the organic layer was separated. The aqueous 
layer was extracted with EtOAc (2 x 3 mL), and the combined organic layers were 
washed with brine (5 mL), dried (MgSO4), filtered, and concentrated in vacuo. The 





To a solution of the imine ent-257b (200 mg, 0.80 mmol) in THF (32 mL) at ‒20 ºC was 
added DIBAL (1.0 M in THF, 3.2 mL, 3.2 mmol) over 2 min. The mixture was warmed 
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gradually to room temperature over 2 h and stirred for a further 13 h. The reaction was 
quenched carefully with 1 M HCl solution until the pH value of the mixture reached 3. 
The mixture was diluted with H2O (20 mL) and EtOAc (30 mL), and the organic layer 
was separated. The aqueous layer was extracted with EtOAc (2 x 30 mL), and the 
combined organic layers were washed with brine (30 mL), dried (MgSO4), filtered, and 
concentrated in vacuo. Purification of the residue by column chromatography 
(33% EtOAc/hexane) gave the cyclic sulfamide 308 as a colourless amorphous solid 
(182 mg, 90%). Rf = 0.26 (30% EtOAc/hexane); [α] 20D  ‒125.0 (c 0.42, CH3OH); 
IR (film) 3271 (NH), 2980, 1454, 1381, 1312, 1265, 1157, 922, 741, 702 cm−1; 
1H NMR (500 MHz, CDCl3) δ 7.43-7.36 (5H, m, ArH), 5.67 (1H, dddd, J = 17.1, 10.2, 
7.8, 7.0 Hz, CH=CH2), 5.21-5.19 (1H, m, =CH2), 5.14 (1H, ddd, J = 17.1, 3.0, 1.3 Hz, 
=CH2), 4.90 (1H, d, J = 5.1 Hz, NH), 4.82 (1H, d, J = 5.1 Hz, CHN), 4.60 (1H, s, NH), 
2.49 (1H, dd, J = 13.7, 7.9 Hz, CH2), 1.59 (1H, dd, J = 13.7, 6.9 Hz, CH2), 1.43 (3H, s, 
CH3); 13C NMR (125.8 MHz, CDCl3) δ 134.1 (C), 131.9 (CH), 128.9 (CH), 128.8 
(2 x CH), 127.3 (2 x CH), 121.2 (CH2), 70.0 (CH), 65.0 (C), 39.7 (CH2), 24.2 (CH3); 
HRMS (EI) Exact mass calcd for C12H16N2O2S [M]+: 252.0927, found: 252.0928. 
(1R,2S)-2-Methyl-1-phenyl-4-butene-1,2-diamine (309) 
 
A solution of cyclic sulfamide 308 (101 mg, 0.40 mmol) and ethylenediamine (267 µL, 
4.00 mmol) in dioxane (6 mL) was stirred at 100 ºC for 15 h. The reaction was cooled to 
room temperature and concentrated in vacuo. To the residue was added a 1.25 M 
solution of HCl in MeOH (2 mL) and the resulting solution was stirred at room 
temperature for 2 h before being concentrated in vacuo. The residue was dissolved in 
H2O (10 mL) and washed with EtOAc (2 x 10 mL). The organic layers were discarded 
and the aqueous phase was basified with 3 M NaOH (2 mL) and extracted with EtOAc 
178 
 
(3 x 20 mL). The combined organic extracts were dried (MgSO4), filtered, and 
concentrated in vacuo to leave the diamine 309 (67 mg, 88%) as a pale yellow oil. 
Rf = 0.15 (EtOAc); [α] 20D  ‒30.0 (c 0.20, MeOH); IR (film) 3400 (NH), 2964, 1638, 1603, 
1492, 1452, 1373, 999, 914, 704 cm−1; 1H NMR (500 MHz, CDCl3) δ 7.39-7.31 (5H, m, 
ArH), 5.89 (1H, ddt, J = 17.5, 10.2, 7.4 Hz, CH=CH2), 5.12 (1H, ddt, J = 10.2, 2.0, 
0.9 Hz, =CH2), 5.08 (1H, ddt, J = 17.0, 2.3, 1.4 Hz, =CH2), 3.82 (1H, s, CHN), 
2.13-2.03 (2H, m, CH2), 1.65 (4H, br s, 2 x NH2), 1.09 (3H, s, CH3); 13C NMR 
(125.8 MHz, CDCl3) δ 142.6 (C), 134.3 (CH), 128.3 (2 x CH), 127.9 (2 x CH), 127.2 
(CH), 118.3 (CH2), 64.2 (CH), 54.7 (C), 44.0 (CH2), 24.7 (CH3); HRMS (EI) Exact 
mass calcd for C12H18N2 [M]+: 190.1465, found: 190.1465.  
3.2 Enantioselective Nickel-Catalysed Michael Additions of 
2-Acetylazaarenes to Nitroalkenes 
3.2.1 Synthesis of 2-Acylheteroarenes 
 
2-Acetylpyrazine (386), 2-acetylthiazole (390), 2-acetylthiophene (455) were purchased 
from Fluorochem. 2-Acetylfuran (423), 2-acetylpyridine (458) and were purchased from 
Acros. Compounds 492,209 493,210 494,211 495,212 520,213 and 521214 were prepared by 
Alain J. Simpson according to previously reported procedures. Yields and recation times 
reported in this Section are unoptimised. 
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2-Bromo-1-(pyridine-2-yl) ethanone (522)  
 
In a modification of a previously reported procedure,215 to a solution of 2-acetylpyridine 
(458) (1.82 g, 15 mmol) in 48% HBr (3 mL) was added a solution of Br2 (1.20 g, 15 
mmol) in 48% HBr (3.2 mL). The mixture was stirred at 65 °C for 1 h, then at room 
temperature for 1 h. It was then quenched with ice (10 g) and the solvent was removed 
under reduced pressure. Ether (5 mL) was added and induced precipitation. The 
off-white solid was filtered and washed with cold ether to afford a white crystalline 522 
(1.17 g, 39%). Rf = 0.15 (40% CH2Cl2/hexane); 1H NMR (500 MHz, DMSO-d6) 
δ 8.6-8.71 (1H, m, ArH), 8.08 (1H, td, J = 7.6, 1.6 Hz, ArH), 8.06-8.02 (1H, m, ArH), 
7.73 (1H, ddd, J = 7.3, 4.8, 1.3 Hz, ArH), 5.01 (2H, s, CH2); 13C NMR (125.8 MHz, 
CDCl3) δ 192.0 (C), 150.5 (C), 149.1 (CH), 138.5 (CH), 128.6 (CH), 122.6 (CH), 65.2 
(CH2). The NMR data were in agreement with the literature.215 
(E)-4-Methoxy-N-[1’-(pyridin-2”-yl)ethylidene]aniline (524) 
 
In a modification of a previously reported procedure,216 5 Å molecular sieves (12.5 g) 
were added to a solution of 2-acetylpyridine (458) (1.21 g, 10 mmol) and p-anisidine 
(1.54 g, 12.5 mmol) in dried toluene (100 mL) and the reaction mixture was heated at 
reflux for 5 h. The mixture was then cooled, the sieves were filtered off, and the filtrate 
was concentrated in vacuo. The residue was purified by flash chromatography on silica 
gel (pre-treated overnight with 10% Et3N in diethyl ether) eluting with a 0→40% 
EtOAc/Et2O to afford 524 (905 mg, 40%) as a yellow oil. Rf = 0.29 (40% 
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EtOAc/hexane); 1H NMR (500 MHz, CDCl3) δ 8.66 (1H, ddd, J = 4.8, 1.6, 0.8 Hz, 
ArH), 8.26 (1H, d, J = 8.0 Hz, ArH), 7.77 (1H, td, J = 7.7, 1.8 Hz, ArH), 7.35 (1H, ddd, 
J = 7.5, 4.8, 1.2 Hz, ArH), 6.95-6.91 (2H, m, ArH), 6.83-6.79 (2H, m, ArH), 3.83 (3H, 
s, OCH3), 2.39 (3H, s, CH3); 13C NMR (125.8 MHz, CDCl3) δ 167.3 (C), 157.0 (C), 
156.2 (C), 148.5 (CH), 144.3 (C), 136.3 (CH), 124.6 (CH), 121.3 (CH), 120.8 (2 x CH), 
114.2 (2 x CH), 55.4 (CH3), 16.3 (CH3). The NMR data were in agreement with the 
literature.216 
3.2.2 Synthesis of Chiral Ligands and Catalysts 
 
Box 501 was purchased from Aldrich. PyBox 506 was purchased from Solvias and Box 
509 was purchased from Strem. Catalyst 426149a was prepared by Alain J. Simpson 
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according to previously reported procedure. Yields and reaction times reported in this 
Section are unoptimised. 
(2S)-(+)-2-Amino-2-phenylethanol (568).  
 
In a modification of a previously reported procedure,217 to a suspension of LiAlH4 
(3.5 g, 88.0 mmol) in THF (150 mL) at 0 °C was added (S)-(+)-2-phenylglycine (567) 
(6.05 g, 40.0 mmol) portionwise over 10 min. The reaction mixture was heated at reflux 
for 18 h, then allowed to cool to room temperature, quenched with saturated aqueous 
K2CO3 (10 mL), and filtered. The filter cake was washed with Et2O (3 x 100 mL) and 
the combined organic extracts were dried (Na2SO4), filtered, and concentrated in vacuo. 
Recrystallisation of the residue from 1:3 EtOAc/hexane afforded the title compound as a 
yellow solid (4.30 g, 78%). 1H NMR (500 MHz, CDCl3) δ 7.38-7.27 (5H, m, ArH), 4.06 
(1H, dd, J = 8.3, 4.4 Hz, CHNH2), 3.75 (1H, dd, J = 10.7, 4.4 Hz, CH2OH), 3.56 (1H, 
dd, J = 10.7, 8.3 Hz, CH′2OH), 1.99 (3H, br s, NH2, OH); 13C NMR (125.8 MHz, 
CDCl3) δ 142.7 (C), 128.6 (2 x CH), 127.5 (CH), 126.4 (2 x CH), 68.0 (CH2), 57.3 
(CH). The NMR data were in agreement with the literature.217 
(S)-2-Amino-3,3-dimethyl-1-butanol (570).  
 
The title compound was prepared according the reported procedure.218 To an ice-cooled 
solution of (S)-tert-leucine (569) (7.45 g, 57 mmol) and sodium borohydride (5.17 g, 
136.8 mmol) in THF 300 mL was slowly added a solution of iodine (14.47 g,  57 mmol) 
in THF 50 mL over a period of 30 min (vigorous H2 formation!). The reaction mixture 
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was warmed to room temperature and stirred for 30 min. The reaction mixture was 
subsequently heated at reflux for 24 h, cooled to 0 °C and then carefully treated with 
MeOH (20 mL). The solvents were removed under reduced pressure and the crude 
product was dissolved in 20% aqueous KOH (120 mL). After stirring for 6 h at room 
temperature, the reaction mixture was extracted with dichloromethane (3 x 100 mL). 
The combined organic layers were dried (MgSO4), filtered and concentrated in vacuo to 
afford (S)-tert-leucinol (570) (5.30 g, 79%) as colourless oil that solidified upon cooling 
to room temperature. 1H NMR (500 MHz, CDCl3) δ 3.71 (1H, dd, J = 10.2, 3.9 Hz, 
CH2OH), 3.21 (1H, t, J = 10.2 Hz, CHNH2), 2.51 (1H, dd, J = 10.1, 3.9 Hz, CH2OH), 
1.83 (3H, s, NH2, OH), 0.9 (9H, s, 3 x CH3); 13C NMR (125.8 MHz, CDCl3) δ 62.3 
(CH), 61.8 (CH2), 33.3 (C), 26.2 (3 x CH3). The NMR data were in agreement with the 
literature.218 
 General Procedure E: Synthesis of Bis-Oxazoline (BOX) Ligands 
 
In a modification of a previously reported procedure,150,219,220 a suspension of 
dimethylmalonic acid (571) (661 mg, 5.00 mmol) and DMF (0.1 mL, 1.3 mmol) in 
dichloromethane (10 mL) at 0 °C was treated with oxalyl chloride (572) (0.9 mL, 
10.5 mmol). The reaction mixture was allowed to warm to room temperature and stirred 
for 2 h, then added by cannula transfer to a vigorously stirred mixture of the appropriate 
aminoalcohol (10 mmol) and Et3N (4.2 mL, 30 mmol) in dichloromethane (10 mL) at 
0 °C. The reaction mixture was allowed to warm to room temperature and stirred for 2 h, 
then diluted with EtOAc (80 mL), washed with 1:1 brine/aqueous HCl (1 M) 
(3 x 50 mL) and brine (80 mL), dried (MgSO4), filtered and concentrated in vacuo to 
afford the intermediate bis-amide in quantitative yield. The crude bis-amide 
(theoretically 4.4 mmol) was then suspended in xylenes (150 mL) and 
(NH4)6Mo7O24·4H2O (768 mg, 0.62 mmol) was added. The mixture was heated at reflux 
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using a Dean-Stark apparatus for 24 h. After cooling to room temperature, the mixture 
was concentrated in vacuo to ca. 25 mL, adsorbed onto silica (ca. 10 g) and concentrated 
in vacuo. Purification of the residue by column chromatography, followed by 
recrystallisation of necessary, afforded the desired bis-oxazolines.  
2,2-Bis[(4R,5S)-4,5-diphenyl-4,5-dihydro-1,3-oxazol-2-yl] 
propane (431). The title compound was prepared according to 
General Procedure E from (1S,2R)-(+)-2-amino-1,2-
diphenylethanol (573) (2.13 g, 10 mmol) and purified by column chromatography 
(20→80% EtOAc/hexane) followed by recrystallisation from heptane to afford a fine 
white needle (1.8 g, 78%). Rf = 0.38 (60% EtOAc/hexane); 1H NMR (500 MHz, CDCl3) 
δ 7.05-7.00 (10H, m, ArH), 6.99-6.95 (10 H, m, ArH), 5.97 (2H, d, J = 10.1 Hz, 
2 x OCH), 5.60 (2H, d, J = 10.2 Hz, 2 x NCH), 1.93 (6H, s, 2 x CH3); 13C NMR 
(125.8 MHz, CDCl3) δ 170.4 (2 x C), 137.5 (2 x C), 136.2 (2 x C), 127.9 (4 x CH), 
127.6 (4 x CH), 127.6 (4 x CH), 127.4 (2 x CH), 126.9 (2 x CH), 126.6 (4 x CH), 86.3 
(2 x CH), 73.8 (2 x CH), 39.6 (C), 24.8 (2 x CH3). The NMR data were in agreement 
with the literature.219 
2,2-Bis[(R)-4-phenyl-4,5-dihydro-1,3-oxazol-2-yl]propane (498). The 
title compound was prepared according to General Procedure E from 
(R)-2-phenylglycinol (1.37 g, 10 mmol) and purified by column 
chromatography (40→80% EtOAc/hexane) to afford a yellow oil (563 mg, 35%). 
Rf = 0.43 (80% EtOAc/hexane); 1H NMR (500 MHz, CDCl3) δ 7.38-7.31 (4H, m, ArH), 
7.30-7.25 (6H, m, ArH), 5.24 (2H, dd, J = 10.1, 7.6 Hz, 2 x OCH), 4.68 (2H, dd, 
J = 10.1, 8.4 Hz, 2 x OCH′), 4.17 (2H, dd, J = 8.3, 7.7 Hz, 2 x NCH), 1.70 (6H, s, 
2 x CH3); 13C NMR (125.8 MHz, CDCl3) δ 170.3 (2 x C), 142.4 (2 x C), 128.6 
(4 x CH), 127.5 (2 x CH), 126.6 (4 x CH), 75.5 (2 x CH), 69.4 (2 x CH2), 38.9 (C), 24.5 





In a modification of a previously reported procedure,219 (1S,2R)-(+)-2-amino-1,2-
diphenylethanol (573) (213 mg, 1 mmol) and triethylamine (0.42 mL, 3 mmol) were 
dissolved in dichloromethane (10 mL) at 0 °C. Dimethylmalonyl chloride (574) (84 mg, 
0.5 mmol) in dichloromethane (2 mL) was added dropwise under N2, keeping the 
temperature below 0 °C. Stirring was continued overnight at room temperature, then the 
reaction mixture was quenched with H2O (10 mL). A white solid was separated, filtered 
and then washed with aq. HCl (1 M, 10 mL) to afford  crude 575 (>99%). To the crude 
bis-amide 575 (0.5 mmol) in dichloromethane (10 mL) and triethylamine (0.42 mL, 
3 mmol), methanesulfonyl chloride (131 mg, 1.15 mmol) was added and the reaction 
mixture was stirred at room temperature for 4 h. Then the solvent was distilled off and to 
the oily residue was added ethanol (10 mL) and aqueous NaOH (2 M, 4 mL). After 3 h 
reflux the residue was purified by column chromatography (7% EtOAc/hexane) to afford 
the product 466 as a white solid (37 mg, 15% yield). Rf = 0.19 (30% EtOAc/hexane); 
1H NMR (500 MHz, CDCl3) δ 7.35-7.25 (20H, m, ArH), 5.31 (2H, d, J = 7.6 Hz, 
2 x OCH), 5.10 (2H, d, J = 7.6 Hz, 2 x NCH), 1.87 (6H, s, 2 x CH3); 13C NMR 
(125.8 MHz, CDCl3) δ 169.7 (2 x C), 142.0 (2 x C), 140.4 (2 x C), 128.9 (4 x CH), 
128.8 (4 x CH), 128.4 (2 x CH), 127.7 (2 x CH), 126.7 (4 x CH), 125.9 (4 x CH), 89.8 
(2 x CH), 78.6 (2 x CH), 39.4 (C), 24.9 (2 x CH3). The NMR data were in agreement 







The title compound was prepared according to a modification of the procedure reported 
by Evans and co-workers.222a A 100-mL two-necked flask with a magnetic stirrer was 
charged with a solution of (S)-tert-leucinol (570) (1.17 g, 10 mmol), in 15 mL of 
dichloromethane. The solution was cooled in an ice bath, and triethylamine (4.17 mL, 
30 mmol) was added dropwise. A solution of dimethylmalonyl dichloride (574) (85 mg, 
5 mmol) in dichloromethane (5 mL) was added to the vigorously stirred mixture over 
10 min. The ice bath was removed, and the thick white suspension was stirred at room 
temperature for 35 min before dichloromethane (10 mL) was added. The reaction 
mixture was washed with 10 mL of aq. HCl (1 M), and the aqueous layer was 
back-extracted with dichloromethane (10 mL). The combined organic extracts were 
washed with saturated aqueous NaHCO3 (10 mL), and brine (20 mL), dried (Na2SO4), 
filtered and concentrated in vacuo to give a crude bis-amide 576 as a white solid (1.31 g, 
83%). A 150-mL round bottom flask with a magnetic stir bar was charged with the crude 
bis-amide 576 (1.28 g, 4.06 mmol), DMAP (50 mg, 0.41 mmol) and dichloromethane 
(20 mL) and triethylamine (2.5 mL, 17.86 mmol). The flask was placed in a water bath 
(room temperature), and a solution of p-toluenesulfonylchloride (1.55 g, 8.12 mmol) in 
dichloromethane (10 mL) was added via a cannula. The bright yellow solution was 
stirred at room temperature for 27 h, then diluted with dichloromethane (20 mL) and 
washed with saturated aqueous NH4Cl (20 mL). Water (20 mL) was added, the layers 
were separated and the aqueous layer was extracted with dichloromethane (3 x 20 mL). 
The combined organic layers were dried (Na2SO4), filtered and concentrated in vacuo. 
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Purification of the residue by column chromatography (20→80% EtOAc/hexane) 
afforded the title compound as a yellow gum (530 mg, 44% from bis-amide). Rf = 0.54 
(20% EtOAc/hexane); 1H NMR (500 MHz, CDCl3) δ 4.17-4.06 (4H, m, 2 x OCH2), 
3.85 (2H, dd, J = 10.0, 7.0 Hz, 2 x NCH), 1.52 (6H, s, 2 x CH3), 0.88 (18H, s, 6 x CH3); 
13C NMR (125.8 MHz, CDCl3) δ 168.6 (2 x C), 75.3 (2 x CH), 69.0 (2 x CH2), 38.6 (C), 
34.0 (2 x C), 25.6 (6 x CH3), 24.4 (2 x CH3). The NMR data were in agreement with the 
literature.222 
 (3aR,8aS)-2{2-[(3aR,8aS)-3aH,8H,8aH-indeno-[1,2-d]-1,3-oxazol-2-yl]propan-2-
yl}-3aH,8H,8aH-indeno[1, 2-d][1, 3]-oxazole (500). 
 
In a modification of a previously reported procedure,223a a 50 mL two-necked 
round-bottomed flask fitted with a reflux condenser was charged with 
2,2-dimethylmalononitrile (577) (115 mg, 1.22 mmol), zinc triflate (885 mg, 2.43 mmol) 
and (1R,2S)-(+)-cis-1-amino-2-indanol (578) (115 mg, 2.43 mmol). The system was 
purged with nitrogen and anhydrous toluene (20 mL) was added. The solution was 
heated at reflux for 48 h. The system was allowed to cool and after diluting with more 
toluene (6 mL) was then washed with brine (3 x 40 mL) and NaHCO3 (3 x 40 mL), dried 
(MgSO4), filtered and concentrated in vacuo to give almost pure product. It was further 
purified by recrystallisation (EtOAc/hexane) to give the desired product 500 as a white 
solid (314 mg, 72%). Rf = 0.16 (60% EtOAc/hexane); 1H NMR (500 MHz, CDCl3) 
δ 7.52-7.48 (2H, m, ArH), 7.30-7.22 (6H, m, ArH), 5.53 (2H, d, J = 7.9 Hz, 2 x OCH), 
5.24-5.29 (2H, m, 2 x NCH), 3.31 (2H, dd, J = 17.9, 7.1 Hz, CH2), 2.96 (2H, d, J = 17.8 
Hz, CH′2), 1.43 (6H, s, 2 x CH3); 13C NMR (125.8 MHz, CDCl3) δ 169.1 (2 x C), 141.8 
(2 x C), 139.7 (2 x C), 128.3 (2 x CH), 127.3 (2 x CH), 125.6 (2 x CH), 125.1 (2 x CH), 
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83.2 (2 x CH), 76.4 (2 x CH), 39.6 (2 x CH2), 38.5 (C), 23.9 (2 x CH3). The NMR data 
were in agreement with the literature.223b 
General Procedure F: Synthesis of PyBox Ligands 
 
PyBox ligands were prepared according to a previously reported procedure.224 Sodium 
methoxide (2 mg, 0.04 mmol) was dissolved in methanol (5 mL) and then treated with 
pyridine-2,6-dicarbonitrile (579) (47 mg, 0.36 mmol). The mixture was stirred at room 
temperature for 48 h, followed by addition of acetic acid (10 μL). The solvent was 
evaporated and the resulting solid, dimethyl pyridine-2,6-dicarboximidate (580), was 
dried under vacuum and used without further purification. A suspension of this 
compound (0.36 mmol) and amino alcohol (0.76 mmol) in dichloromethane (20 mL) 
was stirred at reflux for two days. After removal of the solvent, the residue was 
crystallised from methanol to give the desired PyBox ligands. 
2,6-Bis[(4S)-4-phenyl-4,5-dihydro-1,3-oxazol-2-yl]pyridine 
(502). The title compound was prepared according to General 
Procedure F from (S)-2-phenylglycinol (568) (104 mg, 0.76 mmol) 
and purified by recrystallisation in methanol to afford a white solid 
(84 mg, 63%). Rf = 0.14 (EtOAc); 1H NMR (600 MHz, CDCl3) δ 8.36 (2H, d, J = 7.8 
Hz, ArH), 7.93 (1H, t, J = 7.9 Hz, ArH), 7.40-7.29 (10H, m, ArH), 5.47 (2H, dd, 
J = 10.2, 8.7 Hz, 2 x OCH), 4.94 (2H, dd, J = 10.9, 8.6 Hz, 2 x OCH′), 4.44 (2H, t, 
J = 8.6 Hz, 2 x NCH); 13C NMR (150.8 MHz, CDCl3) δ 163.5 (2 x C), 146.8 (2 x C), 
141.7 (2 x C), 137.4 (CH), 128.8 (4 x CH), 127.8 (2 x CH), 126.8 (4 x CH), 126.3 





oxazol-2-yl]pyridine (503). The title compound was 
prepared according to General Procedure F from 
(1R,2S)-(+)-cis-aminoidal-ol (578) (313 mg, 2.1 mmol) and 
purified by recrystallisation in methanol to afford a white solid (387 mg, 98%). Rf = 0.15 
(EtOAc); 1H NMR (600 MHz, CDCl3) δ 8.11 (2H, d, J = 7.9 Hz, ArH), 7.78 (1H, t, 
J = 7.9 Hz, ArH), 7.58-7.54 (2H, m, ArH), 7.29-7.24 (6H, m, ArH), 5.79 (2H, d, J = 8.0 
Hz, 2 x OCH), 5.6 (2H, dt, J = 8.3, 4.3 Hz, 2 x NCH), 3.5 (4H, d, J = 4.03 Hz, 2 x CH2); 
13C NMR (150.8 MHz, CDCl3) δ 162.8 (2 x C), 147.0 (2 x C), 141.4 (2 x C), 139.9 
(2 x C), 137.1 (CH), 128.6 (2 x CH), 127.4 (2 x CH), 126.0 (2 x CH), 125.6 (2 x CH), 
125.3 (2 x CH), 84.3 (2 x CH), 77.0 (2 x CH), 39.7 (2 x CH2). The data is in agreement 
with the literature.224  
2,6-Bis[(4S)-4-benzyl-4,5-dihydro-1,3-oxazol-2-yl]pyridine 
(504). The title compound was prepared according to General 
Procedure F from (S)-(−)-2-amino-3-phenyl-1-propanol (159 mg, 
1.05 mmol) and purified by recrystallisation in methanol to afford a 
white solid (152 mg, 77%). Rf = 0.26 (EtOAc); 1H NMR (500 MHz, CDCl3) δ 8.22 (2H, 
d, J = 7.8 Hz, ArH), 7.9 (1H, t, J = 7.8 Hz, ArH), 7.34-7.29 (4H, m, ArH), 7.27-7.22 
(6H, m, ArH), 4.66 (2H, tdd, J = 9.1, 7.6, 5.2 Hz, 2 x NCH), 4.47 (2H, dd, J = 9.4, 
8.7 Hz, 2 x OCH), 4.26 (2H, dd, J = 8.6, 7.6 Hz, 2 x OCH′), 3.28 (2H, dd, J = 13.8, 
5.2 Hz, 2 x CH2), 2.76 (2H, dd, J = 13.8, 9.0 Hz, 2 x CH′2); 13C NMR (125.8 MHz, 
CDCl3) δ 162.7 (2 x C), 146.8 (2 x C), 137.7 (2 x C), 137.4 (CH), 129.2 (4 x CH), 128.6 
(4 x CH), 126.6 (2 x CH), 125.8 (2 x CH), 72.6 (2 x CH2), 68.1 (2 x CH), 41.7 
(2 x CH2). The NMR data were in agreement with the literature.225 
2,6-Bis[(4R,5S)-4,5-diphenyl-4,5-dihydro-1,3-oxazol-2-
yl]pyridine (505). The title compound was prepared 
according to General Procedure F from (1S,2R)-(+)-2-amino-
1,2-diphenylethanol (573) (224 mg, 1.05 mmol) and purified by recrystalisation in 
methanol to afford a white solid (486 mg, 93%). Rf = 0.65 (EtOAc); 1H NMR 
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(600 MHz, CDCl3) δ 8.46 (2H, d, J = 7.8 Hz, ArH), 8.04 (1H, t, J = 7.9 Hz, ArH), 
7.09-7.02 (12H, m, ArH), 7.01-6.97 (8H, m, ArH), 6.15 (2H, d, J = 10.3 H, 2 x OCH), 
5.84 (2H, d, J = 10.3 Hz, 2 x NCH); 13C NMR (150.8 MHz, CDCl3) δ 164.0 (2 x C), 
147.2 (2 x C), 137.5 (CH), 137.3 (2 x C), 136.1 (2 x C), 127.9 (4 x CH), 127.7 (4 x CH), 
127.6 (4 x CH), 127.5 (2 x CH), 127.1 (2 x CH), 126.6 (4 x CH), 126.4 (2 x CH), 86.3 
(2 x CH), 74.5 (2 x CH). The NMR data were in agreement with the literature.224 
2-[(4R,5S)-4,5-Diphenyl-4,5-dihydro-1,3-oxazol-2-yl]pyridine (507). 
The title compound was prepared according to General Procedure F 
from (1S,2R)-(+)-2-amino-1,2-diphenylethanol (573) (224 mg, 
1.05 mmol) and 2-cyanopyridine (52 mg, 0.5 mmol) and then  purified 
by column chromatography (40→100% EtOAc/hexane) to afford a colourless gum 
(114.2 mg, 76%). Rf  = 0.32 (EtOAc); [α]20D  +46.4 (c 1.7, CHCl3); IR (film) 2920, 1643, 
1584, 1454, 1337, 1099, 966, 744, 696 cm−1; 1H NMR (600 MHz, CDCl3) δ 8.83-8.81 
(1H, m, ArH), 8.27 (1H, d, J = 7.9 Hz, ArH), 7.86 (1H, td, J = 7.8, 1.7 Hz, ArH), 7.47 
(1H, ddd, J = 7.6, 4.8, 1.1, 1.0 Hz, ArH), 7.08-7.01 (6H, m, ArH), 7.00-6.95 (4H, m, 
ArH), 6.12 (1H, d, J = 10.3 Hz, OCH), 5.83 (1H, d, J = 10.3 Hz, NCH); 13C NMR 
(150.8 MHz, CDCl3) δ 164.1 (C), 150.0 (CH), 146.6 (C), 137.3 (C), 136.7 (CH), 136.1 
(C), 127.9 (2 x CH), 127.6 (4 x CH), 127.4 (CH), 127.0 (CH), 126.4 (2 x CH), 125.8 
(CH), 124.3 (CH), 86.0 (CH), 74.6 (CH); HRMS (ESI) Exact mass calcd for C20H17N2O 








2,6-Bis[(4R,5R)-diphenyl-1,3-oxazolin-2-yl]pyridine (508)  
 
In a modification of a previously reported procedure,226 a solution of pyridine 
2,6-dicarbonylchloride (581) (102 mg, 0.5 mmol) in dried dichloromethane (10 mL), 
was added dropwise to a mixture of (1S,2R)-(+)-2-amino-1,2-diphenylethanol (573) 
(224 mg, 1.05 mmol) and trimethylamine (0.42 mL, 3 mmol) in dried dichloromethane 
(10 mL) at –5 °C. The reaction was stirred at room temperature overnight. The white 
precipitate was filtered and washed with water to give 2,6-bis[(1R,2S)N,N’-2-hydroxy-
1,2-diphenylethyl]pyridinedicarboxamide (582) as a pale yellow solid (231 mg, 83% 
yield). 1H NMR (600 MHz, DMSO-d6) δ 9.03 (2H, d, J = 8.9 Hz, 2 x NH), 8.12-8.01 
(3H, m, ArH), 7.44-7.12 (20H, m, ArH), 5.84 (2H, d, J = 4.7 Hz, 2 x OH), 5.24-5.14 
(4H, m, 2 x NCH, 2 x OCH); 13C NMR (150.8 MHz, DMSO-d6) δ 162.2 (2 x C), 148.9 
(2 x C), 142.8 (2 x C), 139.7 (2 x C), 139.6 (CH), 128.5 (4 x CH), 127.7 (8 x CH), 127.1 
(4 x CH), 126.7 (4 x CH), 124.7 (2 x CH), 74.3 (2 x CH), 58.9 (2 x CH); To a 
suspension of bis-amide (581) (200 mg, 0.36 mmol) in dried dichloromethane (5 mL), a 
solution of SOCl2 (0.42 mL, 5.76 mmol) in the same solvent (1 mL) was added 
dropwise, and the mixture was heated at reflux for 3 h. The solvent and excess SOCl2 
were removed under vacuum and the mixture was washed with water (2 x 10 mL). This 
residue (0.36 mmol) was then suspended in ethanol (4 mL), an aqueous solution of 
NaOH (2M, 4 mL) was added and the mixture was heated at reflux for 3 h. The hot 
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suspension was filtered and the white solid was washed with water (10 mL) give 508 
(20 mg, 12% from 582 as a white solid. 1H NMR (600 MHz, CDCl3) δ 8.39 (2H, d, 
J = 7.8 Hz, ArH), 7.98 (1H, t, J = 7.9 Hz, ArH), 7.50-7.30 (20H, m, ArH), 5.55 (2H, d, 
J = 8.4 H, 2 x OCH), 5.33 (2H, d, J = 8.4 Hz, 2 x NCH); 13C NMR (150.8 MHz, 
CDCl3) δ 163.0 (2 x C), 147.1 (2 x C), 141.3 (2 x C),  139.7 (2 x C), 137.5 (CH), 128.9 
(4 x CH), 128.8 (4 x CH), 128.6 (2 x CH), 127.9 (2 x CH), 126.9 (4 x CH), 126.6 
(2 x CH), 126.3 (4 x CH), 90.1 (2 x CH), 79.0 (2 x CH). The data is in agreement with 
the literature.226 
3.2.3 Synthesis of Nitroalkenes 
 
Nitroalkene 490227 was prepared by Alain J. Simpson according to previously reported 
procedure. Nitrostyrenes 338a,172 338c,172 338d,172 338f,  and 338h172 were prepared by 
Alain J. Simpson according to general procedure J. Yields and reaction times reported in 





Mono-tert-butyloxalic acid-N-methoxy-N-methylamide (583)  
 
According to a previously reported procedure,154 tert-butanol (7.4 g, 100 mmol) was 
slowly added in one charge to a solution of oxalyl chloride (572) (8.76 mL, 102 mmol) 
in THF (100 mL) at 0 °C under nitrogen. After 1 h, N,O-dimethylhydroxylamine 
hydrochloride (9.95 g, 102 mmol) and triethylamine (42 mL, 301 mmol) were added and 
the solution was stirred for 2 h. Water (200 mL) was added, and THF was evaporated 
under reduced pressure. The aqueous layer was extracted with ethyl acetate 
(3 x 100 mL). The combined organic layers were washed with water (100 mL) and brine 
(100 mL), dried (Na2SO4), filtered and concentrated in vacuo. The residue was purified 
by silica gel column chromatography (10% EtOAc/hexane) to give 583 as a pale yellow 
oil (14.85 g, 79%). Rf = 0.40 (40% EtOAc/hexane); 1H NMR (600 MHz, CDCl3) δ 3.72 
(3H, s, OCH3), 3.17 (3H, s, NCH3), 1.53 (9H, s, 3 x CH3); 13C NMR (125.8 MHz, 
CDCl3) δ 162.3 (C), 161.8 (C), 84.1 (CH3), 62.0 (CH3), 31.1 (C), 27.8 (3 x CH3). The 
NMR data were in agreement with the literature.154 
General Procedure G: Synthesis of α-Ketoesters 
 
In a modification of a previously reported procedure,173 to a solution of dialkyl oxalate 
or monoalkyloxalic acid-N-methoxy-N-methylamide (583) (40 mmol) in Et2O (40 mL) 
at 78 °C was added a solution of the appropriate Grignard reagent (42.0 mmol) in THF 
dropwise over 1 h. The reaction mixture was stirred at 78 °C for 1 h, then allowed to 
warm to 10 °C and quenched with aqueous HCl (10% w/v, 10 mL). After stirring at 
room temperature for 5 min, the mixture was diluted with H2O (10 mL) and the layers 
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were separated. The aqueous phase was extracted with Et2O (2 x 50 mL) and the 
combined organic layers were washed with brine (50 mL), dried (MgSO4), filtered, and 
concentrated in vacuo. Purification of the residue by column chromatography afforded 
the α-ketoesters. 
tert-Butyl 2-oxooctanoate (584a). The title compound was 
prepared according to General Procedure G from mono-tert-
butyloxalic acid-N-methoxy-N-methylamide (583) (3.78 g, 20 mmol) and 
hexylmagnesium bromide (2.0 M in Et2O, 10.5 mL, 21 mmol) and purified by column 
chromatography (1→4% EtOAc/hexane) to afford a colourless oil (1.42 g, 33%). 
Rf = 0.53 (10% EtOAc/hexane); 1H NMR (600 MHz, CDCl3) δ 2.75 (2H, t, J = 7.4 Hz, 
CH2), 1.30-1.58 (2H, m, CH2), 1.54 (9H, s, 3 x CH3), 1.35-1.25 (6H, m, 3 x CH2), 0.88 
(3H, t, J = 6.9 Hz, CH3); 13C NMR (150.8 MHz, CDCl3) δ 195.8 (C), 160.9 (C), 83.7 
(C), 39.1 (CH2), 31.4 (CH2), 28.6 (CH2), 27.8 (3 x CH3), 23.0 (CH2), 22.4 (CH2), 13.9 
(CH3). The NMR data were in agreement with the literature.156 
 Ethyl 2-oxooctanoate (585a). The title compound was prepared 
according to General Procedure G from diethyl oxalate (5.85 g, 
40 mmol) and hexylmagnesium bromide (2.0 M in Et2O, 21 mL, 42 mmol) and purified 
by column chromatography (5→20% Et2O/hexane) to afford a colourless oil (6.37 g, 
85%). Rf  = 0.54 (40% Et2O/hexane); 1H NMR (500 MHz, CDCl3) δ 4.38-4.27 (2H, m, 
OCH2), 2.83 (2H, t, J = 7.3 Hz, CH2), 1.68-1.60 (2H, m, CH2), 1.41-1.25 (9H, m, 
3 x CH2, CH3), 0.89 (3H, t, J = 7.0 Hz, CH3); 13C NMR (125.8 MHz, CDCl3) δ 194.8 
(C), 161.3 (C), 62.3 (CH2), 39.3 (CH2), 31.4 (CH2), 28.6 (CH2), 22.9 (CH2), 22.4 (CH2), 
14.0 (2 x CH3). The NMR data were in agreement with the literature.228 
Ethyl 3-methyl-2-oxobutanoate (585b). The title compound was 
prepared according to General Procedure G from diethyl oxalate (5.85 g, 
40 mmol) and isopropylmagnesium chloride (2.0 M in THF, 21 mL, 
42 mmol) and purified by column chromatography (5→20% EtOAc/hexane) to afford a 
colourless oil (5.54 g, 96%). Rf = 0.53 (20% EtOAc/hexane); 1H NMR (500 MHz, 
CDCl3) δ 4.26 (2H, q, J = 7.2 Hz, OCH2), 3.24-3.15 (1H, m, CH), 1.31 (3H, t, J = 7.2 
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Hz, CH3), 1.10 (6H, d, J = 7.0 Hz, 2 x CH3); 13C NMR (125.8 MHz, CDCl3) δ 198.1 
(C), 161.7 (C), 62.0 (CH2), 36.8 (CH), 17.0 (2 x CH3), 13.8 (CH3). The NMR data were 
in agreement with the literature.229 
Ethyl 2-cyclohexyl-2-oxoacetate (585c). The title compound was 
prepared according to General Procedure G from diethyl oxalate (7.31 g, 
50 mmol) and cyclohexylmagnesium chloride (2.0 M in Et2O, 26.5 mL, 
53 mmol) and purified by column chromatography (5% EtOAc/hexane) to afford a 
colourless oil (6.30 g, 85%). Rf = 0.59 (20% EtOAc/hexane); 1H NMR (500 MHz, 
CDCl3) δ 4.32 (2H, q, J = 7.1 Hz, OCH2), 3.06-3.01 (1H, m, CH), 1.93-1.89 (2H, m, 
CH2), 1.83-1.79 (2H, m, CH2), 1.73-1.66 (1H, m, CH2), 1.40-1.31 (7H, m, 2 x CH2, 
CH3), 1.27-1.19 (1H, m, CH2); 13C NMR (125.8 MHz, CDCl3) δ 197.7 (C), 162.0 (C), 
62.2 (CH2), 46.3 (CH), 27.5 (2 x CH2), 25.7 (CH2), 25.3 (2 x CH2), 14.0 (CH3). The 
NMR data were in agreement with the literature.229a 
Methyl 2-oxooctanoate (586). The title compound was prepared 
according to General Procedure G from dimethyl oxalate 
(2.36 g, 20 mmol) and hexylmagnesium bromide (2.0 M in Et2O, 10.5 mL, 21 mmol) 
and purified by column chromatography (2→8% EtOAc/hexane) to afford a colourless 
oil (585 mg, 17%). Rf  = 0.59 (20% EtOAc/hexane); 1H NMR (400 MHz, CDCl3) δ 3.87 
(3H, s, OCH3), 2.84 (2H, t, J = 7.3 Hz, CH2), 1.68-1.57 (2H, m, CH2), 1.38-1.24 (6H, m, 
3 x CH2), 0.89 (3H, t, J = 6.9 Hz, CH3); 13C NMR (100.6 MHz, CDCl3) δ 194.4 (C), 
161.6 (C), 52.9 (CH3), 39.3 (CH2), 31.4 (CH2), 28.6 (CH2), 22.9 (CH2), 22.4 (CH2), 14 
(CH3). The data NMR were in agreement with the literature.230 






In a modification of a previously reported procedure,173 magnesium turning (2.56 g, 
105 mmol) were heated (60 °C) at reduced pressure for 10 min in a three-necked 
round-bottomed flask with condenser. After cooling to room temperature, THF (90 mL) 
was added, followed by a solution of alkyl or aryl halide (105 mmol) in THF (10 mL) 
which was added dropwise.The reaction mixture was stirred at reflux for 10 min and 
then at room temperature for 4 h to afford the corresponding Grignard reagent. This was 
added to a solution of dialkyl oxalate or monoalkyloxalic acid-N-methoxy-N-
methylamide (583) (100 mmol) in Et2O (100 mL) at –78 °C dropwise over 1 h. The 
reaction mixture was stirred at –78 °C for 1 h, then allowed to warm to 10 °C and 
quenched with aqueous HCl (10% w/v, 20 mL). After stirring at room temperature for 
5 min, the mixture was diluted with H2O (20 mL) and the layers were separated. The 
aqueous phase was extracted with Et2O (3 x 50 mL) and the combined organic layers 
were washed with brine (50 mL), dried (MgSO4), filtered, and concentrated in vacuo. 
Purification of the residue by column chromatography afforded the α-ketoesters. 
Ethyl 2-(4-methylphenyl)-2-oxoacetate (585d). The title compound 
was prepared according to General Procedure H from diethyl oxalate 
(14.6 g, 100 mmol), magnesium turning (2.67 g, 110 mmol) and 
4-bromophenol (18.80 g, 110 mmol) and purified by column chromatography (40% 
Et2O/hexane) to afford a colourless oil (9.02 g, 47%). Rf = 0.54 (30% EtOAc/hexane); 
1H NMR (500 MHz, CDCl3) δ 7.91 (2H, d, J = 8.2 Hz, ArH), 7.31 (2H, d, J = 8.3 Hz, 
ArH), 4.45 (2H, q, J = 7.2 Hz, OCH2), 2.44 (3H, s, CH3), 1.42 (3H, t, J = 7.2 Hz, CH3); 
13C NMR (125.8 MHz, CDCl3) δ 186.1 (C), 164.0 (C), 146.2 (C), 130.1 (2 x CH), 
130 (C), 129.6 (2 x CH), 62.2 (CH2), 21.9 (CH3), 14.1 (CH3). The NMR data were in 
agreement with the literature.231 
Ethyl 2-(3-methylphenyl)-2-oxoacetate (585e). The title compound was 
prepared according to General Procedure H from diethyl oxalate (7.3 g, 
50 mmol), magnesium turning (1.46 g, 60 mmol) and 3-bromophenol 
(9.2 g, 53 mmol) and purified by column chromatography (2→6% EtOAc/hexane) to 
afford a colourless oil (6.41 g, 67%). Rf = 0.47 (20% EtOAc/hexane); 1H NMR 
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(400 MHz, CDCl3) δ 7.83-7.79 (2H, m, ArH), 7.50-7.46 (1H, m, ArH), 7.43-7.38 (1H, 
m, ArH), 4.46 (2H, q, J = 7.1 Hz, OCH2), 2.43 (3H, s, CH3), 1.43 (3H, t, J = 7.2 Hz, 
CH3); 13C NMR (100.6 MHz, CDCl3) δ 186.7 (C), 164.0 (C), 138.8 (C), 135.7 (CH), 
132.5 (C), 130.3 (CH), 128.8 (CH), 127.4 (CH), 62.3 (CH2), 21.3 (CH3), 14.1 (CH3). 
The NMR data were in agreement with the literature.231 
Ethyl 2-(2-chlorophenyl)-2-oxoacetate (585f). The title compound was 
prepared according to General Procedure H from diethyl oxalate (2.2 g, 
15 mmol), magnesium turning (437 mg, 18 mmol) and 1-bromo-2-
chlorobenzene (2.87 g, 15 mmol) and purified by column chromatography (2→6% 
EtOAc/hexane) to afford a colourless oil (1.74 g, 55%). Rf = 0.42 (10% EtOAc/hexane); 
1H NMR (600 MHz, CDCl3) δ 7.75 (1H, dd, J = 7.7, 1.6 Hz, ArH), 7.53-7.49 (1H, m, 
ArH), 7.45-7.37 (2H, m, ArH), 4.41 (2H, q, J = 7.1 Hz, OCH2), 1.38 (3H, t, J = 7.1 Hz, 
CH3); 13C NMR (150.8 MHz, CDCl3) δ 186.5 (C), 163.0 (C), 134.2 (CH), 133.7 (C), 
133.3 (C), 131.5 (CH), 130.5 (CH), 127.2 (CH), 62.7 (CH2), 13.8 (CH3). The NMR data 
were in agreement with the literature.232 
 tert-Butyl 2-oxo-2-phenylacetate (584b). The title compound was 
prepared according to General Procedure H from mono-tert-butyloxalic 
acid-N-methoxy-N-methylamide (583) (3.78 g, 20 mmol), magnesium turning (583 mg, 
24 mmol) and bromobenzene (3.14 g, 20 mmol) and purified by column 
chromatography (1→4% EtOAc/hexane) to afford a yellow oil (3.1 g, 75 %). Rf = 0.54 
(10% EtOAc/hexane); 1H NMR (600 MHz, CDCl3) δ 7.97 (2H, d, J = 7.3 Hz, ArH), 
7.64 (1H, t, J = 7.4 Hz, ArH), 7.51 (2H, t, J = 7.8 Hz, ArH), 1.63 (9H, s, 3 x CH3); 
13C NMR (150.8 MHz, CDCl3) δ 186.8 (C), 163.7 (C), 134.6 (CH), 132.5 (C), 129.8 
(2 x CH), 128.8 (2 x CH), 84.7 (C), 28.0 (3 x CH3). The NMR data were in agreement 
with the literature.233 
Ethyl 2-oxohex-5-enoate (585g). The title compound was prepared 
according to General Procedure H from diethyl oxalate (4.5 g, 30 
mmol), magnesium turning (972 mg, 40 mmol) and 4-bromo-1-butene 
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(5 g, 37 mmol) and purified by column chromatography (1→3% EtOAc/hexane) to 
afford a pale yellow oil (2.26 g, 39%). Rf = 0.42 (20% EtOAc/hexane); 1H NMR 
(500 MHz, CDCl3) δ 5.88-5.77 (1H, m, CH=), 5.11-5.00 (2H, m, CH2=), 4.33 (2H, qd, 
J = 7.1, 0.9 Hz, OCH2), 2.98-2.93 (2H, m, CH2), 2.44-2.37 (2H, m, CH2), 1.38 (3H, td, 
J = 7.1, 0.8 Hz, CH3); 13C NMR (125.8 MHz, CDCl3) δ 193.8 (C), 161.1 (C), 136.1 
(CH2), 115.9 (CH), 62.4 (CH2), 38.4 (CH2), 26.9 (CH2), 14.0 (CH3). The NMR data 
were in agreement with the literature.234 
 Ethyl 2-oxo-4-phenylbutanoate (585h). The title compound was 
prepared according to General Procedure H from diethyl oxalate (5.85 
g, 40 mmol), magnesium turning (972 mg, 40 mmol) and (2-bromoethyl) benzene (7.4 g, 
40 mmol) and purified by column chromatography (5→20% EtOAc/hexane) to afford a 
pale yellow oil (1.98 g, 24%). Rf = 0.34 (20% EtOAc/hexane); 1H NMR (500 MHz, 
CDCl3) δ 7.32.7.28 (2H, m, ArH), 7.24-7.20 (3H, m, ArH), 4.32 (2H, q, J = 7.1 Hz, 
OCH2), 3.19 (2H, t, J = 7.4 Hz, CH2), 2.97 (2H, t, J = 7.5 Hz, CH2), 1.37 (3H, t, J = 7.1 
Hz, CH3); 13C NMR (125.8 MHz, CDCl3) δ 193.6 (C), 160.9 (C), 140.1 (C), 128.6 
(2 x CH), 128.4 (2 x CH), 126.4 (CH), 62.5 (CH2), 40.9 (CH2), 29.0 (CH2), 14.0 (CH3). 
The NMR data were in agreement with the literature.232,235 
 Ethyl 5-methyl-2-oxo-hexanoate (585i). The title compound was 
prepared according to General Procedure H from diethyl oxalate 
(14.6 g, 100 mmol), magnesium turning (2.92 g, 120 mmol) and 1-bromo-3-methyl 
butane (15.9 g, 100 mmol) and purified by column chromatography (2→5% 
EtOAc/hexane) to afford a colourless oil (5.0 g, 29%). Rf = 0.50 (20% EtOAc/hexane); 
1H NMR (500 MHz, CDCl3) δ 4.39-4.27 (2H, m, OCH2), 2.83 (2H, dd, J = 8.0, 7.2 Hz, 
CH2), 1.65-1.49 (3H, m, CH, CH2), 1.41-1.32 (3H, m, CH3),  0.92 (6H, d, J = 6.5 Hz, 
2 x CH3); 13C NMR (125.8 MHz, CDCl3) δ 194.9 (C), 161.0 (C), 62.3 (CH2), 37.3 
(CH2), 31.7 (CH2), 27.6 (CH), 22.2 (2 x CH3), 14.0 (CH3). The NMR data were in 
agreement with the literature.236 
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Ethyl 4-(1,3-dioxan-2-yl)-2-oxobutanoate (585j). The title 
compound was prepared according to General Procedure H from 
diethyl oxalate (3.75 g, 25.6 mmol), magnesium turning (1.25 g, 
51 mmol) and 2-(2-bromoethyl)-1,3-dioxane (5 g, 25.6 mmol) and purified by column 
chromatography (2→20% EtOAc/hexane) to afford a colourless oil (1.54 g, 28%). 
Rf = 0.20 (20% EtOAc/hexane); 1H NMR (500 MHz, CDCl3) δ 4.61 (1H, t, J = 4.7 Hz, 
OCH), 4.31 (2H, q, J = 7.1 Hz, OCH2), 4.09-4.03 (2H, m, OCH2), 3.76-3.69 (2H, m, 
OCH2),  2.94 (2H, t, J = 7.1 Hz, CH2), 2.09-1.98 (1H, m, CH2), 1.97 (2H, td, J = 7.1, 
4.7 Hz, CH2), 1.36 (3H, t, J = 7.1 Hz, CH3), 1.34-1.29 (1H, m, CH2); 13C NMR 
(125.8 MHz, CDCl3) δ 194.0 (C), 161.0 (C), 100.2 (CH), 66.7 (2 x CH2), 62.2 (CH2), 
33.5 (CH2), 29.0 (CH2), 25.6 (CH2), 14.0 (CH3). The NMR data were in agreement with 
the literature.237 
1,5-Diethyl 2-oxopentanedioate (585k) 
 
In a modification of a previously reported procedure,238 to a solution of α-oxo-glutaric 
acid (587) (5.88 g, 40 mmol) in ethanol (60 mL) was added acetyl chloride (550 µL, 8 
mmol) dropwise. The reaction mixture was stirred at room temperature for 20 h and then 
concentrated in vacuo. The residue was dissolved in dichloromethane (100 mL) and 
washed with water (2 x 50 mL). The organic phase was separated, dried (MgSO4), 
filtered and concentrated in vacuo to afford 585k as a colourless oil (7.24 g, 
90%). Rf = 0.32 (20% EtOAc/hexane); 1H NMR (500 MHz, CDCl3) δ 4.34 (2H, q, J = 
7.1 Hz, OCH2), 4.15 (2H, q, J = 7.1 Hz, OCH2), 3.16 (2H, t, J = 6.5 Hz, CH2), 2.67 (2H, 
t, J = 6.5 Hz, CH2), 1.38 (3H, t, J = 7.1 Hz, CH3), 1.27 (3H, t, J = 7.1 Hz, CH3); 
13C NMR (125.8 MHz, CDCl3) δ 192.7 (C), 172.0 (C), 160.6 (C), 62.6 (CH2), 60.9 
(CH2), 34.2 (CH2), 27.7 (CH2), 14.1 (CH3), 14.0 (CH3). The NMR data were in 
agreement with the literature.238,239 
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General Procedure I: Synthesis of β-Nitro-α-Hydroxyesters 
 
In a modification of a procedure previously reported by List and co-workers.173 In a 
dried two-necked round-bottomed flask, a solution of the α-ketoester (120 mmol) in 
nitromethane (100 mL) was treated with triethylamine (3.3 mL, 24 mmol). The mixture 
was then stirred at room temperature until complete conversion of the α-ketoester as 
indicated by TLC analysis. The solvent was removed in vacuo, and the residue was 
purified by flash chromatography to give the β-nitro-α-hydroxyesters. 
Ethyl 2-hydroxy-2-(4-methylphenyl)-3-nitropropanoate (588a). 
The title compound was prepared according to General Procedure I 
from ketoester 585d (7.8 g, 40.6 mmol) and purified by column 
chromatography (20% Et2O/hexane) to afford colourless oil (7.15 g, 70%). Rf = 0.35 
(20% EtOAc/hexane); 1H NMR (500 MHz, CDCl3) δ 7.50-7.47 (2H, m, ArH), 
7.23-7.20 (2H, m, ArH), 5.25 (1H, dd, J = 14.2, 1.0 Hz, CH2NO2), 4.67 (1H, d, J = 14.2 
Hz, CH2NO2), 4.43-4.31 (2H, m, OCH2), 4.19 (1H, d, J = 1.0 Hz, OH), 2.37 (3H, s, 
CH3), 1.35 (3H, t, J = 7.1 Hz, CH3); 13C NMR (125.8 MHz, CDCl3) δ 171.8 (C), 139.1 
(C), 133.5 (C), 129.6 (2 x CH), 125.1 (2 x CH), 80.8 (CH2), 75.9 (C), 63.5(CH2), 21.0 
(CH3), 13.9 (CH3). The NMR data were in agreement with the literature.173 
Ethyl 2-hydroxy-2-(3-methylphenyl)-3-nitropropanoate (588b). The 
title compound was prepared according to General Procedure I from 
ketoester 585e (3.34 g, 17.35 mmol) and purified by column 
chromatography (2→10% EtOAc/hexane) to afford a colourless oil (4.15 g, 95%). 
Rf = 0.45 (20% EtOAc/hexane); 1H NMR (600 MHz, CDCl3) δ 7.44 (1H, s, ArH), 7.38 
(1H, d, J = 7.9 Hz, ArH), 7.29 (1H, t, J = 7.7 Hz, ArH), 7.19 (1H, d, J = 7.5 Hz, ArH), 
5.26 (1H, d, J = 14.1 Hz, CH2NO2), 4.68 (1H, d, J = 14.1 Hz, CH2NO2), 4.43-4.33 (2H, 
m, OCH2), 4.21 (1H, s, OH), 2.39 (3H, s, CH3), 1.35 (3H, t, J =7.1 Hz, CH3); 13C NMR 
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(150.8 MHz, CDCl3) δ 171. (C), 138.8 (C), 136.4 (C), 129.8 (CH), 128.7 (CH), 125.8 
(CH), 122.2 (CH), 80.8 (CH2), 76.0 (C), 63.5 (CH2), 21.5 (CH3), 13.9 (CH3). The NMR 
data were in agreement with the literature.240 
Ethyl 2-(2-chlorophenyl)-2-hydroxy-3-nitropropanoate (588c). The 
title compound was prepared according to General Procedure I from 
ketoester 585f (1.54 g, 7.24 mmol) and purified by column 
chromatography (10→40% EtOAc/hexane) to afford a colourless oil (1.38 g, 69%). 
Rf = 0.30 (20% EtOAc/hexane); IR (film) 3472 (OH), 2924, 1736 (C=O), 1555 (NO2), 
1468, 1377 (NO2), 1225, 1119, 1036, 754 cm−1; 1H NMR (600 MHz, CDCl3) 
δ 7.68-7.64 (1H, m, ArH), 7.43-7.39 (1H, m, ArH), 7.38-7.32 (2H, m, ArH), 5.43 (1H, 
d, J = 13.1 Hz, CH2NO2), 5.05 (1H, d, J = 13.1 Hz, CH2NO2), 4.7 (1H, s, OH),  
4.40-4.26 (2H, m, OCH2), 1.29 (3H, t, J = 7.1 Hz, CH3), 13C NMR (150.8 MHz, CDCl3) 
δ 170.0 (C), 134.5 (C), 131.6 (C), 131.3 (CH), 130.5 (CH), 128.0 (CH), 127.4 (CH), 
78.7 (CH2), 76.4 (C), 63.3 (CH2), 13.7 (CH3); HRMS (ESI) Exact mass calcd for 
C11H12NO5ClNa [M+Na]+: 296.0296, found 296.0291. 
tert-Butyl 2-hydroxy-3-nitro-2-phenylpropanoate (589a). The title 
compound was prepared according to General Procedure I from ketoester 
584b (1.99 g, 9.65 mmol) and purified by column chromatography (10% EtOAc/hexane) 
to afford a colourless oil (1.63 g, 63 %). Rf = 0.24 (10% EtOAc/hexane); 1H NMR 
(600 MHz, CDCl3) δ 7.63-7.60 (2H, m, ArH), 7.43-7.35 (3H, m, ArH), 5.21 (1H, dd, 
J = 14.0, 0.9 Hz, CH2NO2), 4.66 (1H, d, J = 14.0 Hz, CH2NO2), 4.25 (1H, d, J = 1.0 Hz, 
OH), 1.53 (9H, s, CH3); 13C NMR (150.8 MHz, CDCl3) δ 170.5 (C), 137.0 (C), 128.9 
(CH), 128.8 (2 x CH), 125.2 (2 x CH), 85.0 (C)  80.1 (CH2), 75.9 (C), 27.7 (3 x CH3). 
The NMR data were in agreement with the literature.173 
tert-Butyl 2-hydroxy-2-(nitromethyl)nonanoate (589b). The 
title compound was prepared according to General Procedure I 
from ketoester 584a (1.2 g, 5.6 mmol) and purified by column chromatography (4→20% 
EtOAc/hexane) to afford a colourless oil (1.21 g, 79 %). Rf = 0.59 (20% EtOAc/hexane); 
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IR (film) 3495 (OH), 2924, 1730 (C=O), 1560 (NO2), 1369 (NO2), 1254, 1234, 1146, 
1105, 843 cm−1; 1H NMR (600 MHz, CDCl3) δ 4.76 (1H, d, J = 13.4 Hz, CH2NO2), 
4.53 (1H, d, J = 13.4 Hz, CH2NO2), 3.71 (1H, s, OH), 1.62 (2H, dtd, J = 25.3, 13.3, 4.6 
Hz, CH2), 1.53-1.44 (1H, m, CH2), 1.54 (9H, s, 3 x CH3), 1.35-1.23 (6H, m, 3 x CH2), 
1.21-1.12 (1H, m, CH2), 0.89 (3H, t, J = 6.8 Hz, CH3); 13C NMR (150.8 MHz, CDCl3) δ 
171.8 (C), 84.2 (C), 81.1 (CH2), 75.1 (C), 36.7 (CH2), 31.5 (CH2), 29.1 (CH2), 27.8 (3 x 
CH3), 22.5 (CH2), 22.4 (CH2), 14.0 (CH3); HRMS (ESI) Exact mass calcd for 
C13H25NO5Na [M+Na]+: 298.1625, found 298.1620. 
 Ethyl 2-hydroxy-2-(nitromethyl)octanoate (588d). The title 
compound was prepared according to General Procedure I from 
ketoester 585a (6 g, 32.22 mmol) and purified by column chromatography (20% 
Et2O/hexane) to afford a colourless oil (5.85 g, 73.4%). Rf = 0.60 (20% EtOAc/hexane); 
1H NMR (500 MHz, CDCl3) δ 4.82 (1H, dd, J = 13.6, 0.4 Hz, CH2NO2), 4.57 (1H, d, 
J = 13.6 Hz, CH2NO2), 4.43-4.27 (2H, m, OCH2), 3.70 (1H, s, OH), 1.73-1.58 (2H, m, 
CH2), 1.54-1.41 (1H, m, CH2), 1.34 (3H, t, J = 7.1 Hz, CH3), 1.33-1.22 (6H, m, 
3 x CH2), 1.20-1.10 (1H, m, CH2), 0.89 (3H, t, J = 7.0 Hz, CH3); 13C NMR 
(125.8 MHz, CDCl3) δ 172.9 (C), 80.9 (CH2), 75.3 (C), 63.0 (CH2), 36.6 (CH2), 31.4 
(CH2), 29.0 (CH2), 22.6 (CH2), 22.4 (CH2), 140.1 (CH3), 14.0 (CH3). The NMR data 
were in agreement with the literature.239b 
Ethyl 2-hydroxy-2-methyl-3-nitropropanoate (588e). The title 
compound was prepared according to General Procedure I from 
commercial available ethyl pyruvate (13.9 g, 120 mmol) and purified by column 
chromatography (Et2O) to afford a colourless oil (19.5 g, 92 %). Rf = 0.23 (20% 
EtOAc/hexane); 1H NMR (500 MHz, CDCl3) δ 4.84 (1H, d, J = 13.8 Hz, CH2NO2), 
4.56 (1H, d, J = 13.8 Hz, CH2NO2), 4.40-4.28 (2H, m, OCH2), 3.77 (1H, s, OH), 
1.47-1.44 (3H, m, CH3), 1.35-1.30 (3H, m, CH3); 13C NMR (125.8 MHz, CDCl3) δ 
173.4 (C), 81.0 (CH2), 72.4 (C), 63.0 CH2), 23.8 (CH3), 13.9 (CH3). The NMR data 
were in agreement with the literature.173 
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Ethyl 2-hydroxy-2-(nitromethyl)hex-5-enoate (588f). The title 
compound was prepared according to General Procedure I from 
ketoester 585g (1.73 g, 11.1 mmol) and purified by column chromatography (4→16% 
EtOAc/hexane) to afford a colourless oil (2.16 g, 89%). Rf = 0.30 (20% EtOAc/hexane); 
1H NMR (500 MHz, CDCl3) δ 5.76 (1H, ddt, J = 16.8, 10.2, 6.5 Hz, CH=), 5.07-4.98 
(2H, m, CH2=), 4.83 (1H, dd, J = 13.6, 0.7 Hz, CH2NO2), 4.58 (1H, d, J = 13.6 Hz, 
CH2NO2), 4.41-4.29 (2H, m, OCH2), 3.76 (1H, s, OH), 2.30-2.20 (1H, m, CH2), 
2.01-1.92 (1H, m, CH2), 1.84-1.71 (2H, m, CH2), 1.34 (3H, t, J = 7.1 Hz, CH3); 
13C NMR (125.8 MHz, CDCl3) δ 172.7 (C), 136.5 (CH), 115.8 (CH2), 80.8 (CH2), 75.0 
(C), 63.1 (CH2), 35.6 (CH2), 26.9 (CH2), 14.0 (CH3). The NMR data were in agreement 
with the literature.241 
Ethyl 2-hydroxy-2-(nitromethyl)-4-phenylbutanoate (588g). The 
title compound was prepared according to General Procedure I from 
ketoester 585h (1.71 g, 8.3 mmol) and purified by column chromatography (2→10% 
EtOAc/hexane) to afford a colourless oil (1.51 g, 68 %). Rf = 0.48 (20% EtOAc/hexane); 
1H NMR (500 MHz, CDCl3) δ 7.32-7.28 (2H, m, ArH), 7.24-7.20 (1H, m, ArH), 
7.18-7.15 (2H, m, ArH), 4.84 (1H, dd, J = 13.6, 0.5 Hz, CH2NO2), 4.60 (1H, d, J = 13.6 
Hz, CH2NO2), 4.40-4.27 (2H, m, OCH2), 3.84 (1H, s, OH), 2.84 (1H, ddd, J = 13.7, 
11.1, 5.4 Hz, CH2), 2.51 (1H, ddd, J = 13.7, 11.4, 5.6 Hz, CH2), 2.07-1.94 (2H, m, 
CH2), 1.35 (3H, t, J = 7.1 Hz, CH3); 13C NMR (125.8 MHz, CDCl3) δ 172.7 (C), 140.2 
(C), 128.6 (2 x CH), 128.3 (2 x CH), 126.4 (CH), 80.9 (CH2), 75.0 (C), 63.2 (CH2), 38.2 
(CH2), 29.0 (CH2), 14.1 (CH3). The NMR data were in agreement with the literature.241 
1,5-Diethyl 2-hydroxy-2-(nitromethyl)pentanedioate (588h). The 
title compound was prepared according to General Procedure I from 
ketoester 585k (2.02 g, 10 mmol) and purified by column chromatography (5→20% 
EtOAc/hexane) to afford a colourless oil (2.33 g, 88 %). Rf = 0.36 (30% EtOAc/hexane); 
IR (film) 3485 (OH), 2984, 1728 (C=O), 1557 (NO2), 1377 (NO2), 1221, 1184, 1132, 
1097, 1014 cm−1; 1H NMR (500 MHz, CDCl3) δ 4.86 (1H, d, J = 13.7 Hz, CH2NO2), 
4.58 (1H, d, J = 13.7 Hz, CH2NO2), 4.42-4.28 (2H, m, OCH2), 4.14 (2H, q, J = 7.1 Hz, 
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OCH2), 3.81 (1H, s, OH), 2.55-2.47 (1H, m, CH2), 2.32-2.23 (1H, m, CH2), 2.10-1.98 
(2H, m, CH2), 1.34 (3H, t, J = 7.1 Hz, CH3), 1.26 (3H, t, J = 7.1 Hz, CH3); 13C NMR 
(125.8 MHz, CDCl3) δ 172.4 (C), 172.3 (C), 80.6 (CH2), 74.4 (C), 63.3 (CH2), 60.9 
(CH2), 31.3 (CH2), 27.8 (CH2), 14.2 (CH3), 14.0 (CH3); HRMS (ESI) Exact mass calcd 
for C10H18NO7 [M+H]+: 264.1078, found 264.1080. 
Ethyl 2-hydroxy-5-methyl-2-(nitromethyl)hexanoate (588i). The 
title compound was prepared according to General Procedure I from 
ketoester 585i (3.69 g, 21.4 mmol) and purified by column chromatography (4→12% 
EtOAc/hexane) to afford a colourless oil (4.60 g, 92%). Rf = 0.46 (20% EtOAc/hexane); 
1H NMR (500 MHz, CDCl3) δ 4.83 (1H, d, J = 13.6 Hz, CH2NO2), 4.58 (1H, d, J = 
13.6 Hz, CH2NO2), 4.41-4.31 (2H, m, OCH2), 3.69 (1H, s, OH), 1.74-1.60 (2H, m, 
CH2), 1.57-1.46 (1H, m, CH), 1.44-1.36 (1H, m, CH2), 1.35 (3H, t, J = 7.1 Hz, CH3), 
1.06-0.96 (1H, m, CH2), 0.89 (6H, dd, J = 6.6, 5.23 Hz, 2 x CH3); 13C NMR 
(125.8 MHz, CDCl3) δ 172.9 (C), 80.9 (CH2), 75.3 (C), 63.0 (CH2), 34.5 (CH2), 31.4 
(CH2), 27.9 (CH), 22.4 (CH3), 22.3 (CH3), 14.1 (CH3). The NMR data were in 
agreement with the literature.241 
Ethyl 4-(1,3-dionan-2-yl)-2-hydroxy-2-(nitromethyl) butanoate 
(588j). The title compound was prepared according to General 
Procedure I from ketoester 585j (1.33 g, 5.14 mmol) and purified 
by column chromatography (10→30% EtOAc/hexane) to afford a colourless oil (1.04 g, 
73%). Rf = 0.29 (40% EtOAc/hexane); IR (film) 3435 (OH), 2853, 2363, 1736 (C=O), 
1558 (NO2), 1377 (NO2), 1263, 1219, 1144, 1010 cm−1; 1H NMR (500 MHz, CDCl3) δ 
4.83 (1H, d, J = 13.5 Hz, CH2NO2), 4.59-4.54 (2H, m, CH2NO2, O2CH), 4.41-4.27 (2H, 
m, OCH2), 4.12-4.06 (2H, m, OCH2), 3.93 (1H, s, OH), 3.79-3.71 (2H, m, OCH2), 
2.11-2.00 (1H, m, CH2), 1.90-1.72 (3H, m, 2 x CH2), 1.59-1.51 (1H, m, CH2), 1.37-1.31 
(4H, m, CH2, CH3); 13C NMR (125.8 MHz, CDCl3) δ 172.7 (C), 100.9 (CH), 80.9 
(CH2), 74.9 (C), 66.9 (2 x CH2), 63.0 (CH2), 30.6 (CH2), 28.5 (CH2), 25.6 (CH2), 14.0 




Ethyl 2-hydroxy-3-methyl-2-(nitromethyl)butanoate (588k). The title 
compound was prepared according to General Procedure I from ketoester 
585b (5 g, 34.68 mmol) and purified by column chromatography (20% Et2O/hexane) to 
afford a colourless oil (6.47 g, 91%). Rf = 0.44 (20% EtOAc/hexane); 1H NMR 
(500 MHz, CDCl3) δ 4.82 (1H, d, J = 13.5 Hz, CH2NO2), 4.67 (1H, d, J = 13.5 Hz, 
CH2NO2), 4.40-4.30 (2H, m, OCH2), 3.62 (1H, s, OH), 1.98 (1H, hept, J = 6.8 Hz, CH), 
1.34 (3H, t, J = 7.1 Hz, CH3), 0.99 (3H, d, J = 6.8 Hz, CH3), 0.90 (3H, d, J = 6.8 Hz, 
CH3); 13C NMR (125.8 MHz, CDCl3) δ 173.0 (C), 80.1 (CH2), 77.5 (C), 62.9 (CH2), 
34.1 (CH), 16.8 (CH3), 16.2 (CH3), 14.0 (CH3). The NMR data were in agreement with 
the literature.173 
Ethyl 2-cyclohexyl-2-hydroxy-3-nitropropanoate (588l). The title 
compound was prepared according to General Procedure I from 
ketoester 585c (5.2 g, 28 mmol) and purified by column chromatography 
(5→15%EtOAc/hexane) to afford a colourless oil (6.41 g, 93%). Rf = 0.43 (20% 
EtOAc/hexane); 1H NMR (500 MHz, CDCl3) δ 4.81 (1H, dd, J = 13.5, 0.8 Hz, 
CH2NO2), 4.68 (1H, d, J = 13.5 Hz, CH2NO2), 4.39-4.28 (2H, m, OCH2), 3.64 (1H, s, 
OH), 1.84-1.74 (2H, m, CH2), 1.73-1.60 (2H, m, CH2), 1.43-1.37 (1H, m, CH), 1.33 
(3H, td, J = 7.1, 0.6 Hz, CH3), 1.30-1.05 (6H, m, 3 x CH2); 13C NMR (125.8 MHz, 
CDCl3) δ 172.9 (C), 79.9 (CH2), 77.6 (C), 62.8 (CH2), 43.8 (CH), 26.7 (CH3), 26.1 
(CH2), 26.0 (CH2), 25.9 (CH2), 25.8 (CH2), 14.0 (CH3). The NMR data were in 
agreement with the literature.239b 
 Methyl 2-hydroxy-2-(nitromethyl)octanoate (590). The title 
compound was prepared according to General Procedure I from 
ketoester 586 (500 mg, 2.9 mmol) and purified by column chromatography (2→10% 
EtOAc/hexane) to afford a colourless oil (633 mg, 94 %). Rf = 0.50 (20% 
EtOAc/hexane); IR (film) 3510 (OH), 2924, 1742 (C=O), 1558 (NO2), 1445, 1379 
(NO2), 1223, 1153, 1103, 968 cm−1; 1H NMR (600 MHz, CDCl3) δ 4.82 (1H, d, J = 13.6 
Hz, CH2NO2), 4.57 (1H, d, J = 13.6 Hz, CH2NO2), 3.89 (3H, s, CH3), 3.69 (1H, s, OH), 
1.72-1.60 (2H, m, CH2), 1.52-1.43 (1H, m, CH2), 1.33-1.22 (6H, m, 3 x CH2), 1.18-1.10 
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(1H, m, CH2), 0.88 (3H, t, J = 7.0 Hz, CH3); 13C NMR (150.8 MHz, CDCl3) δ 173.5 
(C), 80.9 (CH2), 75.4 (C), 53.6 (CH3), 36.6 (CH2), 31.4 (CH2), 29.0 (CH2), 22.6 (CH2), 
22.4 (CH2), 13.9 (CH3); HRMS (ESI) Exact mass calcd for C10H20NO5 [M+H]+: 
234.1336, found 234.1382. 
2-Hydroxy-3-nitro-1,2-diphenylpropan-1-one (591). The title 
compound was prepared according to General Procedure I (with a reaction 
time of 7 days) from commercially available benzyl (6.3 g, 30 mmol) and 
purified by column chromatography (5→15% Et2O/hexane) to afford a colourless gum 
(2.95 g, 36%). Rf = 0.26 (10% EtOAc/hexane); IR (film) 3516 (OH), 3061, 2358, 1678 
(C=O), 1552 (NO2), 1448, 1371 (NO2), 1265, 1240, 1169 cm−1; 1H NMR (500 MHz, 
CDCl3) δ 7.96-7.92 (2H, m, ArH), 7.62-7.59 (2H, m, ArH), 7.52-7.47 (1H, m, ArH), 
7.47-7.42 (2H, m, ArH), 7.41-7.37 (1H, m, ArH), 7.37-7.32 (2H, m, ArH), 5.11 (1H, s, 
OH), 5.35 (1H, d, J = 14.9 Hz, CH2NO2), 4.55 (1H, d, 14.9 Hz, CH2NO2); 13C NMR 
(125.8 MHz, CDCl3) δ 197.8 (C), 135.8 (C), 133.4 (CH), 133.3 (C), 130.7 (2 x CH), 
129.3 (2 x CH), 129.1 (CH), 128.2 (2 x CH), 124.9 (2 x CH), 81.9 (C), 81.5 (CH2); 
HRMS (ESI) Exact mass calcd for C15H14NO4 [M+H]+: 272.0917, found 272.0929. 
General Procedure J: Synthesis of β-Acylnitroalkenes 
 
In a modification of a previously reported procedure by List and co-workers,173 to a 
solution of the appropriate β-nitro-α-hydroxyester (22.6 mmol) in DMSO (40 mL) was 
added Ac2O (6.4 mL, 67.7 mmol). The reaction was then stirred at room temperature. 
After complete consumption of the starting material as indicated by TLC analysis, the 
mixture was poured into water (50 mL). The two phases were separated and the aqueous 
phase was extracted with dichloromethane (3 x 50 mL). The combined organic phases 
were washed with saturated aqueous NaHCO3, dried (MgSO4), filtered and concentrated 
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in vacuo. The residue was purified by flash chromatography to afford the pure 
β-acylnitroalkenes. 
 Ethyl (2Z)-2-(4-methylphenyl)-3-nitroprop-2-enoate (338b). The 
title compound was prepared according to General Procedure J from 
nitroalcohol 588a (6.65 g, 26.26 mmol) and purified by column 
chromatography (10→20% EtOAc/hexane) to afford a yellow oil (4.96 g, 80%). 
Rf = 0.31 (20% EtOAc/hexane); 1H NMR (400 MHz, CDCl3) δ 7.42-7.39 (2H, m, ArH), 
7.36 (1H, s, CHNO2), 7.30-7.26 (2H, m, ArH), 4.49 (2H, q, J = 7.2 Hz, OCH2), 2.42 
(3H, s, CH3), 1.41 (3H, t, J = 7.2 Hz, CH3); 13C NMR (100.6 MHz, CDCl3) δ 165.0 (C), 
143.4 (C), 143.1 (C), 133.6 (CH), 130.3 (2 x CH), 127.5 (2 x CH), 126.6 (C), 62.7 
(CH2), 21.5 (CH3), 13.9 (CH3). The NMR data were in agreement with the literature.173 
 Ethyl (2Z)-2-(3-methylphenyl)-3-nitroprop-2-enoate (338e). The title 
compound was prepared according to General Procedure J from 
nitroalcohol 588b (3.11 g, 12.28 mmol) and purified by column 
chromatography (2→10%EtOAc/hexane) to afford a colourless oil (2.29 g, 80%). 
Rf = 0.51 (20% EtOAc/hexane); IR (film) 2984, 1732 (C=O), 1622, 1518 (NO2), 1346 
(NO2), 1327, 1265, 1213, 1180, 789 cm−1; 1H NMR (600 MHz, CDCl3) δ 7.37-7.32 
(3H, m, ArH), 7.32-7.30 (2H, m, ArH, CHNO2), 4.48 (2H, q, J = 7.2 Hz, OCH2), 2.40 
(3H, s, CH3), 1.40 (3H, t, J = 7.2 Hz, CH3); 13C NMR (150.8 MHz, CDCl3) δ 164.8 (C), 
143.5 (C), 139.4 (C), 134.3 (CH), 132.9 (CH), 129.4 (C), 129.3 (CH), 127.9 (CH), 124.6 
(CH), 62.7 (CH2), 21.3 (CH3), 13.8 (CH3); HRMS (ESI) Exact mass calcd for 
C12H14NO4 [M+H]+: 236.0917, found 236.0926. 
 Ethyl (2Z)-2-(2-chlorophenyl)-3-nitroprop-2-enoate (338g). The title 
compound was prepared according to General Procedure J from 
nitroalcohol 588c (1.27 g, 4.63 mmol) and purified by column 
chromatography (2→10%Et2O/hexane) to afford a pale yellow oil (131 mg, 11%). 
Rf = 0.34 (20% EtOAc/hexane); IR (film) 2984, 1730 (C=O), 1531 (NO2), 1470, 1348 
(NO2), 1325, 1205, 1069, 1022, 752 cm−1; 1H NMR (500 MHz, CDCl3) δ 7.52-7.48 
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(1H, m, ArH), 7.46 (1H, dd, J = 7.6, 1.6 Hz, ArH), 7.42 (1H, td, J = 7.7, 1.8, ArH), 7.36 
(1H, td, J = 7.5, 1.3 Hz, ArH), 7.23 (1H, s, CHNO2), 4.39 (2H, q, J = 7.1 Hz, OCH2), 
1.36 (3H, t, J = 7.1 Hz, CH3); 13C NMR (125.8 MHz, CDCl3) δ 163.7 (C), 139.5 (CH), 
138.8 (C), 133.2 (C), 131.8 (CH), 130.8 (CH), 130.6 (CH), 129.6 (C), 127.4 (CH), 62.9 
(CH2), 13.7 (CH3); HRMS (ESI) Exact mass calcd for C11H10NO4ClNa [M+Na]+: 
278.0191, found 278.0188.  
 tert-Butyl (2Z)-3-nitro-2-phenylprop-2-enoate (470b). The title 
compound was prepared according to General Procedure J from 
nitroalcohol 589a (1.51 g, 5.66 mmol) and purified by column chromatography (2→8% 
EtOAc/hexane) to afford a yellow solid (1.16 g, 83%). m.p. 75-76 °C (CH2Cl2); 
Rf = 0.39 (10% EtOAc/hexane); 1H NMR (600 MHz, CDCl3) δ 7.55-7.51 (3H, m, ArH), 
7.49-7.45 (2H, m, ArH), 7.31 (1H, s, CHNO2), 1.63 (9H, s, 3 x CH3); 13C NMR 
(150.8 MHz, CDCl3) δ 163.5 (C), 143.6 (C), 133.7 (CH), 131.8 (CH), 130.0 (C), 129.4 
(2 x CH), 127.4 (2 x CH), 84.8 (C), 27.9 (3 x CH3). The data is in agreement with the 
literature.173 
tert-Butyl (2Z)-2-(nitromethylidene)octanoate (470c). The 
title compound was prepared according to General Procedure J 
from nitroalcohol 589b (1.05 g, 3.8 mmol) and purified by column chromatography 
(1→4% EtOAc/hexane) to afford a colourless oil (421 mg, 43%). Rf = 0.62 (20% 
EtOAc/hexane); IR (film) 2932, 1728 (C=O), 1647, 1530 (NO2), 1352  (NO2), 1236, 
1159, 1140, 841, 737 cm−1; 1H NMR (600 MHz, CDCl3) δ 6.78 (1H, s, CHNO2), 2.37 
(2H, t, J = 7.6 Hz, CH2), 1.54 (9H, s, 3 x CH3), 1.54-1.51 (1H, m, CH2), 1.39-1.25 (7H, 
m, 4 x CH2), 0.89 (3H, t, J = 6.7 Hz, CH3); 13C NMR (150.8 MHz, CDCl3) δ 164.8 (C), 
146.0 (C), 134.4 (CH), 84.0 (C), 31.9 (CH2), 31.3 (CH2), 28.4 (CH2), 27.8 (3 x CH3), 
26.4 (CH2), 22.4 (CH2), 13.9 (CH3); HRMS (ESI) Exact mass calcd for 
C13H23NO4Na[M+Na]+: 280.1519, found 280.1510. 
 Ethyl (2E)-2-(nitromethylidene)octanoate (E-510a). The title 
compound was prepared according to General Procedure J from 
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nitroalcohol 588d (5.2 g, 21 mmol) and purified by column chromatography 
(1→3%Et2O/hexane) to afford a pale yellow oil (100 mg, 2%). Rf = 0.58 (10% 
EtOAc/hexane); IR (film) 2931, 1726 (C=O), 1637, 1529 (NO2), 1354 (NO2), 1244, 
1188, 1140, 1067, 860 cm−1; 1H NMR (500 MHz, CDCl3) δ 7.67-7.65 (1H, m, CHNO2), 
4.32 (2H, qd, J = 7.1, 0.2 Hz, OCH2), 2.77-2.72 (2H, m, CH2), 1.57-1.49 (2H, m, CH2), 
1.42-1.26 (9H, m, CH3 and 3 x CH2), 0.93-0.87 (3H, m, CH3); 13C NMR (125.8 MHz, 
CDCl3) δ 165.2 (C), 143.3 (CH), 141.2 (C), 62.4 (CH2), 31.3 (CH2), 29.3 (CH2), 28.5 
(CH2), 27.3 (CH2), 22.4 (CH2), 14.0 (2 x CH3); 1H-1H NOESY showed no cross peaks 
between proton CHNO2 and protons =CCH2; HRMS (ESI) Exact mass calcd for 
C11H20NO4 [M+H]+: 230.1387, found 230.1396. 
 Ethyl (2Z)-2-(nitromethylidene)octanoate (Z-510a). The title 
compound was isolated from the same reaction mixture as above 
to afford a pale yellow oil (2.56 g, 53%). Rf = 0.52 (10% EtOAc/hexane); IR (film) 
2932, 1732 (C=O), 1649, 1530 (NO2), 1466, 1350 (NO2), 1217, 1140, 1015, 856 cm−1; 
1H NMR (500 MHz, CDCl3) δ 6.85 (1H, t, J = 1.5 Hz, CHNO2), 4.37 (2H, q, J = 7.1 
Hz, OCH2), 2.43-2.39 (2H, m, CH2), 1.58-1.50 (2H, m, CH2), 1.40-1.25 (9H, m, CH3 
and 3 x CH2), 0.93-0.87 (3H, m, CH3); 13C NMR (125.8 MHz, CDCl3) δ 166.0 (C), 
145.5 (C), 135.3 (CH), 62.3 (CH2), 31.9 (CH2), 31.3 (CH2), 28.5 (CH2), 26.5 (CH2), 22.4 
(CH2), 14.0 (CH3), 13.8 (CH3); 1H-1H NOESY, proton CHNO2 showed cross peaks 
with protons =CCH2; HRMS (ESI) Exact mass calcd for C11H20NO4 [M+H]+: 230.1387, 
found 230.1423. 
 Ethyl (2Z)-2-(nitromethyl)oct-2-enoate (Z-512). The title 
compound was isolated from the same reaction mixture as above 
to afford a pale yellow oil (60 mg, 1.2 %). Rf = 0.39 (10% EtOAc/hexane); IR (film) 
2926, 1707 (C=O), 1653, 1558 (NO2), 1373 (NO2), 1219, 1198, 1151, 1020, 804  cm−1; 
1H NMR (500 MHz, CDCl3) δ 6.42 (1H, t, J = 7.5 Hz, CH=), 5.08 (2H, d, J = 0.5 Hz, 
CH2NO2), 4.25 (2H, q, J = 7.1 Hz, OCH2), 2.71 (2H, q, J = 7.5 Hz, CH2), 1.54-1.47 
(2H, m, CH2), 1.38-1.26 (7H, m, CH3 and 2 x CH2), 0.94-0.85 (3H, m, CH3); 13C NMR 






(CH2), 29.8 (CH2), 28.4 (CH2), 22.4 (CH2), 14.0 (CH3), 13.9 (CH3); 1H-1H NOESY, 
protons CH2NO2 showed cross peaks with proton CH=; HRMS (ESI) Exact mass calcd 
for C11H20NO4 [M+H]+: 230.1387, found 230.1400. 
 Ethyl (2E)-2-(nitromethyl)oct-2-enoate (E-512). The title 
compound was isolated from the same reaction mixture as above 
to afford a pale yellow oil (300 mg, 6.2%). Rf = 0.27 (10% 
EtOAc/hexane); IR (film) 2931, 1708 (C=O), 1653, 1557 (NO2), 1466, 1387 (NO2), 
1294, 1219, 1094, 777 cm−1; 1H NMR (500 MHz, CDCl3) δ 7.28 (1H, t, J = 7.9 Hz, 
CH=), 5.24 (2H, s, CH2NO2), 4.26 (2H, q, J = 7.1 Hz, OCH2), 2.29 (2H, dd, J = 15.1, 
7.6 Hz, CH2), 1.55-1.48 (2H, m, CH2), 1.37-1.28 (7H, m, CH3 and 2 x CH2), 0.90 (3H, t, 
J = 7.0 Hz, CH3); 13C NMR (125.8 MHz, CDCl3) δ 165.3 (C), 152.1 (CH), 122.5 (C), 
70.2 (CH2), 61.4 (CH2), 31.4 (CH2), 29.2 (CH2), 27.9 (CH2), 22.3 (CH2), 14.1 (CH3), 
13.9 (CH3); 1H-1H NOESY, protons CH2NO2 showed cross peaks with protons 
=CHCH2; HRMS (ESI) Exact mass calcd for C11H20NO4 [M+H]+: 230.1387, found 
230.1405. 
 (Z)-Ethyl 2-methyl-3-nitroacrylate (Z-510b). The title compounds were 
prepared according to General Procedure J from nitroalcohol 588e (4.0 g, 
22.58 mmol) and purified by column chromatography (4→20% EtOAc/hexane) to 
afford (Z)-ethyl 2-methyl-3-nitroacrylate as a colourless oil (551 mg, 15 %). Rf = 0.45 
(20% EtOAc/hexane); 1H NMR (500 MHz, CDCl3) δ 7.74 (1H, q, J = 1.7 Hz, CHNO2), 
4.33 (2H, q, J = 7.1 Hz, OCH2), 2.33 (3H, d, J = 1.7 Hz, CH3), 1.36 (3H, t, J = 7.1 Hz, 
CH3); 13C NMR (125.8 MHz, CDCl3) δ 165.2 (C), 144.0 (C), 136.9 (CH), 62.6 (CH2), 
14.0 (CH3), 13.7 (CH3).173 
(E)-Ethyl 2-methyl-3-nitroacrylate (E-510b). The title compound was 
isolated from the same reaction mixture as above to afford a colourless oil 
(1.53 g, 43%). Rf = 0.30 (20% EtOAc/hexane); 1H NMR (500 MHz, CDCl3) 
δ 6.88 (1H, dd, J = 3.2, 1.6 Hz, CHNO2), 4.35 (2H, qd, J = 7.1, 1.3 Hz, OCH2), 2.11 
(3H, d, J = 1.6 Hz, CH3), 1.34 (3H, td, J = 7.2, 1.2 Hz, CH3); 13C NMR (125.8 MHz, 
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CDCl3) δ 166.1 (C), 140.9 (C), 135.6 (CH), 62.4 (CH2), 17.5 (CH3), 13.7 (CH3). The 
NMR data were in agreement with the literature.173 
 Ethyl (2Z)-2-(nitromethylidene)hex-5-enoate (510c). The title 
compound was prepared according to General Procedure J from 
nitroalcohol 588f (1.73 g, 2.96 mmol) and purified by column chromatography (1→2% 
EtOAc/hexane) to afford a pale yellow oil (777 mg, 82%). Rf = 0.41 (20% 
EtOAc/hexane); IR (film) 2984, 1732 (C=O), 1530 (NO2), 1447, 1352 (NO2), 1219, 
1134, 1013, 918, 856 cm−1; 1H NMR (500 MHz, CDCl3) δ 6.86 (1H, s, CHNO2), 
5.83-5.71 (1H, m, CH=), 5.15-5.06 (2H, m, CH2=), 4.37 (2H, qd, J = 7.1, 1.7 Hz, 
OCH2), 2.51 (2H, t, J = 7.5 Hz, CH2), 2.35-2.28 (2H, m, CH2), 1.36 (3H, td, J = 7.1, 1.6 
Hz, CH3); 13C NMR (125.8 MHz, CDCl3) δ 165.7 (C), 144.2 (C), 135.7 (CH), 135.2 
(CH), 117.0 (CH2), 62.4 (CH2), 31.1 (CH2), 30.5 (CH2), 13.8 (CH3); HRMS (ESI) Exact 
mass calcd for C9H13NO4Na [M+Na]+: 222.0737, found 222.0747. 
 Ethyl (2Z)-2-(nitromethylidene)-4-phenylbutanoate (510d). The 
title compound was prepared according to General Procedure J from 
nitroalcohol 588g (573 mg, 2.15 mmol) and purified by column chromatography (2% 
EtOAc/hexane) to afford a colourless oil (212 mg, 39%). Rf = 0.38 (20% 
EtOAc/hexane); IR (film) 2982, 1730 (C=O), 1647, 1528 (NO2), 1454, 1352 (NO2), 
1221, 1109, 1015, 700 cm−1; 1H NMR (500 MHz, CDCl3) δ 7.35-7.30 (2H, m, ArH), 
7.27-7.23 (1H, m, ArH), 7.21-7.18 (2H, m, ArH),  6.74 (1H, t, J = 1.4 Hz, CHNO2), 
4.38 (2H, q, J = 7.1 Hz, OCH2), 2.88 (2H, t, J = 7.7 Hz, CH2), 2.73-2.69 (2H, m, CH2), 
1.37 (3H, t, J = 7.2 Hz, CH3); 13C NMR (125.8 MHz, CDCl3) δ 165.7 (C), 143.7 (C), 
138.9 (C), 135.9 (CH), 128.7 (2 x CH), 128.4 (2 x CH), 126.8 (CH), 62.5 (CH2), 33.6 
(CH2), 32.8 (CH2), 13.8 (CH3); HRMS (ESI) Exact mass calcd for C13H16NO4 [M+H]+: 
250.1074, found 250.1077. 
 1,5-Diethyl (2Z)-2-(nitromethylidene)pentanedioate (510e). The 
title compound was prepared according to General Procedure J from 
nitroalcohol 588h (1.35 g, 5.1 mmol) and purified by column chromatography (4→10% 
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EtOAc/hexane) to afford a light yellow oil (551 mg, 44%). Rf = 0.26 (20% 
EtOAc/hexane); IR (film) 2984, 1730 (C=O), 1651, 1531 (NO2), 1352 (NO2), 1221, 
1178, 1123, 1016, 735 cm−1; 1H NMR (500 MHz, CDCl3) δ 6.93 (1H, t, J = 1.3 
CHNO2), 4.36 (2H, q, J = 7.1 Hz, OCH2), 4.17 (2H, q, J = 7.1 Hz, OCH2), 2.76-2.70 
(2H, m, CH2), 2.61-2.56 (2H, m, CH2), 1.35 (3H, t, J = 7.2 Hz, CH3), 1.27 (3H, t, 
J = 7.1 Hz, CH3); 13C NMR (125.8 MHz, CDCl3) δ 171.0 (C), 165.3 (C), 142.7 (C), 
136.4 (CH), 62.5 (CH2), 61.1 (CH2), 31.0 (CH2), 26.7 (CH2), 14.1 (CH3), 13.8 (CH3); 
HRMS (ESI) Exact mass calcd for C10H16NO6 [M+H]+: 246.0972, found 246.0981. 
 Ethyl (2Z)-5-methyl-2-(nitromethylidene)hexanoate (510f). The 
title compound was prepared according to General Procedure J from 
nitroalcohol 588i (4.38 g, 18.79 mmol) and purified by column 
chromatography (1→3% EtOAc/hexane) to afford a pale yellow oil (2.44 g, 60%). 
Rf = 0.30 (10% EtOAc/hexane); IR (film) 2959, 1732 (C=O), 1649, 1530 (NO2), 1467, 
1352 (NO2), 1219, 1097, 1013, 736 cm−1; 1H NMR (500 MHz, CDCl3) δ 6.85 (1H, t, 
J = 1.5 Hz, CHNO2), 4.36 (2H, q, J = 7.1 Hz, OCH2), 2.43-2.39 (2H, m, CH2), 
1.69-1.57 (1H, m, CH(CH3)2), 1.45-1.39 (2H, m, CH2), 1.35 (3H, t, J = 7.2 Hz, CH3), 
0.92 (6H, d, J = 6.6 Hz, 2 x CH3); 13C NMR (125.8 MHz, CDCl3) δ 166.0 (C), 145.7 
(C), 135.2 (CH), 62.3 (CH2), 35.4 (CH2), 29.8 (CH2), 27.5 (CH), 22.1 (2 x CH3), 13.8 
(CH3); HRMS (ESI) Exact mass calcd for C10H18NO4 [M+H]+: 216.1230, found 
216.1234.  
 Ethyl (2Z)-4-(1,3-dioxan-2-yl)-2-(nitromethylidene) butanoate 
(510g). The title compound was prepared according to General 
Procedure J from nitroalcohol 588j (978 mg, 3.53 mmol) and 
purified by column chromatography (3→15% EtOAc/hexane) to afford a pale yellow oil 
(293 mg, 32%). Rf = 0.21 (30% EtOAc/hexane); IR (film) 2852, 1724 (C=O), 1638, 
1530 (NO2), 1447, 1367 (NO2), 1246, 1140, 1018, 851 cm−1; 1H NMR (500 MHz, 
CDCl3) δ 7.66 (1H, s, CHNO2), 4.57 (1H, t, J = 4.9 Hz, OCH), 4.31 (2H, q, J = 7.1 Hz, 
OCH2), 4.08-4.03 (2H, m, OCH2), 3.75-3.67 (2H, m, OCH2), 2.89 (2H, t, J = 7.2 Hz, 
CH2), 2.11-1.99 (1H, m, CH2), 1.88 (2H, td, J = 7.2, 4.9 Hz, CH2), 1.36 (3H, t, J = 7.1 
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Hz, CH3), 1.34-1.29 (1H, m, CH2); 13C NMR (125.8 MHz, CDCl3) δ 165.0 (C), 143.5 
(CH), 140.6 (C), 101.2 (CH), 66.7 (2 x CH2), 62.4 (CH2), 33.3 (CH2), 25.5 (CH2), 21.9 
(CH2), 14.1 (CH3); HRMS (ESI) Exact mass calcd for C11H18NO6 [M+H]+: 260.1129, 
found 260.1144.  
 Ethyl (2Z)-3-methyl-2-(nitromethylidene)butanoate (510h). The title 
compound was prepared according to General Procedure J from 
nitroalcohol 588k (4.88 g, 23.8 mmol) and purified by column chromatography (10% 
Et2O/hexane) to afford a colourless oil (1.52 g, 35%). Rf = 0.45 (30% EtOAc/hexane); 
1H NMR (500 MHz, CDCl3) δ 6.85-6.83 (1H, m, CHNO2), 4.37 (2H, qd, J = 7.1, 1.7 
Hz, OCH2), 2.80-2.70 (1H, m, CH), 1.36 (3H, td, J = 7.1, 1.7 Hz, CH3), 1.21 (6H, dd, 
J = 6.9, 1.6 Hz, 2 x CH3); 13C NMR (125.8 MHz, CDCl3) δ 165.6 (C), 150.7 (C), 134.8 
(CH), 62.2 (CH2), 31.5 (CH), 20.3 (2 x CH3), 13.9 (CH3); The data is in agreement with 
the literature.173 
 Ethyl (2Z)-2-cyclohexyl-3-nitroprop-2-enoate (510i). The title 
compound was prepared according to General Procedure J from 
nitroalcohol 588l (4.8 g, 19.6 mmol) and purified by column 
chromatography (2→6% EtOAc/hexane) to afford a colourless oil (3.3 g, 74%). 
Rf = 0.45 (10% EtOAc/hexane); 1H NMR (500 MHz, CDCl3) δ 6.81 (1H, dd, J = 6.6, 
1.3 Hz, CHNO2), 4.36 (2H, q, J = 7.2 Hz, OCH2), 2.43-2.35 (1H, m, CH), 1.92-1.82 
(4H, m, 2 x CH2), 1.76-1.60 (1H, m, CH2), 1.35 (3H, t, J = 7.2 Hz, CH3), 1.35-1.15 (5H, 
m, 3 x CH2); 13C NMR (125.8 MHz, CDCl3) δ 165.8 (C), 150.1 (C), 134.9 (CH), 62.2 
(CH2), 40.8 (CH), 30.8 (2 x CH2), 25.8 (2 x CH2), 25.4 (CH2), 13.9 (CH3). The NMR 
data were in agreement with the literature.242 
 Methyl (2Z)-2-(nitromethylidene)octanoate (514). The title 
compound was prepared according to General Procedure J from 
nitroalcohol 590 (563 g, 2.41 mmol) and purified by column chromatography 
(2→10%EtOAc/hexane) to afford a colourless oil (61 mg, 12%). Rf = 0.35 (10% 
EtOAc/hexane); IR (film) 2932, 1738 (C=O), 1649, 1529 (NO2), 1437, 1354 (NO2), 
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1265, 1225, 964, 735 cm−1; 1H NMR (600 MHz, CDCl3) δ 6.85 (1H, t, J = 1.4 Hz, 
CHNO2), 3.88 (3H, s, OCH3), 2.42-2.38 (2H, m, CH2), 1.56-1.48 (2H, m, CH2), 
1.39-1.24 (6H, m, 3 x CH2), 0.90-0.87 (3H, m, CH3); 13C NMR (150.8 MHz, CDCl3) δ 
166.4 (C), 145.1 (CH), 135.5 (C), 53.0 (CH3), 31.8 (CH2), 31.3 (CH2), 28.5 (CH2), 26.5 
(CH2), 22.3 (CH2), 13.9 (CH3); 1H-1H NOESY, proton CHNO2 shows cross peaks with 
protons =CCH2; HRMS (ESI) Exact mass calcd for C10H17NO4Na [M+Na]+: 238.1050, 
found 238.1059. 
Methyl (2E)-2-(nitromethyl)oct-2-enoate (592). The title 
compound was isolated from the same reaction mixture as above 
to afford a colourless oil (127 mg, 25%). Rf = 0.28 (10% 
EtOAc/hexane); IR (film) 2930, 1691 (C=O), 1557 (NO2), 1424, 1379 (NO2), 1221, 
1186, 1157, 963, 743 cm−1; 1H NMR (600 MHz, CDCl3) δ 7.28 (1H, t, J = 7.8 Hz, 
CH=), 5.23 (2H, s, CH2NO2), 3.78 (3H, s, OCH3), 2.28 (2H, dd, J = 15.1, 7.6 Hz, CH2), 
1.53-1.46 (2H, m, CH2), 1.34-1.26 (4H, m, 2 x CH2), 0.88 (3H, t, J = 7.0 Hz, CH3); 
13C NMR (150.8 MHz, CDCl3) δ 165.8 (C), 152.5 (CH), 122.3 (C), 70.2 (CH2), 52.3 
(CH3), 31.3 (CH2), 29.1 (CH2), 27.8 (CH2), 22.3 (CH2), 13.8 (CH3); 1H-1H NOESY, 
protons CH2NO2 showed cross peaks with protons =CHCH2; HRMS (ESI) Exact mass 
calcd for C10H17NO4Na [M+Na]+: 238.1050, found 238.1043. 
 (2Z)-3-Nitro-1,2-diphenylprop-2-en-1-one (515). The title compound 
was prepared according to General Procedure J from nitroalcohol 591 (2.96 
g, 10.3 mmol) and purified by column chromatography (5→30% Et2O/hexane) to afford 
a yellow amorphous solid (2.10 g, 81%). m.p. 104-105 °C (CH2Cl2); Rf = 0.17 (10% 
EtOAc/hexane); IR (film) 3101, 1676 (C=O), 1597, 1514 (NO2), 1447, 1344 (NO2), 
1246, 1219, 1177, 770 cm−1; 1H NMR (500 MHz, CDCl3) δ 7.97-7.93 (2H, m, ArH), 
7.63-7.58 (1H, m, ArH), 7.58 (1H, s, CHNO2), 7.54-7.41 (7H, m, ArH); 13C NMR 
(125.8 MHz, CDCl3) δ 192.2 (C), 150.3 (C), 134.9 (CH), 134.8 (C), 134.3 (CH), 132.1 
(CH), 130.3 (C), 129.6 (2 x CH), 129.0 (2 x CH), 128.8 (2 x CH), 127.6 (2 x CH); 








In a modification of a previously reported procedure,163 to a solution of the 
trifluoromethyl ketone (593) (3.5 g, 20 mmol) in MeNO2 (40 mL) was added Et3N 
(3.04 g, 30 mmol). The mixture was stirred overnight at room temperature, then diluted 
with ethyl acetate (40 mL) and washed successively with aq. HCl (1 M), water (40 mL), 
and brine (40 mL). The organic phase was separated and dried (MgSO4), filtered and 
concentrated in vacuo. The residue was purified by flash chromatography on silica gel 
(5→10% EtOAc/hexane) to afford the corresponding nitroalcohol 594 as a colourless oil 
(1.44 g, 31%). Rf = 0.15 (10% EtOAc/hexane); 1H NMR (500 MHz, CDCl3) δ 7.63-7.58 
(2H, m, ArH), 7.49-7.44 (3H, m, ArH), 5.10 (1H, d, J = 13.7 Hz, CH2NO2), 5.02 (1H, d, 
J = 13.7 Hz, CH2NO2), 4.63 (1H, s, OH); 13C NMR (125.8 MHz, CDCl3) δ 133.0 (C), 
130.0 (CH), 129.0 (2 x CH), 126.1 (2 x CH), 123.4 (q, J = 285.6 Hz, C), 77.5 (CH2), 
76.2 (dd, J = 59.7, 29.8 Hz, C); 19F NMR (400 MHz, CDCl3) δ –78.67 (s, 3F). The 
NMR data were in agreement with the literature.243 
 [(1E)-3, 3, 3-Trifluoro-1-nitroprop-1-en-2-yl]benzene (465a) 
 
In the modification of a previously reported procedure, 163 to a solution of nitroalcohol 
594 (730 mg, 3.1 mmol) in toluene (20 mL) were added SOCl2 (340 µL, 4.7 mol) and 
pyridine (501 µL, 6.2 mmol) at 0 °C. The mixture was stirred at room temperature for 
6 h, then diluted with ethyl acetate (20 mL), washed with water (30 mL), and brine 
(20 mL). The organic phase was separated and dried (MgSO4), filtered and concentrated 
in vacuo. The residue was purified by flash chromatography on silica gel (5→10% 
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EtOAc/hexane) (2% EtOAc/hexane) to afford the corresponding nitroalkene 465a as a 
pale yellow oil (347 mg, 52%). Rf = 0.51 (20% EtOAc/hexane); 1H NMR (500 MHz, 
CDCl3) δ 7.55-7.53 (1H, m, ArH), 7.53-7.44 (3H, CHNO2, ArH), 7.34-7.30 (2H, m, 
ArH); 13C NMR (125.8 MHz, CDCl3) δ 140.0 (CH), 136.0 (q, J = 32.0 Hz, C), 130.5 
(CH), 128.9 (2 x CH), 128.2 (2 x CH), 126.8 (C), 121.9 (q, J = 275.7 Hz, C); 19F NMR 
(400 MHz, CDCl3) δ –66.78 (s, 3F). The NMR data were in agreement with the 
literature.163 
Dimethyl benzoylphosphonate (597) 
 
In a modification of a previously reported procedure,244 benzoyl chloride (595) (28 g, 
200 mmol) was added to a solution of trimethyl phosphite 596 (25 g, 200 mmol) in dry 
toluene (200 mL). The mixture was stirred at room temperature overnight. The solvent 
was removed in vacuo and a residue was distilled (120 °C) under vacuum to afford a 
colourless oil (35.4 g, 91%). Rf = 0.30 (30% EtOAc/hexane); 1H NMR (500 MHz, 
CDCl3) δ 8.18 (2H, dt, J = 8.5, 1.5 Hz, ArH), 7.58 (1H, ddt, J = 7.1, 2.6, 1.6 Hz, ArH), 
2.47-2.42 (2H, m, ArH), 3.85 (6H, d, J = 10.9 Hz, 2 x OCH3); 13C NMR (125.8 MHz, 
CDCl3) δ 198.1 (d, J = 174.7 Hz, C), 135.3 (d, J = 63.7 Hz, C), 134.8 (s, CH), 129.7 (d, 
J = 1.6 Hz, 2 x CH), 128.7 (s, 2 x CH), 53.9 (d, J = 7.4 Hz, 2 x CH3); 31P NMR 
(400 MHz, CDCl3) δ 0.7 (s). The NMR data were in agreement with the literature.244 
Dimethyl (1-hydroxy-2-nitro-1-phenylethyl)phosphonate (598). The 
title compound was prepared according to General Procedure I from 
dimethyl benzoylphosphonate (597) (8.57 g, 40 mmol) and purified by recrystallisation 
(6:4 EtOAc/hexane) to afford a yellow crystalline (8 g, 73%). Rf = 0.26 (80% 
EtOAc/hexane); 1H NMR (600 MHz, CDCl3) δ 7.65-7.61 (2H, m, ArH), 7.45-7.41 (2H, 
m, ArH), 7.39-7.35 (1H, m, ArH), 5.13 (2H, ddd, J = 17.9, 13.5, 6.1 Hz, CH2NO2), 3.81 
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(3H, d, J = 10.5 Hz, OCH3), 3.55 (3H, d, J = 10.5 Hz, OCH3); 13C NMR (150.8 MHz, 
CDCl3) δ 135.0 (d, J = 2.7 Hz, C), 128.9 (d, J = 3.0 Hz, CH), 128.7 (d, J = 2.7 Hz, 
2 x CH), 125.9 (d, J = 4.2 Hz, 2 x CH), 79.7 (d, J = 9.7 Hz, CH2), 75.7 (d, J = 165.5 Hz, 
C), 55.1 (d, J = 7.3 Hz, CH3), 54.6 (d, J = 7.6 Hz, CH3); 31P NMR (400 MHz, CDCl3) 
δ 18.7 (s). The NMR data were in agreement with the literature.174,245 
Dimethyl [(E)-2-nitro-1-phenylethenyl]phosphonate (516) 
 
The title compound was prepared according to the procedure reported by Yuan and 
co-workers.174 A solution of dimethyl (1-hydroxy-2-nitro-1-phenylethyl) phosphonate 
(598) (7.61 g, 27.65 mmol) in CHCl3 (100 ml) was heated at reflux under nitrogen. 
Under vigorous stirring, thionyl chloride (2.02 mL, 27.65 mmol) was added slowly, 
followed by dropwise addition of pyridine (4.47 ml, 55.3 mmol). After being stirred for 
15 min, the mixture was cooled to room temperature and then washed with brine 
(4 x 50 mL) until pH 7. The organic layer was dried (Na2SO4), filtered and concentrated 
in vacuo. The residue was then purified by column chromatography on silica gel 
(20→60% EtOAc/hexane) to afford a yellow solid (3.19 g, 45%). m.p. 59-60 °C 
(CH2Cl2); Rf = 0.39 (80% EtOAc/hexane); IR (film) 2957, 1533 (NO2), 1445, 1357 
(NO2), 1260 (P=O), 1177, 1015 (P-O-C), 933, 835, 744 cm−1; 1H NMR (500 MHz, 
CDCl3) δ 7.62 (1H, d, J = 15.3 Hz, ArH), 7.43-7.38 (3H, m, ArH, CHNO2), 7.29-7.25 
(2H, m, ArH), 3.77 (6H, d, J = 11.2 Hz, 2 x OCH3); 13C NMR (125.8 MHz, CDCl3) 
δ 144.8 (d, J = 20.5 Hz, CH), 135.6 (d, J = 171.6 Hz, C), 129.7 (d, J = 3.0 Hz, C), 129.4 
(d, J = 2.3 Hz, CH), 128.7 (d, J = 1.6 Hz, 2 x CH), 127.6 (d, J = 5.2 Hz, 2 x CH), 53.8 
(d, J = 6.2 Hz, 2 x CH3); 31P NMR (400 MHz, CDCl3) δ 13.9 (s). HRMS (ESI) Exact 
mass calcd for C10H13NO5P [M+H]+: 258.0531, found 358.0533. 
217 
 
3.2.4 Michael Addition of 2-Acetylazaarenes to β,β-Disubstituted 
Nitroalkenes 
General Procedure K: Michael Addition of 2-Acetylazaarenes to Aromatic 
Substituted Nitroalkenes 
431 (5.5 mol %)
Ni(OAc)2·4H2O (5 mol %)
1:1 i-PrOH/CH2Cl2 (0.5 M),
r.t., 3-7 days




















A suspension of Ni(OAc)2·4H2O (6.2 mg, 0.025 mmol) and ligand 431 (13.4 mg, 0.0275 
mmol) in 1:1 i-PrOH/CH2Cl2 (0.5 mL) was stirred at room temperature for 30 min. To 
the resulting solution was added a solution of the appropriate 2-acetylazaarene 
(0.60 mmol) and the appropriate nitroalkene (0.50 mmol) in 1:1 i-PrOH/CH2Cl2 
(0.5 mL), and the reaction mixture was stirred until complete consumption of the 
nitroalkene as indicated by TLC analysis. The reaction mixture was filtered through a 
short pad of silica gel (washed several times with EtOAc) and concentrated in vacuo. 
Purification of the residue by column chromatography afforded the nitroalkane products. 
Ethyl 2-(4-methylphenyl)-2-(nitromethyl)-4-oxo-4-(pyridin-2-
yl)butanoate (496h). The title compound was prepared according to 
General Procedure K from 2-acetylpyridine (458) (73 mg, 
0.60 mmol) and nitroalkene 338b (118 mg, 0.50 mmol) for a 
reaction time of 72 h and purified by column chromatography 
(5→20% EtOAc/hexane) to afford a pale yellow solid (145 mg, 81%). m.p. 65-66 °C 
(CH2Cl2); Rf = 0.32 (30% Et2O/hexane); [α]
20
D  –52.5 (c 1.4, CHCl3); IR (film) 2982, 
1730 (C=O), 1699 (C=O), 1549 (NO2), 1437, 1356 (NO2), 1211, 1192, 995, 771 cm−1; 
1H NMR (500 MHz, CDCl3) δ 8.74 (1H, ddd, J = 4.7, 1.7, 0.9 Hz, ArH), 8.05 (1H, dt, 
J = 7.9, 1.1 Hz, ArH), 7.86 (1H, td, J = 7.7, 1.7 Hz, ArH), 7.53 (1H, ddd, J = 7.6, 4.7, 
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1.2 Hz, ArH), 7.37-7.33 (2H, m, ArH), 7.22-7.18 (2H, m, ArH), 5.40-5.32 (2H, m, 
CH2NO2), 4.63 (1H, d, J =19.3 Hz, CH2C=O), 4.26 (1H, dd, J  = 19.2, 0.7 Hz, 
CH2C=O), 4.26-4.12 (2H, m, OCH2), 2.35 (3H, s, CH3), 1.16 (3H, t, J = 7.1 Hz, CH3); 
13C NMR (125.8 MHz, CDCl3) δ 198.9 (C), 171.7 (C), 152.8 (C), 149.1 (CH), 138.2 
(C), 136.9 (CH), 134.0 (C), 129.8 (2 x CH), 127.6 (CH), 125.8 (2 x CH), 121.8 (CH), 
79.7 (CH2), 62.0 (CH2), 50.5 (C), 40.3 (CH2), 21.0 (CH3), 13.8 (CH3); HRMS (ESI) 
Exact mass calcd for C19H21N2O5 [M+H]+: 357.1445, found 357.1457; Enantiomeric 
excess was determined by HPLC with a Chiralpak AD-H column (20:80, 
i-PrOH:hexane, 0.8 mL/min, 280 nm, 25 °C); tr (major) = 16.6 min, 
tr (minor) = 27.5 min; 98% ee. 
Ethyl 2-(4-methylphenyl)-2-(nitromethyl)-4-oxo-4-(pyrazin-2-yl) 
butanoate (496i). The title compound was prepared according to 
General Procedure K from 2-acetylpyrazine (386) (73, 0.60 mmol) 
and nitroalkene 338b (118 mg, 0.50 mmol) for a reaction time of 
72 h and purified by column chromatography (5→30% 
Et2O/hexane) to afford a white solid (145 mg, 81%). m.p. 114-115 °C (CH2Cl2); 
Rf = 0.27 (30% Et2O/hexane); [α]20D  –44.2 (c 0.97, CHCl3); IR (film) 2982, 1730 (C=O), 
1703 (C=O), 1548 (NO2), 1375 (NO2), 1354, 1265, 1194, 1018, 734 cm−1; 1H NMR 
(500 MHz, CDCl3) δ 9.24 (1H, d, J = 1.3 Hz, ArH), 8.82 (1H, d, J = 2.4 Hz, ArH), 8.70 
(1H, dd, J = 2.4, 1.5 Hz, ArH), 7.34-7.30 (2H, m, ArH), 7.22-7.18 (2H, m, ArH), 5.36 
(2H, q, J = 12.4 Hz, CH2NO2), 4.60 (1H, d, J = 19.3 Hz, CH2C=O), 4.28-4.15 (3H, m, 
CH2C=O and OCH2), 2.35 (3H, s, CH3), 1.19 (3H, t, J = 7.1 Hz, CH3); 13C NMR 
(125.8 MHz, CDCl3) δ 198.4 (C), 171.4 (C), 148.4 (CH), 147.1 (C), 143.6 (CH), 143.5 
(CH), 138.4 (C), 133.7 (C), 129.8 (2 x CH), 125.7 (2 x CH), 79.4 (CH2), 62.2 (CH2), 
50.4 (C), 40.3 (CH2), 21.0 (CH3), 13.8 (CH3); HRMS (ESI) Exact mass calcd for 
C18H20N3O5 [M+H]+: 358.1397, found 398.1412; Enantiomeric excess was determined 
by HPLC with a Chiralpak AD-H column (20:80, i-PrOH:hexane, 0.8 mL/min, 280 nm, 




yl)butanoate (496j). The title compound was prepared according to 
General Procedure K from 2-acetylthiazole (390) (76, 0.60 mmol) 
and nitroalkene 338b (118 mg, 0.50 mmol) for a reaction time of 
72 h and purified by column chromatography (20% Et2O/hexane) to afford a white solid 
(158 mg, 87%). m.p. 66-67 °C (CH2Cl2); Rf = 0.35 (30% Et2O/hexane); [α]20D  –41.1 
(c 1.36, CHCl3); IR (film) 2982, 1730 (C=O), 1686 (C=O), 1549 (NO2), 1377 (NO2), 
1265, 1205, 1194, 960, 823 cm−1; 1H NMR (500 MHz, CDCl3) δ 8.07 (1H, d, J = 3.0 
Hz, ArH), 7.73 (1H, d, J = 3.0 Hz, ArH), 7.32-7.29 (2H, m, ArH), 7.21-7.17 (2H, m, 
ArH), 5.38 (2H, dt, J = 25.8, 6.6 Hz, CH2NO2), 4.56 (1H, d, J = 19.0 Hz, CH2C=O), 
4.27-4.14 (3H, m, CH2C=O and OCH2), 2.34 (3H, s, CH3), 1.18 (3H, t, J = 7.1 Hz, 
CH3); 13C NMR (125.8 MHz, CDCl3) δ 190.9 (C), 171.2 (C), 166.1 (C), 145.0 (CH), 
138.4 (C), 133.5 (C), 129.8 (2 x CH), 126.8 (CH), 125.7 (2 x CH), 79.4 (CH2), 62.2 
(CH2), 50.5 (C), 40.8 (CH2), 21.0 (CH3), 13.8 (CH3); HRMS (ESI) Exact mass calcd for 
C17H19N2O5S [M+H]+: 363.1009, found 363.1027; Enantiomeric excess was determined 
by HPLC with a Chiralpak AD-H column (20:80, i-PrOH:hexane, 0.8 mL/min, 280 nm, 
25 ºC); tr (major) = 20.6 min, tr (minor) = 23.4 min;  99% ee. 
Ethyl 2-(3-methylphenyl)-2-(nitromethyl)-4-oxo-4-(pyridin-2-yl) 
butanoate (496p). The title compound was prepared according to 
General Procedure K from 2-acetylpyridine (458) (73 mg, 
0.60 mmol) and nitroalkene 338b (118 mg, 0.50 mmol) for a 
reaction time of 72 h and purified by column chromatography (5→20% EtOAc/hexane) 
to afford a white solid (166 mg, 93%). m.p. 101-102 °C (CH2Cl2); Rf = 0.35 (30% 
EtOAc/hexane); [α]20D  –95.8 (c 1.0, CHCl3); IR (film) 2982, 1732 (C=O), 1699 (C=O), 
1549 (NO2), 1439, 1377 (NO2), 1267, 1211, 995, 770 cm−1; 1H NMR (400 MHz, 
CDCl3) δ 8.74 (1H, ddd, J = 4.7, 1.7, 0.9 Hz, ArH), 8.04 (1H, dt, J = 7.9, 1.0 Hz, ArH), 
7.86 (1H, td, J = 7.7, 1.7 Hz, ArH), 7.52 (1H, ddd, J = 7.6, 4.7, 1.2 Hz, ArH), 7.29-7.22 
(3H, m, ArH), 7.15-7.11 (21H, m, ArH), 5.40-5.32 (2H, m, CH2NO2), 4.63 (1H, d, 
J =19.3 Hz, CH2C=O), 4.28-4.11 (3H, m, CH2C=O, OCH2), 2.37 (3H, s, CH3), 1.15 
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(3H, t, J = 7.1 Hz, CH3); 13C NMR (100.6 MHz, CDCl3) δ 198.9 (C), 171.7 (C), 152.8 
(C), 149.1 (CH), 138.7 (C), 137.0 (CH), 136.9 (C), 129.2 (CH), 128.9 (CH), 127.6 (CH), 
126.6 (CH), 123.0 (CH), 121.8 (CH), 79.7 (CH2), 62.0 (CH2), 50.7 (C), 40.3 (CH2), 21.6 
(CH3), 13.8 (CH3); HRMS (ESI) Exact mass calcd for C19H21N2O5 [M+H]+: 357.1445, 
found 357.1460; Enantiomeric excess was determined by HPLC with a Chiralpak AD-H 
column (20:80, i-PrOH:hexane, 0.8 mL/min, 280 nm, 25 ºC); tr (major) = 12.1 min, 
tr (minor) = 19.9 min; 96% ee. 
tert-Butyl 2-(nitromethyl)-4-oxo-2-phenyl-4-(pyridin-2-yl) 
butanoate (497a). The title compound was prepared according to 
General Procedure K from 2-acetylpyridine (548) (73, 0.60 mmol) 
and nitroalkene 470b (125 mg, 0.50 mmol) for a reaction time of 72 h and purified by 
column chromatography (5% EtOAc/hexane) to afford a white solid (161 mg, 87%). 
m.p. 79-80 °C (CH2Cl2); Rf = 0.14 (10% EtOAc/hexane); [α]20D  –88.0 (c 0.64, CHCl3); 
IR (film) 2983, 1728 (C=O), 1701 (C=O), 1549 (NO2), 1369 (NO2), 1279, 1215, 1155, 
995, 771 cm−1; 1H NMR (600 MHz, CDCl3) δ 8.73 (1H, ddd, J = 4.7, 1.5, 0.8 Hz, ArH), 
8.06 (1H, d, J = 7.8 Hz, ArH), 7.86 (1H, td, J = 7.7, 1.7 Hz, ArH), 7.51 (1H, ddd, J = 
7.5, 4.7, 1.2 Hz, ArH), 7.49-7.46 (2H, m, ArH), 7.41-7.37 (2H, m, ArH), 7.35-7.31 (1H, 
m, ArH), 5.35 (2H, dt, J = 12.4, 6.5 Hz, CH2NO2), 4.55 (1H, d, J =19.1 Hz, CH2C=O), 
4.26 (1H, dd, J = 19.1, 0.7 Hz, CH2C=O), 1.38 (9H, s, CH3); 13C NMR (150.8 MHz, 
CDCl3) δ 198.9 (C), 170.2 (C), 153.0 (C), 149.1 (CH), 137.6 (C), 136.9 (CH), 128.9 (2 x 
CH), 128.2 (CH), 127.5 (CH), 125.9 (2 x CH), 121.7 (CH), 82.7 (C), 79.7 (CH2), 51.4 
(C), 40.3 (CH2), 27.5 (3 x CH3); HRMS (ESI) Exact mass calcd for C20H23N2O5 
[M+H]+: 371.1601, found 371.1615; Enantiomeric excess was determined by HPLC 
with a Chiralpak AD-H column (20:80, i-PrOH:hexane, 0.8 mL/min, 280 nm, 25 ºC); 
tr (major) = 11.1 min, tr (minor) = 13.4 min; 98% ee. 
2-(Nitrophenyl)-1,2-diphenyl-4-(pyrazin-2-yl)butane-1,4-dione 
(517a). The title compound was prepared according to General 
Procedure K from 2-acetylpyrazine (386) (73 mg, 0.60 mmol) and 
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nitroalkene 515 (127 mg, 0.50 mmol) for a reaction time of 7 days and purified by 
column chromatography (4→12% EtOAc/hexane) to afford a yellow amorphous solid 
(125 mg, 67%). m.p. 94-95 °C (CH2Cl2); Rf = 0.29 (40% EtOAc/hexane); [α]20D  –107.9 
(c 0.63, CHCl3); IR (film) 2918, 1701 (C=O), 1680 (C=O), 1545 (NO2), 1446 (NO2), 
1375, 1354, 1265, 997, 700 cm−1; 1H NMR (500 MHz, CDCl3) δ 9.12 (1H, s, ArH), 
8.75 (1H, d, J = 2.3 Hz, ArH), 8.60 (1H, dd, J = 2.2, 1.6 Hz, ArH), 7.55-7.47 (4H, m, 
ArH), 7.46-7.42 (1H, m, ArH), 7.35-7.29 (3H, m, ArH), 7.22-7.17 (2H, m, ArH), 5.41 
(1H, dd, J = 11.8, 1.2 Hz, CH2NO2), 5.30 (1H, d, J = 11.8 Hz, CH2NO2), 4.81 (1H, d, 
J = 19.4 Hz, CH2C=O), 4.26 (1H, dd, J = 19.4, 1.2 Hz, CH2C=O); 13C NMR 
(125.8 MHz, CDCl3) δ 198.9 (C), 197.6 (C), 148.4 (CH), 146.7 (C), 143.5 (2 x CH), 
136.3 (C), 136.1 (C), 132.0 (CH), 129.8 (2 x CH), 129.0 (CH), 128.8 (2 x CH), 128.2 
(2 x CH), 126.6 (2 x CH), 81.6 (CH2), 55.1 (C), 40.6 (CH2); HRMS (ESI) Exact mass 
calcd for C21H18N3O4 [M+H]+: 376.1292, found 376.1293; Enantiomeric excess was 
determined by HPLC with a Chiralpak AD-H column (10:90, i-PrOH:hexane, 
0.8 mL/min, 280 nm, 25 ºC); tr (minor) = 21.2 min, tr (major) = 28.9 min; 97% ee. 
4-(1-Methyl-1H-imidazol-2-yl)-2-(nitromethyl)-1,2-
diphenylbutane-1,4-dione (517b). The title compound was 
prepared according to General Procedure K from 1-methyl-
2-acetylimidazole (494) (75 mg, 0.60 mmol) and nitroalkene 515 (127 mg, 0.50 mmol) 
for a reaction time of 7 days and purified by column chromatography (60→100% 
Et2O/hexane) to afford a white solid (155.1 mg, 82%). m.p. 146-147 °C 
(EtOAc/hextane); Rf = 0.26 (40% EtOAc/hexane); [α]20D  –264.3 (c 0.96, CHCl3); 
IR (film) 2918, 1681 (C=O), 1547 (NO2), 1447 (NO2), 1410, 1375, 1354, 1221, 993, 
700 cm−1; 1H NMR (500 MHz, CDCl3) δ 7.52 (2H, dt, J = 8.6, 2.4 Hz, ArH), 7.49-7.44 
(2H, m, ArH), 7.44-7.39 (1H, m, ArH), 7.35-7.30 (3H, m, ArH), 7.21-7.16 (2H, m, 
ArH), 7.11 (1H, d, J = 0.7 Hz, ArH), 6.98 (1H, s, ArH), 5.38 (1H, dd, J = 11.7, 1.3 Hz, 
CH2NO2), 5.29 (1H, d, J = 11.7 Hz, CH2NO2), 4.76 (1H, d, J = 19.1 Hz, CH2C=O), 4.28 
(1H, dd, J = 19.1, 1.3 Hz, CH2C=O), 3.89 (3H, s, CH3); 13C NMR (125.8 MHz, CDCl3) 
δ 199.1 (C), 198.4 (C), 142.1 (C), 136.3 (C), 136.2 (C), 131.9 (CH), 129.7 (2 x CH), 
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129.4 (CH), 129.0 (2 x CH), 128.9 (CH), 128.2 (2 x CH), 127.4 (CH), 126.7 (2 x CH), 
81.9 (CH2), 55.1 (C), 41.6 (CH2), 36.1 (CH3); HRMS (ESI) Exact mass calcd for 
C21H20N3O4 [M+H]+: 378.1448, found 378.1447; Enantiomeric excess was determined 
by HPLC with a Chiralpak AD-H column (10:90, i-PrOH:hexane, 0.8 mL/min, 280 nm, 
25 ºC); tr (major) = 18.8 min, tr (minor) = 23.3 min; 99% ee. 
4-(1,3-Benzothiazol-2-yl)-2-(nitromethyl)-1,2-diphenylbutane-
1,4-dione (517c). The title compound was prepared according to 
General Procedure K from 2-acetylbenzothiazole (495) (106 mg, 
0.60 mmol) and nitroalkene 515 (127 mg, 0.50 mmol) for a 
reaction time of 7 days and purified by column chromatography (2→6% EtOAc/hexane) 
to afford a yellow solid (170 mg, 79%). m.p. 64-65 °C (CH2Cl2); Rf = 0.15 (20% 
EtOAc/hexane); [α]20D  –152.4 (c 0.89, CHCl3); IR (film) 3063, 1693 (C=O), 1547 (NO2), 
1483 (NO2), 1447, 1375, 1204, 948, 758, 700 cm−1; 1H NMR (500 MHz, CDCl3) 
δ 8.19-8.16 (1H, m, ArH), 7.96-7.93 (1H, m, ArH), 7.61-7.49 (6H, m, ArH), 7.47-7.43 
(1H, m, ArH), 3.35-3.30 (3H, m, ArH), 7.22-7.17 (2H, m, ArH), 5.45 (1H, dd, J = 12.0, 
1.2 Hz, CH2NO2), 5.33 (1H, d, J = 12.0 Hz, CH2NO2), 4.91 (1H, d, J = 19.2 Hz, 
CH2C=O), 4.37 (1H, dd, J = 19.2, 1.2 Hz, CH2C=O); 13C NMR (125.8 MHz, CDCl3) 
δ 198.7 (C), 191.7 (C), 164.9 (C), 153.3 (C), 137.4 (C), 136.2 (C), 135.9 (C), 132.1 
(CH), 129.8 (2 x CH), 129.1 (CH), 128.9 (2 x CH), 128.3 (2 x CH), 128.0 (CH), 127.2 
(CH), 126.6 (2 x CH), 125.6 (CH), 122.4 (CH), 81.4 (CH2), 55.3 (C), 41.4 (CH2); 
HRMS (ESI) Exact mass calcd for C24H19N2O4S [M+H]+: 431.1060, found 431.1056; 
Enantiomeric excess was determined by HPLC with a Chiralpak AD-H column (10:90, 
i-PrOH:hexane, 0.8 mL/min, 280 nm, 25 ºC); tr (major) = 15.8 min, tr 






Screening and Optimisation for Aliphatic Substituted Nitroalkenes  
Catalyst Screening (Table 2.5) 
 
A suspension of Ni(OAc)2·4H2O (1.2 mg, 0.005 mmol) and ligand (0.0055 mmol) in 1:1 
i-PrOH/CH2Cl2 (0.3 mL) was stirred at room temperature for 30 min. This resulting 
solution was then added to a 1 mL vial containing 2-acetylpyridine (458) (0.12 mmol) 
and nitroalkene Z-510a (0.1 mmol), and the reaction mixture was stirred until complete 
consumption of the nitroalkene as indicated by TLC analysis. The reaction mixture was 
then filtered through a short pad of silica gel (washed several times with EtOAc) and 
concentrated in vacuo. The percent conversions were determined by 1H NMR analysis of 
crude mixture using 1,3,5-tetramethoxybenzene as internal standard. 




A suspension of Ni(OAc)2·4H2O (1.2 mg, 0.005 mmol) and ligand 503 (2.2 mg, 0.0055 
mmol) in pure solvent or mixed solvent (0.3 mL) was stirred at room temperature for 
30 min. This resulting solution was then added to a 1 mL vial containing 
2-acetylpyridine (458) (0.12 mmol) and nitroalkene Z-510a (0.1 mmol), and the reaction 
mixture was stirred until complete consumption of the nitroalkene as indicated by TLC 
analysis. The reaction mixture was then filtered through a short pad of silica gel (washed 
several times with EtOAc) and concentrated in vacuo. The percent conversions were 
determined by 1H NMR analysis of crude mixtures using 1,3,5-tetramethoxybenzene as 
internal standard. 
General Procedure L: Michael Addition of 2-Acetylazaarenes to Aliphatic 
Substituted Nitroalkenes 
 
A suspension of Ni(OAc)2·4H2O (6.2 mg, 0.025 mmol) and ligand 503 (10.8 mg, 0.0275 
mmol) in 1:1 i-PrOH/CH2Cl2 (0.5 mL) was stirred at room temperature for 30 min. To 
the resulting solution was added a solution of the appropriate 2-acetylazaarene 
(0.50 mmol) and the appropriate nitroalkene (0.75 mmol) in 1:1 i-PrOH/CH2Cl2 
(0.5 mL), and the reaction mixture was stirred until complete consumption of 
2-acetylazaarene as indicated by TLC analysis. The reaction mixture was filtered 
through a short pad of silica gel (washed several times with EtOAc) and concentrated in 





octanoate (497b). The title compound was prepared according to 
General Procedure L from 2-acetylpyridine (458) (61, 0.50 mmol) 
and Z-nitroalkene 470c (193 mg, 0.75 mmol) for a reaction time of 40 h and purified by 
column chromatography (2→6% EtOAc/hexane) to afford a white solid (171 mg, 90%). 
m.p. 42-43 °C (CH2Cl2); Rf = 0.24 (20% EtOAc/hexane); [α]20D  –9.9 (c 1.0, CHCl3); 
IR (film) 2930, 1726 (C=O), 1701 (C=O), 1549 (NO2), 1369 (NO2), 1252, 1213, 1155, 
845, 766 cm−1; 1H NMR (500 MHz, CDCl3) δ 8.68 (1H, ddd, J = 4.7, 1.5, 0.8 Hz, ArH), 
8.05-8.01 (1H, m, ArH), 7.85 (1H, td, J = 7.7, 1.7 Hz, ArH), 7.49 (1H, ddd, J = 7.6, 4.8, 
1.2 Hz, ArH), 5.01 (1H, d, J = 11.9 Hz, CH2NO2), 4.93 (1H, d, J = 11.9 Hz, CH2NO2), 
3.74 (2H, q, J = 19.3 Hz, CH2C=O), 1.78-1.68 (2H, m, CH2), 1.49-1.41 (1H, m, CH2), 
1.45 (9H, s, 3 x CH3), 1.34-1.23 (7H, m, 4 x CH2), 0.88 (3H, t, J = 6.7 Hz, CH3); 
13C NMR (125.8 MHz, CDCl3) δ 198.9 (C), 171.4 (C), 152.9 (C), 148.9 (CH), 137.0 
(CH), 127.4 (CH), 121.7 (CH), 82.2 (C), 77.0 (CH2), 47.6 (C), 41.6 (CH2), 35.7 (CH2), 
31.4 (CH2), 29.3 (CH2), 27.8 (3 x CH3), 23.5 (CH2), 22.4 (CH2), 14.0 (CH3); HRMS 
(ESI) Exact mass calcd for C20H31N2O5 [M+H]+: 379.2228, found 379.2248; 
Enantiomeric excess was determined by HPLC with a Chiralpak AD-H column (20:80, 
i-PrOH:hexane, 0.8 mL/min, 280 nm, 25 ºC); tr (minor) = 5.9 min, tr (major) = 6.8 min; 
52% ee. 
Ethyl 2-(nitromethyl)-2-[2-oxo-2-(pyridin-2-yl)ethyl] octanoate 
(511a). The title compound was prepared according to General 
Procedure L from 2-acetylpyridine (458) (60.6, 0.50 mmol) and 
Z-nitroalkene (510a) (172 mg, 0.75 mmol) for a reaction time of 40 h and purified by 
column chromatography (5→20% Et2O/hexane) to afford a colourless oil (172 mg, 
98%). Rf = 0.39 (20% EtOAc/hexane); [α]20D  –17.7 (c 0.96, CHCl3); IR (film) 2928, 1732 
(C=O), 1699 (C=O), 1549 (NO2), 1439, 1377 (NO2), 1211, 1196, 995, 764 cm−1; 
1H NMR (500 MHz, CDCl3) δ 8.67 (1H, ddd, J = 4.8, 1.7, 0.9 Hz, ArH), 8.01 (1H, dt, 
J = 7.9, 1.1 Hz, ArH), 7.83 (1H, td, J = 7.7, 1.7 Hz, ArH), 7.48 (1H, ddd, J = 7.6, 4.8, 
1.2 Hz, ArH), 5.01 (2H, dd, J = 26.5, 12.0 Hz, CH2NO2), 4.26-4.16 (2H, m, OCH2), 
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3.85 (1H, d, J = 19.2 Hz, CH2C=O), 3.74 (1H, d, J = 19.2 Hz, CH2C=O), 1.80-1.70 (2H, 
m, CH2), 1.49-1.39 (1H, m, CH2), 1.34-1.18 (10H, 4 x CH2, CH3), 0.86 (3H, t, J = 6.9 
Hz, CH3); 13C NMR (125.8 MHz, CDCl3) δ 198.9 (C), 172.5 (C), 152.8 (C), 149.0 
(CH), 136.9 (CH), 127.5 (CH), 121.7 (CH), 76.9 (CH2), 61.5 (CH2), 47.2 (C), 41.4 
(CH2), 35.5 (CH2), 31.3 (CH2), 29.2 (CH2), 23.5 (CH2), 22.4 (CH2), 14.0 (CH3), 13.9 
(CH3); HRMS (ESI) Exact mass calcd for C18H27N2O5 [M+H]+: 351.1915, found 
351.1928; Enantiomeric excess was determined by HPLC with a Chiralpak AD-H 
column (20:80, i-PrOH:hexane, 0.8 mL/min, 280 nm, 25 ºC); tr (minor) = 8.6 min, 
tr (major) = 10.4 min; 78% ee. 
Ethyl 2-methyl-2-(nitromethyl)-4-oxo-4-(pyridin-2-yl) butanoate 
(511b). The title compound was prepared according to General 
Procedure L from 2-acetylpyridine (458) (61, 0.50 mmol) and 
E-nitroalkene 510b (119 mg, 0.75 mmol) for a reaction time of 40 h and purified by 
column chromatography (4→12% EtOAc/hexane) to afford a colourless oil (106 mg, 
76%). m.p. 51-52 °C (CH2Cl2); Rf = 0.28 (20% EtOAc/hexane); [α]
20
D  –11.7 (c 1.02, 
CHCl3); IR (film) 2982, 1730 (C=O), 1697 (C=O), 1549 (NO2), 1464, 1358 (NO2), 
1211, 1111, 1016, 764 cm−1; 1H NMR (500 MHz, CDCl3) δ 8.70-8.67 (1H, ddd, m, 
ArH), 8.03 (1H, d, J = 7.8 Hz, ArH), 7.86 (1H, td, J = 7.7, 1.7 Hz, ArH), 7.51 (1H, ddd, 
J = 7.6, 4.8, 1.2 Hz, ArH), 5.00 (1H, d, J = 12.0 Hz, CH2NO2), 4.91 (1H, d, J = 12.0 Hz, 
CH2NO2), 4.22 (2H, q, J = 7.1 Hz, OCH2), 3.83-3.73 (2H, m, CH2C=O), 1.49 (3H, s, 
CH3), 1.25 (3H, t, J = 7.1 Hz, CH3); 13C NMR (125.8 MHz, CDCl3) δ 198.6 (C), 173.3 
(C), 152.8 (C), 149.0 (CH), 137.0 (CH), 127.6 (CH), 121.8 (CH), 79.7 (CH2), 61.7 
(CH2), 43.7 (C), 42.4 (CH2), 22.2 (CH3), 13.9 (CH3); HRMS (ESI) Exact mass calcd for 
C13H17N2O5 [M+H]+: 281.1132, found 281.1142; Enantiomeric excess was determined 
by HPLC with a Chiralpak AD-H (20:80, i-PrOH:hexane, 0.8 mL/min, 280 nm, 25 ºC); 





(511c). The title compound was prepared according to General 
Procedure L from 2-acetylpyridine (458) (61 mg, 0.50 mmol) and 
Z-nitroalkene 510c (149 mg, 0.75 mmol) for a reaction time of 40 h and purified by 
column chromatography (3→12% EtOAc/hexane) to afford a colourless gum (150 mg, 
94%). Rf = 0.38 (20% EtOAc/hexane); [α]20D  –13.6 (c 1.32, CHCl3); IR (film) 2980, 1730 
(C=O), 1699 (C=O), 1549 (NO2), 1439, 1377 (NO2), 1211, 1096, 995, 914, 764 cm−1; 
1H NMR (500 MHz, CDCl3) δ 8.66 (1H, ddd, J = 4.8, 1.7, 0.9 Hz, ArH), 8.00 (1H, dt, 
J = 7.9, 1.1 Hz, ArH), 7.83 (1H, td, J = 7.7, 1.7 Hz, ArH), 7.48 (1H, ddd, J = 7.6, 4.8, 
1.2 Hz, ArH), 5.74 (1H, ddt, J = 16.8, 10.2, 6.5 Hz, CH=), 5.07-4.95 (4H, m, CH2=, 
CH2NO2), 4.27-4.16 (2H, m, OCH2), 3.79 (2H, dt, J = 19.3, 9.8 Hz, CH2C=O), 
2.26-2.17 (1H, m, CH2), 2.09-1.97 (1H, m, CH2), 1.92-1.82 (2H, m, CH2), 1.24 (3H, t, 
J = 7.1 Hz, CH3); 13C NMR (125.8 MHz, CDCl3) δ 198.7 (C), 172.2 (C), 152.7 (C), 
149.0 (CH), 136.9 (CH), 136.6 (CH), 127.5 (CH), 121.6 (CH), 115.6 (CH2), 76.8 (CH2), 
61.6 (CH2), 46.9 (C), 41.2 (CH2), 34.5 (CH2), 28.0 (CH2), 14.0 (CH3); HRMS (ESI) 
Exact mass calcd for C16H21N2O5 [M+H]+: 321.1445, found 321.1447;  Enantiomeric 
excess was determined by HPLC with a Chiralpak AD-H column (20:80, 
i-PrOH:hexane, 0.8 mL/min, 280 nm, 25 ºC); tr (minor) = 9.8 min, tr (major) = 15.3 min; 
73% ee. 
Ethyl 5-methyl-2-[2-(1-methyl-1H-imidazol-2-yl)-2-oxoethyl]-2-
(nitromethyl)hexanoate (511d). The title compound was prepared 
according to General Procedure L from 1-methyl-2-acetylimidazole 
(494) (62 mg, 0.50 mmol) and Z-nitroalkene 510f (161 mg, 
0.75 mmol) for a reaction time of 96 h and purified by column chromatography 
(10→30% EtOAc/hexane) to afford a colourless oil (115 mg, 68%). Rf = 0.35 (40% 
EtOAc/hexane); [α]20D  –25.3 (c 0.91, CHCl3); IR (film) 2957, 1732 (C=O), 1676 (C=O), 
1549 (NO2), 1468, 1414, 1379 (NO2), 1211, 999, 776 cm−1; 1H NMR (500 MHz, 
CDCl3) δ 7.14 (1H, d, J = 0.9 Hz, ArH), 7.04 (1H, s, ArH), 4.98 (2H, dd, J = 30.1, 
12.0 Hz, CH2NO2), 4.27-4.16 (2H, m, OCH2), 3.98 (3H, s, CH3), 3.76-3.65 (2H, m, 
228 
 
CH2C=O), 1.77-1.69 (2H, m, CH2), 1.55-1.43 (1H, m, CH), 1.36-1.27 (1H, m, CH2), 
1.25 (3H, t, J = 7.1 Hz, CH3), 1.17-1.06 (1H, m, CH2), 0.88-0.84 (6H, m, 2 x CH3); 
13C NMR (125.8 MHz, CDCl3) δ 189.3 (C), 172.4 (C), 142.3 (C), 129.1 (CH), 127.2 
(CH), 76.9 (CH2), 61.5 (CH2), 47.1 (C), 42.5 (CH2), 36.1 (CH3), 33.3 (CH2), 32.4 (CH2), 
28.1 (CH), 22.4 (CH3), 22.3 (CH3), 14.1 (CH3); HRMS (ESI) Exact mass calcd for 
C16H26N3O5 [M+H]+: 340.1867, found 340.1873; Enantiomeric excess was determined 
by HPLC with a Chiralpak AD-H column (20:80, i-PrOH:hexane, 0.8 mL/min, 280 nm, 
25 ºC); tr (minor) = 8.9 min, tr (major) = 14.2 min; 92% ee. 
Ethyl 2-[2-(1,3-benzothiazol-2-yl)-2-oxoethyl]-5-methyl-2-
(nitromethyl)hexanoate (511e). The title compound was 
prepared according to General Procedure L from 
2-acetylbenzothiazole (495) (89 mg, 0.50 mmol) and 
Z-nitroalkene 510f (161 mg, 0.75 mmol) for a reaction time of 
96 h and purified by column chromatography (1→3% EtOAc/hexane) to afford a white 
solid (105 mg, 54%). m.p. 78-79 °C (hextane); Rf = 0.29 (10% EtOAc/hexane); [α]
20
D   
−35.9 (c 0.72, CHCl3); IR (film) 2957, 2928, 1731 (C=O), 1693 (C=O), 1551 (NO2), 
1485 (NO2), 1377, 1206, 1015, 764 cm−1; 1H NMR (500 MHz, CDCl3) δ 8.20 (1H, dd, 
J = 7.5, 0.7 Hz, ArH), 8.01-7.98 (1H, m, ArH), 7.62-7.53 (2H, m, ArH), 5.03 (2H, q, 
J = 12.3 Hz, CH2NO2), 4.30-4.20 (2H, m, OCH2), 3.88 (2H, dd, J = 43.0, 19.0 Hz, 
CH2C=O), 1.84-1.76 (2H, m, CH2), 1.57-1.48 (1H, m, CH), 1.39-1.31 (1H, m, CH2), 
1.28 (3H, t, J = 7.1 Hz, CH3), 1.21-1.12 (1H, m, CH2), 0.89 (6H, t, J = 6.4 Hz, 2 x CH3); 
13C NMR (125.8 MHz, CDCl3) δ 192.5 (C), 172.0 (C), 165.3 (C), 153.4 (C), 137.3 (C), 
128.0 (CH), 127.2 (CH), 125.6 (CH), 122.4 (CH), 76.8 (CH2), 61.8 (CH2), 47.3 (C), 41.9 
(CH2), 33.3 (CH2), 32.4 (CH2), 28.1 (CH), 22.4 (CH3), 22.3 (CH3), 14.1 (CH3); HRMS 
(ESI) Exact mass calcd for C19H24N2O5SNa [M+Na]+: 415.1298, found 415.1313; 
Enantiomeric excess was determined by HPLC with a Chiralpak AD-H column (20:80, 





butanoate (511f). The title compound was prepared according to 
General Procedure L from 2-acetylpyrazine (386) (61, 0.75 mmol) 
and nitroalkene 510d (187 mg, 0.60 mmol) for a reaction time of 
48 h and purified by column chromatography (5→30% EtOAc/hexane) to afford a 
colourless oil (158 mg, 85%). Rf = 0.15 20% EtOAc/hexane); [α]20D  –1.0 (c 0.92, CHCl3); 
IR (film) 2928, 1730 (C=O), 1701 (C=O), 1549 (NO2), 1375 (NO2), 1219, 1198, 1016, 
1003, 750 cm−1; 1H NMR (500 MHz, CDCl3) δ 9.23 (1H, d, J = 1.5 Hz, ArH), 8.79 (1H, 
d, J = 2.5 Hz, ArH), 8.65 (1H, dd, J = 2.4, 1.5 Hz, ArH), 7.31-7.26 (2H, m, ArH), 
7.22-7.14 (3H, m, ArH), 5.10 (2H, s, CH2NO2), 4.33-4.22 (2H, m, OCH2), 3.87 (1H, d, 
J = 19.4 Hz, CH2C=O), 3.75 (1H, d, J = 19.4 Hz, CH2C=O), 2.86-2.78 (1H, m, CH2), 
2.60-2.52 (1H, m, CH2), 2.16-2.03 (2H, m, CH2), 1.31 (3H, t, J = 7.1 Hz, CH3); 
13C NMR (125.8 MHz, CDCl3) δ 198.2 (C), 172.0 (C), 148.3 (CH), 146.9 (C), 143.6 
(CH), 143.5 (CH), 140.2 (C), 128.6 (2 x CH), 128.3 (2 x CH), 126.3 (CH), 76.7 (CH2), 
61.9 (CH2), 47.1 (C), 41.3 (CH2), 37.4 (CH2), 30.2 (CH2), 14.1 (CH3); HRMS (ESI) 
Exact mass calcd for C19H22N3O5 [M+H]+: 372.1554, found 372.1568; Enantiomeric 
excess was determined by HPLC with a Chiralpak AD-H column (30:70, 
i-PrOH:hexane, 0.1 mL/min, 280 nm, 25 ºC); tr (minor) = 98.0 min, 
tr (major) = 103.2 min; 82% ee. 
Ethy 2-[2-(1,3-dioxan-2-yl)ethyl]-2-(nitromethyl)-4-oxo-4-
(pyrazin-2-yl)butanoate (511g). The title compound was prepared 
according to General Procedure L from 2-acetylpyrazine (386) (61, 
0.50 mmol) and Z-nitroalkene 510g (195 mg, 0.75 mmol) for a 
reaction time of 48 h and purified by column chromatography 
(10→40% EtOAc/hexane) to afford a pale yellow gum (148 mg, 78%). Rf = 0.22 (40% 
EtOAc/hexane); [α]20D  –11.9 (c 1.51, CHCl3); IR (film) 2853, 1730 (C=O), 1701 (C=O), 
1549 (NO2), 1377 (NO2), 1206, 1142, 1097, 1005, 853 cm−1; 1H NMR (500 MHz, 
CDCl3) δ 9.24 (1H, br s, ArH), 8.77 (1H, br s, ArH), 8.65 (1H, br s, ArH), 5.04 (1H, d, 
J = 12.2 Hz, CH2NO2), 4.96 (1H, d, J = 12.2 Hz, CH2NO2), 4.49 (1H, t, J = 4.9, 
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OCHO),  4.27-4.17 (2H, m, OCH2), 4.06 (2H, ddd, J = 11.7, 4.8, 1.1 Hz, CH2), 
3.84-3.68 (4H, m, 2 x CH2), 2.09-1.98 (1H, m, CH2), 1.97-1.84 (2H, m, CH2), 1.77-1.69 
(1H, m, CH2), 1.60-1.52 (1H, m, CH2), 1.35-1.29 (1H, m, CH2), 1.26 (3H, t, J = 7.1 Hz, 
CH3); 13C NMR (125.8 MHz, CDCl3) δ 198.3 (C), 171.9 (C), 148.1 (CH), 147.2 (C), 
143.7 (CH), 143.3 (CH), 101.2 (CH), 76.9 (CH2), 66.8 (2 x CH2), 61.9 (CH2), 46.7 (C), 
40.9 (CH2), 29.5 (2 x CH2), 25.6 (CH2), 14.0 (CH3); HRMS (ESI) Exact mass calcd for 
C17H24N3O7 [M+H]+: 382.1609, found 382.1636; Enantiomeric excess was determined 
by HPLC with a Chiralpak AD-H column (20:80, i-PrOH:hexane, 0.8 mL/min, 280 nm, 
25 ºC); tr (minor) = 23.7 min, tr (major) = 68.5 min; 81% ee. 
1,5-Diethyl 2-(nitromethyl)-2-[2-oxo-2-(1,3-thiazol-2-yl)ethyl] 
pentanedioate (511h). The title compound was prepared according 
to General Procedure L from 2-acetylthiazole (390) (64 mg, 
0.50 mmol) and Z-nitroalkene 5510e (184 mg, 0.75 mmol) for a 
reaction time of 72 h and purified by column chromatography (5→30% EtOAc/hexane) 
to afford a colourless gum (117 mg, 63%). Rf = 0.08 (20% EtOAc/hexane); [α]
20
D  –12.6 
(c 0.87, CHCl3); IR (film) 2982, 1730 (C=O), 1686 (C=O), 1551 (NO2), 1447, 1379 
(NO2), 1300, 1190, 1018, 756 cm−1; 1H NMR (500 MHz, CDCl3) δ 8.03 (1H, d, J = 3.0 
Hz, ArH), 7.73 (1H, d, J = 3.0 Hz, ArH), 5.05 (1H, d, J = 12.6 Hz, CH2NO2), 4.97 (1H, 
d, J = 12.6 Hz, CH2NO2), 4.23 (2H, q, J =7.1 Hz, OCH2), 4.12 (2H, q, J = 7.1 Hz, 
OCH2), 3.77 (2H, d, J = 2.4 Hz, CH2CO), 2.50 (1H, ddd, J = 16.4, 10.5, 6.0 Hz, CH2), 
2.36 (1H, ddd, J = 16.2, 10.6, 5.5 Hz, CH2), 2.22-2.07 (2H, m, CH2), 1.29-1.23 (6H, m, 
2 x CH3); 13C NMR (125.8 MHz, CDCl3) δ 190.6 (C), 171.8 (C), 171.4 (C), 165.9 (C), 
145.0 (CH), 126.8 (CH), 76.8 (CH2), 62.3 (CH2), 60.8 (CH2), 46.5 (C), 41.2 (CH2), 30.0 
(CH2), 28.8 (CH2), 14.1 (CH3), 13.9 (CH3); HRMS (ESI) Exact mass calcd for 
C15H21N2O7S [M+H]+: 373.1064, found 373.1074; Enantiomeric excess was determined 
by HPLC with a Chiralpak AD-H column (3:97, i-PrOH:hexane, 0.4 mL/min, 280 nm, 




octanoate (511i). The title compound was prepared according 
to General Procedure L from 2-acetylquinoline (493) (86, 
0.50 mmol) and nitroalkene 510a (172 mg, 0.75 mmol) for a reaction time of 96 h and 
purified by column chromatography (1→3% EtOAc/hexane) to afford a colourless oil 
(26 mg, 13%). Rf = 0.16 (5% EtOAc/hexane); [α]20D  –26.9 (c 0.52, CHCl3); IR (film) 
2929, 1728 (C=O), 1697 (C=O), 1549, 1460, 1377, 1215, 1016, 833, 748 cm−1; 
1H NMR (500 MHz, CDCl3) δ 8.29 (1H, d, J = 8.5 Hz, ArH), 8.21 (1H, d, J = 8.6 Hz, 
ArH), 8.11 (1H, d, J = 8.5 Hz, ArH), 7.88 (1H, d, J = 8.1 Hz, ArH), 7.80 (1H, ddd, 
J = 8.4, 6.9, 1.4 Hz, ArH), 7.67 (1H, ddd, J = 8.1, 6.9, 1.1 Hz, ArH), 5.06 (2H, q, 
J = 12.1 Hz, CH2NO2), 4.30-4.20 (2H, m, OCH2), 4.07 (1H, d, J = 19.1 Hz, CH2C=O), 
3.92 (1H, d, 19.1 Hz, CH2C=O), 1.87-1.79 (2H, m, CH2), 1.54-1.45 (1H, m, CH2), 
1.35-1.24 (10H, m, 4 x CH2, CH3), 0.88 (3H, t, J = 6.8 Hz, CH3); 13C NMR 
(125.8 MHz, CDCl3) δ 199.4 (C), 172.7 (C), 152.4 (C), 147.2 (C), 137.0 (CH), 130.7 
(CH), 130.1 (CH), 129.8 (C), 128.8 (CH), 127.6 (CH), 117.8 (CH), 77.0 (CH2), 61.6 
(CH2), 47.4 (C), 41.2 (CH2), 35.5 (CH2), 31.4 (CH2), 29.3 (CH2), 23.6 (CH2), 22.5 
(CH2), 14.0 (2 x CH3); HRMS (ESI) Exact mass calcd for C22H29N2O5 [M+H]+: 
401.2071, found 401.2091; 70% ee. Enantiomeric excess was determined by HPLC with 
a Chiralcel OD-H column (10:90, i-PrOH:hexane, 0.8 mL/min, 280 nm, 25 ºC); 
tr (minor) = 7.8 min, tr (major) = 9.9 min; 70% ee. 
Ethyl 2-(nitromethyl)-2-[2-oxo-2-(quinolin-2-yl)ethyl] hex-5-
enoate (511j). The title compound was prepared according to 
General Procedure L from 2-acetylquinoline (493) (86 mg, 
0.50 mmol) and Z-nitroalkene 5510c (140 mg, 0.75 mmol) for a reaction time of 96 h 
and purified by column chromatography (2→6% EtOAc/hexane) to afford a colourless 
oil (17 mg, 9%). Rf = 0.39 (10% EtOAc/hexane); [α]20D  –13.5 (c 0.16, CHCl3); IR (film) 
2924, 1732 (C=O), 1697 (C=O), 1549 (NO2), 1377 (NO2), 1217, 1204, 1003, 833, 
752 cm−1; 1H NMR (500 MHz, CDCl3) δ 8.30 (1H, d, J = 8.4 Hz, ArH), 8.23 (1H, dd, 
J = 8.3, 0.6 Hz, ArH), 8.11 (1H, d, J = 8.5 Hz, ArH), 7.89 (1H, dd, J = 8.2, 1.1 Hz, 
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ArH), 7.81 (1H, ddd, J = 8.4, 6.9, 1.4 Hz, ArH), 7.68 (1H, ddd, J = 8.4, 6.9, 1.2 Hz, 
ArH), 5.85-5.73 (1H, m, =CH), 5.13-4.99 (4H, m, =CH2, CH2NO2), 4.31-4.22 (2H, m, 
OCH2), 4.09 (1H, d, J = 19.1 Hz, CH2C=O), 3.95 (1H, d, J = 19.0 Hz, CH2C=O), 
2.32-2.22 (1H, m, CH2), 2.15-2.06 (1H, m, CH2), 2.00-1.89 (2H, m, CH2), 1.28 (3H, t, 
J = 7.1 Hz, CH3); 13C NMR (125.8 MHz, CDCl3) δ 199.2 (C), 172.4 (C), 152.3 (C), 
147.1 (C), 137.1 (CH), 136.7 (CH), 130.6 (CH), 130.2 (CH), 129.8 (C), 128.9 (CH), 
127.7 (CH), 117.8 (CH), 115.7 (CH2), 77.0 (CH2), 61.7 (CH2), 47.2 (C), 41.1 (CH2), 
34.6 (CH2), 28.1 (CH2), 14.0 (CH3); HRMS (ESI) Exact mass calcd for C20H23N2O5 
[M+H]+: 371.1602, found 371.1610; Enantiomeric excess was determined by HPLC 
with a Chiralcel OD-H column (10:90, i-PrOH:hexane, 0.8 mL/min, 280 nm, 25 ºC); 
tr (minor) = 9.2 min, tr (major) = 10.9 min; 51% ee. 
Methyl 2-(nitromethyl)-2-[2-oxo-2-(pyridin-2-yl)ethyl] 
octanoate (514). The title compound was prepared according to 
General Procedure L from 2-acetylpyridine (458) (61, 0.50 mmol) 
and Z-nitroalkene 513 (151 mg, 0.75 mmol) for a reaction time of 40 h and purified by 
column chromatography (4→12% EtOAc/hexane) to afford a colourless oil (158 mg, 
94%). Rf = 0.24 (20% EtOAc/hexane); [α]20D  –18.1 (c 0.99, CHCl3); IR (film) 2928, 1736 
(C=O), 1697 (C=O), 1549 (NO2), 1437, 1377 (NO2), 1358, 1211, 995, 764 cm−1; 
1H NMR (500 MHz, CDCl3) δ 8.68 (1H, ddd, J = 4.8, 1.7, 0.9 Hz, ArH), 8.02 (1H, dt, 
J = 7.9, 1.0 Hz, ArH), 7.85 (1H, td, J = 7.7, 1.7 Hz, ArH), 7.50 (1H, ddd, J = 7.6, 4.8, 
1.2 Hz, ArH), 5.01 (2H, q, J = 12.0 Hz, CH2NO2), 3.88 (1H, d, J = 19.3 Hz, CH2C=O), 
3.74 (1H, d, J = 19.3 Hz, CH2C=O), 3.75 (3H, s, OCH3), 1.80-1.73 (2H, m, CH2), 
1.48-1.38 (1H, m, CH2), 1.34-1.16 (7H, 4 x CH2), 0.87 (3H, t, J = 6.8 Hz, CH3); 
13C NMR (125.8 MHz, CDCl3) δ 198.8 (C), 173.1 (C), 152.7 (C), 149.0 (CH), 137.0 
(CH), 127.6 (CH), 121.7 (CH), 76.9 (CH2), 52.5 (CH3), 47.3 (C), 41.5 (CH2), 35.5 
(CH2), 31.4 (CH2), 29.2 (CH2), 23.7 (CH2), 22.5 (CH2), 14.0 (CH3); HRMS (ESI) Exact 
mass calcd for C17H25N2O5 [M+H]+: 337.1758, found 337.1760; Enantiomeric excess 
was determined by HPLC with a Chiralpak AD-H column (20:80, i-PrOH:hexane, 







General Procedure M: Michael Addition of 2-Acetylazaarenes to 
Nitroalkene 516 
 
A suspension of Ni(OAc)2·4H2O (6.2 mg, 0.025 mmol) and ligand 502 (10.2 mg, 0.0275 
mmol) in 1:1 dioxane:CH2Cl2 (0.3 mL) was stirred at room temperature for 3 h. To the 
resulting solution was added a solution of the appropriate 2-acetylazaarene (0.60 mmol) 
and the appropriate nitroalkene (126.8 mg, 0.5 mmol) in 1:1 dioxane:CH2Cl2 (0.2 mL), 
and the reaction mixture was stirred for 96 h. The reaction mixture was then filtered 
through a short pad of silica gel (washed several times with EtOAc) and concentrated 
in vacuo. Purification of the residue by column chromatography afforded the nitroalkane 
products. 
Dimethyl [1-nitro-4-oxo-2-phenyl-4-(pyridin-2-yl)butan-2-yl] 
phosphonate (518a). The title compound was prepared according 
to General Procedure M from 2-acetylpyridine (458) (73 mg, 
0.60 mmol) and purified by column chromatography (80% EtOAc/hexane) to afford a 
white solid (44 mg, 23%). m.p. 153-154 °C (EtOAc); Rf = 0.26 (20% EtOAc/hexane); 
[α]20D  +62.1 (c 0.66, CHCl3); IR (film) 2957, 1703 (C=O), 1554 (NO2), 1437, 1375 
(NO2), 1246 (P=O), 1047, 1026 (P-O), 829, 770 cm−1; 1H NMR (500 MHz, CDCl3) 
δ 8.74 (1H, ddd, J = 4.7, 1.6, 0.9  Hz, ArH), 8.02-7.99 (1H, m, ArH), 7.85 (1H, td, 
J = 7.7, 1.7 Hz, ArH), 7.54-7.49 (3H, m, ArH), 7.39 (2H, t, J = 7.8 Hz, ArH), 7.34-7.29 
(1H, m, ArH), 5.79 (1H, dd, J = 12.8, 8.3 Hz, CH2NO2), 5.63 (1H, dd, J = 21.5, 12.8 Hz, 
CH2NO2), 4.48 (2H, ddd, J = 33.8, 18.9, 11.8 Hz, CH2C=O), 3.53 (3H, d, J = 10.7 Hz, 
OCH3), 3.40 (3H, d, J = 10.6 Hz, OCH3); 13C NMR (125.8 MHz, CDCl3) δ 198.1 (d, 
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J = 11.4 Hz, C), 153.2 (d, J = 1.8 Hz, C), 149.0 (CH), 137.0 (CH), 134.9 (d, J = 8.3 Hz, 
C), 128.8 (d, J = 2.9 Hz, 2 x CH), 128.0 (d, J = 3.1 Hz, CH), 127.4 (CH), 127.2 (d, J = 
5.1 Hz, 2 x CH), 121.8 (CH), 75.7 (CH2), 54.0 (dd, J = 63.2, 7.5 Hz, 2 x CH3), 45.9 (d, 
J = 136.5 Hz, C), 36.0 (d, J = 2.4 Hz, CH2); 31P NMR (400 MHz, CDCl3) δ 25.19 (s); 
HRMS (ESI) Exact mass calcd for C17H20N2O6P [M+H]+: 379.1053, found 379.1049; 
Enantiomeric excess was determined by HPLC with a Chiralpak AD-H column (20:80, 
i-PrOH:hexane, 0.8 mL/min, 280 nm, 25 ºC); tr (minor) = 19.6 min, 
tr (major) = 29.1 min; 92% ee. 
Dimethyl [1-nitro-4-oxo-2-phenyl-4-(1, 3-thiazol-2-yl)butan-2-
yl]phosphonate (518b). The title compound was prepared 
according to General Procedure M from 2-acetylthiazole (390) (76 
mg, 0.60 mmol) and purified by column chromatography (20→80% EtOAc/hexane) to 
afford a white solid (42 mg, 22%). m.p. 123-124 °C (EtOAc); Rf = 0.23 (20% 
EtOAc/hexane); [α]20D  +71.9 (c 0.15, CHCl3); IR (film) 2954, 1688 (C=O), 1557 (NO2), 
1446, 1384 (NO2), 1375, 1248 (P=O), 1047, 1026 (P-O), 829, 696 cm−1; 1H NMR 
(500 MHz, CDCl3) δ 8.07 (1H, d, J = 3.0 Hz, ArH), 7.73 (1H, d, J = 3.0 Hz, ArH), 
7.54-7.50 (2H, m, ArH), 7.43-7.38 (2H, m, ArH), 7.35-7.31 (1H, m, ArH), 5.80 (1H, dd, 
J = 13.3, 7.3 Hz, CH2NO2), 5.57 (1H, dd, J = 18.8, 13.3 Hz, CH2NO2), 4.58-4.24 (2H, 
m, CH2C=O), 3.51 (3H, d, J = 10.7 Hz, OCH3), 3.38 (3H, d, J = 10.6 Hz, OCH3); 
13C NMR (125.8 MHz, CDCl3) δ 190.1 (d, J = 10.1 Hz, C), 166.9 (d, J = 2.3 Hz, C), 
144.8 (CH), 134.5 (d, J = 8.3 Hz, C), 128.9 (d, J = 2.8 Hz, 2 x CH), 128.2 (d, J = 3.2 Hz, 
CH), 127.1 (d, J = 5.1 Hz, 2 x CH), 126.8 (CH), 75.4 (CH2), 54.1 (dd, J = 79.6, 7.6 Hz, 
2 x CH3), 45.9 (d, J = 136.0 Hz, C), 37.0 (d, J = 3.0 Hz, CH2); 31P NMR (400 MHz, 
CDCl3) δ 25.53 (s); HRMS (ESI) Exact mass calcd for C15H18N2O6PS [M+H]+: 
385.0618, found 385.0605; Enantiomeric excess was determined by HPLC with a 
Chiralpak AD-H column (20:80, i-PrOH:hexane, 0.8 mL/min, 280 nm, 25 ºC); 
tr (major) = 24.5 min, tr (minor) = 34.9 min; 96% ee. 
235 
 
General procedure N: Michael addition of 2-acetylazaarenes to nitroalkene 
465a 
 
A suspension of Ni(OAc)2·4H2O (6.2 mg, 0.025 mmol) and ligand 502a (10.2 mg, 
0.0275 mmol) in THF (0.5 mL) was stirred at room temperature for 3 h. To the resulting 
solution was added a solution of the appropriate 2-acetylazaarene (0.75 mmol) and 
nitroalkene 465a (109 mg, 0.5 mmol) in THF (0.5 mL), and the reaction mixture was 
stirred for 72 h. The reaction mixture was then filtered through a short pad of silica gel 
(washed several times with EtOAc) and concentrated in vacuo. Purification of the 
residue by column chromatography afforded the nitroalkane products. 
4,4,4-Trifluoro-3-(nitromethyl)-3-phenyl-1-(pyridin-2-yl) butan-
1-one (519a). The title compound was prepared according to 
General Procedure N from 2-acetylpyridine (458) (91 mg, 
0.75 mmol) and purified by column chromatography (2→4% Et2O/hexane) to afford a 
white solid (137 mg, 81%). m.p. 145-146 °C (EtOAc/hexane); Rf = 0.34 (20% 
EtOAc/hexane); [α]20D  +81.8 (c 0.50, CHCl3); IR (film) 2918, 1705 (C=O), 1556 (NO2), 
1437, 1371 (NO2), 1224, 1180, 1151, 995, 767 cm−1; 1H NMR (500 MHz, CDCl3) 
δ 8.76 (1H, ddd, J = 4.8, 1.7, 0.9 Hz, ArH), 7.99 (1H, dt, J = 7.9, 1.0 Hz, ArH), 7.86 
(1H, td, J = 7.7, 1.7 Hz, ArH), 7.55 (1H, ddd, J = 7.6, 4.8, 1.2 Hz, ArH), 7.42-7.36 (5H, 
m, ArH),  5.76-5.60 (2H, m, CH2NO2), 4.70-4.30 (2H, m, CH2C=O); 13C NMR 
(125.8 MHz, CDCl3) δ 197.0 (C), 152.8 (C), 149.1 (CH), 137.1 (CH), 133.5 (C), 129.0 
(3 x CH),  127.8 (CH), 126.8 (2 x CH), 125.9 (q, J = 284.4 Hz, C), 121.9 (CH), 74.8 
(CH2), 50.0 (q, J = 25.5 Hz, C), 35.5 (d, J = 1.4 Hz, CH2); 19F NMR (400 MHz, CDCl3) 
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δ –72.87 (s, 3F); HRMS (ESI) Exact mass calcd for C16H14F3N2O3 [M+H]+: 339.0951, 
found 339.0955; Enantiomeric excess was determined by HPLC with a Chiralpak AD-H 
column (90:10, hexane:i-PrOH, 0.8 mL/min, 280 nm, 25 ºC); tr (major) = 15.2 min, 
tr (minor) = 17.6 min; 80% ee. 
4,4,4-Trifluoro-3-(nitromethyl)-3-phenyl-1-(1,3-thiazol-2-yl) 
butan-1-one (519b). The title compound was prepared according to 
General Procedure N from 2-acetylthiazole (390) (95 mg, 
0.75 mmol) and purified by column chromatography (4→12% Et2O/hexane) to afford a 
white solid (107 mg, 62%). m.p. 165-166 ºC (EtOAc/hextane); Rf = 0.26 (20% 
EtOAc/hexane); [α]20D  +45.7 (c 0.35, CHCl3); IR (film) 2918, 1691 (C=O), 1557 (NO2), 
1423, 1379 (NO2), 1221, 1186, 1157, 962, 742 cm−1; 1H NMR (400 MHz, CDCl3) 
δ 8.09 (1H, d, J = 3.0, Hz, ArH), 7.76 (1H, d, J = 3.0 Hz, ArH), 7.45-7.37 (5H, m, ArH), 
5.66 (2H, s, CH2NO2), 4.43 (2H, dd, J = 49.7, 19.0 Hz, CH2C=O); 13C NMR (100.6 
MHz, CDCl3) δ 189.0 (C), 166.1 (C), 145.0 (CH), 133.1 (C), 129.2 (CH), 129.1 
(2 x CH),  127.2 (CH), 126.7 (2 x CH), 125.7 (d, J = 284.4 Hz, C), 74.6 (d, J = 1.3 Hz, 
CH2), 50.0 (q, J = 25.8 Hz, C), 36.4 (d, J = 1.5 Hz, CH2); 19F NMR (400 MHz, CDCl3) 
δ 72.80 (s, 3F); HRMS (ESI) Exact mass calcd for C14H12F3N2O3S [M+H]+: 345.0515, 
found 345.0519; Enantiomeric excess was determined by HPLC with a Chiralpak AD-H 
column (90:10, hexane:i-PrOH, 0.8 mL/min, 280 nm, 25 ºC); tr (major) = 15.2 min, 







3.2.5 X-Ray Crystallography Data 
The X-Ray crystallography data can be obtained free of charge from The Cambridge 
Crystallographic Data Centre (CCDC) via  www.ccdc.cam.ac.uk/data_request/cif. 
Compound Number Flack Parameter CCDC Number 
511e −0.001(9) YLHWLA 
517b −0.05(4) SCHWLB 
518a −0.02(13) YLHWLC 
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